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Zusammenfassung 
In etwa 25 % der Patienten mit akuter myeloischer Leukämie (AML) treten interne 
Duplikationen (ITD) in der juxtamembranen Domäne des Rezeptors auf, die zu einer 
konstitutiv aktiven Kinase mit veränderter Signalaktivität führen. Trotz der Entwicklung 
und Zulassung von kleinen Tyrosinkinase-Inhibitoren (TKI), die FLT3 ITD inaktivieren, 
bleibt AML eine Erkrankung mit schlechter klinischer Prognose. Bei AML-Patienten 
treten häufig Rückfälle auf, welche teilweise auf zusätzliche erworbene Mutationen von 
FLT3 ITD zurückzuführen sind und zu einer Resistenzbildung der Kinase gegen TKI 
beitragen. Die 5-Jahres-Überlebensrate beträgt lediglich 40 - 50 %. Daher sind 
alternative Behandlungsstrategien von FLT3 ITD-positiven AML-Patienten wichtig.  
Unsere Arbeitsgruppe hat die regulierende Rolle der Rezeptor-Protein-Tyrosin-
Phosphatasen (RPTP) Ptprj/DEP-1 und Ptprc/CD45 auf das FLT3-Wildtypprotein in 
Modellzellsystemen gezeigt. Darüber hinaus zeigen Array-Daten, dass ein niedriges 
Expressionslevel von Ptprj oder Ptprc zu einer schlechteren Prognose von FLT3 ITD-
positiven AML-Patienten führt. 
 
Um die regulatorische Funktion von Ptprj und Ptprc auf die FLT3 ITD-Aktivität in vitro 
weitergehend zu untersuchen, wurden die Ptprj bzw. Ptprc Gene in dem 
Modellzellsystem 32D muFLT3 ITD inaktiviert. Die in dieser Arbeit dargestellten 
Ergebnisse deuten auf eine Beeinflussung beider RPTP auf die Aktivität von FLT3 ITD 
hin. Die größten Effekte in Hinblick auf die Inaktivierung der RPTP wurden in Bezug auf 
die Src-Aktivität beobachtet. Gegenwärtig kann nicht differenziert werden, ob die 
Beeinflussung der FLT3 ITD Aktivität direkt oder indirekt erfolgt. Es lässt sich vermuten, 
dass neben spezifischen Effekten auf FLT3 ITD noch weitere physiologische Funktionen 
durch die beiden RPTP beeinflusst werden.  
 
Um die Rolle von Ptprj und Ptprc auf FLT3 ITD in vivo zu untersuchen, wurden Ptprj-/- 
bzw. Ptprc-/- in FLT3ITD/ITD Mäusen inaktiviert. FLT3ITD/ITD Ptprj-/- Mäuse zeigten eine 
drastische Verkürzung der Lebensdauer, Leukozytose, einer drastisch verringerte B-
Zellpopulation und eine Infiltration myeloischer Zellen in peripheren Organen, was zu 
Splenohepatomegalie und anormaler Organarchitektur führte. FLT3ITD/ITD Ptprj-/- Mäuse 
zeigten weiterhin eine stärker ausgeprägte myeloproliferative Neoplasie mit 
extramedullärer Hämatopoese, als für FLT3ITD/ITD Mäuse gezeigt. Die erhöhte FLT3 
Phosphorylierung in FLT3ITD/ITD Ptprj-/- Mäusen zeigte, dass der beobachtete Phänotyp 
auf eine erhöhte FLT3 ITD-Aktivität zurückgeführt werden kann.  
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Die Inaktivierung des Ptprc Gens in FLT3ITD/ITD Mäusen führte zu einer dramatischen 
Verkürzung der Lebensdauer, einem ähnlichen hämatologischen Phänotyp wie in 
FLT3TD/ITD Ptprj-/- Mäusen sowie zur Entwicklung einer schweren Monozytose. Außerdem 
wurde eine Leukozytose mit anämischen Merkmalen, und ein Mangel an Lymphozyten 
sowie Thrombozyten beobachtet. Eine myeloproliferative Neoplasie, welche durch 
starke Infiltration myeloischer Zellen in periphere Organe gekennzeichnet war, führte zu 
einer Splenohepatomegalie und einer Nephromegalie. Darüber hinaus wurden 
signifikant erhöhte Mengen an hämatopoetischen Vorläufer- und Stammzellen sowie 
Megakaryozyten in den peripheren Organen gefunden, was wiederum auf eine 
extramedulläre Hämatopoese hindeutet. Die phänotypischen Veränderungen waren mit 
einer erhöhten onkogenen Signalaktivität von FLT3 ITD und der Aktivierung des 
nachgeschalteten Zielproteins STAT5 verbunden. Diese Daten zeigten, dass Ptprc die 
FLT3 ITD-Signalaktivität in vivo beeinflusst. Darüber hinaus zeigten histopathologische 
und computertomographische (CT) Untersuchungen der FLT3ITD/ITD Ptprc-/- Mäuse einen 
unerwarteten Knochenphänotyp wie verkürzte Knochenlänge, reduzierte Knochendichte, 
erhöhtes Knochenvolumen und erhöhter Oberflächenrauheit sowie ektopische 
Knochenbildung in peripheren Organen was in keiner der Kontrolltiere festgestellt wurde. 
Diese Beobachtungen deuten auf eine bisher unerwartete Rolle von FLT3 ITD (und 
vermutlich FLT3) bei der Regulierung der Knochenentwicklung und des 
Knochenumbaus hin.  
Zusammenfassend konnte die regulierende Rolle von Ptprj und Ptprc auf die onkogene 
FLT3 ITD-Aktivität in vivo nachgewiesen werden. Ähnliche physiologische Effekte in 
Antwort auf die Inaktivierung von Ptprj oder Ptprc in vitro und in vivo deuten auf eine 
ähnliche Wirkungsweise der beiden Membran-gebundenen Proteintyrosin-Phosphatasen 
hin. 
 
  Summary 
IX 
 
Summary 
Activating internal tandem duplication (ITD) mutations in the juxtamembrane domain of 
FLT3 leading to constitutively active kinase with altered signaling quantity were identified 
in about 25 % of acute myeloid leukemia (AML) patients. Despite development and 
approval of small tyrosine kinase inhibitors (TKI), targeting FLT3 ITD, AML remains a 
disease with poor clinical prognosis. AML patients frequently relapse partially due to 
additional acquired mutations on FLT3 ITD resulting in resistance of kinases to TKI. The 
5-year survival rate is only 40-50 %. Alternative treatment strategies of FLT3 ITD-
positive AML patients are urgently needed. 
Recently our research group observed an attenuating role of receptor protein-tyrosine 
phosphatases (RPTP) Ptprj/DEP-1 and Ptprc/CD45 on FLT3 wild type protein in model 
cell systems. In addition, array data demonstrated that low level of Ptprj and Ptprc, 
respectively result in poor prognosis of FLT3 ITD positive AML patients.  
 
To get further inside in the regulatory function of Ptprj and Ptprc on FLT3 ITD activity in 
vitro, Ptprj or Ptprc genes were inactivated in the model cell system 32D muFLT3 ITD 
cells. The results presented in this thesis suggest that both RPTP influence the activity 
of FLT3 ITD. The greatest effects in terms of inactivation of RPTP were observed in 
terms of Src activity. At present it cannot be differentiated whether the FLT3 ITD activity 
is directly or indirectly influenced. It can be assumed that in addition to specific effects on 
FLT3 ITD, other physiological functions are influenced by the two RPTP. 
 
To study the role of Ptprj and Ptprc on FLT3 ITD in vivo Ptprj-/- or Ptprc-/- was inactivated 
in FLT3ITD/ITD mice. FLT3ITD/ITD Ptprj-/- mice demonstrated drastically shortened life span, 
leukocytosis, drastically decreased B cell population and infiltration myeloid cells in 
peripheral organs, leading to splenohepatomegaly and aberrant organ architecture. 
FLT3ITD/ITD Ptprj-/- mice showed a further pronounced myeloproliferative neoplasm with 
extramedullary hematopoiesis as demonstrated for FLT3ITD/ITD mice. Increased FLT3 
phosphorylation in FLT3ITD/ITD Ptprj-/- mice indicated that the observed phenotype is due 
to increased FLT3 ITD activity.  
Inactivation of Ptprc gene in FLT3ITD/ITD mice resulted in drastically shortened life span, 
similar hematopoietic phenotype like in FLT3ITD/ITD Ptprj-/- and development of severe 
monocytosis. In addition, leukocytosis with anemic features, lack of lymphocytes and 
platelets were observed. Myeloproliferative neoplasm was characterized by severe 
infiltration of myeloid cells in peripheral organs which resulted in splenohepatomegaly as 
well as nephromegaly. Furthermore, significantly increased amount of hematopoietic 
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progenitor and stem cells and surprisingly megakaryocytes were observed in peripheral 
organs indicating extramedullary hematopoiesis. Phenotypic alterations were associated 
with increased oncogenic signaling of FLT3 ITD and activation of downstream target 
STAT5. These data demonstrated that Ptprc affects FLT3 ITD signaling activity in vivo. 
In addition, histopathology and computed tomography (CT) revealed unexpected bone 
phenotype with shortened bone length, reduced bone density, increased bone volume 
and increased surface roughness along with ectopic bone formation in peripheral organs 
in FLT3ITD/ITD Ptprc-/- mice but in none of the control animals. These observations suggest 
a previously unexpected role of FLT3 ITD (and presumably FLT3) to regulate bone 
development and remodelling.  
Taken together, regulatory role of Ptprj and Ptprc on oncogenic FLT3 ITD activity could 
be demonstrated in vivo. Similar in vitro and in vivo physiologic effects in response of 
inactivation of Ptprj or Ptprc indicate similar mode of action of both membrane bound 
PTP. 
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1. Introduction 
1.1 Hematopoietic system 
The mammalian hematopoietic system contains more than ten different mature cell 
types deriving from a common progenitor, the hematopoietic stem cell (HSC). The 
process of blood cell differentiation – hematopoiesis – is a dynamic and hierarchical 
process to maintain self-renewal capacity of HSC as well as to generate progeny of fully 
functional mature hematopoietic cells throughout lifetime (Seita and Weissman 2010). 
By undergoing specific differentiation HSC lose their self-renewal capacity. First HSC 
differentiate into multipotent progenitors (MPP) which can still differentiate into all 
lineages but have lost their self-renewal capacity. MPP perform then lineage restricted 
differentiation into either common myeloid (CMP) or common lymphoid progenitors 
(CLP) (Reya et al. 2001). From CMP evolve megakaryocyte-erythrocyte progenitors 
(MEP), granulocyte-macrophage progenitors (GMP) and mast cells. GMP will 
differentiate into basophil, neutrophil or eosinophil granulocytes or into monocytes which 
subsequently differentiate into macrophages and myeloid dendritic cells. MEP develop 
into erythrocytes or megakaryocytes which differentiate into platelets. B cells, T cells, 
natural killer (NK) cells and lymphoid dendritic cells, the so called lymphoid lineage, 
mature from CLP (Figure 1) (Giebel and Punzel 2008).  
Imbalances in regulation of hematopoiesis e.g. caused by genetic alterations of HSC or 
progenitors lead to hematopoietic malignancies like leukemia or myeloproliferative 
neoplasms (MPN). These disorders can be classified by cellular origin – myeloid or 
lymphoid  or by progression of disease – chronic or acute (Sell 2005).  
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Figure 1. Hierarchy of hematopoietic system. Hematopoietic stem cells (HSC) balance self-renewal and 
differentiation to maintain blood production throughout life time. HSC differentiate into lineage specific 
common myeloid progenitor (CMP) or common lymphoid progenitor (CLP). CLP differentiate into lymphoid 
cells (cell types labeled in green) including natural killer (NK) cells, B cells, T cells and lymphoid dendritic 
cells. CMP differentiate either into megakaryocyte-erythrocyte progenitors (MEP), mast cells or granulocyte-
macrophage progenitors (GMP). The myeloid differentiated lineage (cell types labeled in red) arisen from 
GMP is composed of eosinophil, basophil and neutrophil granulocytes as well as monocytes which further 
differentiate into macrophages and myeloid dendritic cells. MEP differentiate into erythrocytes or 
megakaryocytes subsequently producing platelets. Figure adapted from Stirewalt & Radich (Stirewalt and 
Radich 2003).  
1.2 Acute myeloid leukemia (AML) 
1.2.1 General aspects of AML 
AML is a phenotypically and genetically heterogeneous disease of hematopoietic 
myeloid progenitor cells characterized by uncontrolled proliferation and impaired function 
due to undifferentiated phenotype (Fröhling et al. 2005). These abnormal progenitor 
(blast) cells accumulate in the bone marrow and peripheral organs, leading to 
displacement of mature functional hematopoietic cells and organ failure. Symptoms of 
AML are fatigue, weakness, hepatomegaly, splenomegaly, fever, increased infection 
susceptibility and bleeding (Liesveld 2010, Döhner et al. 2015). AML has a very drastic 
progression leading to death within one year without treatment (Estey and Döhner 2006, 
Schlenk et al. 2008). Poor prognosis for AML especially for patients at age 65 and older 
has been described. AML is a disease of mainly elderly people but also occurs in 
children. The median age at diagnosis is 68 years (Figure 2). The median age at death 
is 72 years (Howlader N 2017) (Figure 2). It is the most common myeloid leukemia with 
a prevalence of 4.2 cases per 100 000 adults (Liesveld 2010). AML can be acquired by 
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several risk factors like ionizing radiation or benzene (smoking) (Kane et al. 1999). In 
10 - 15 % AML evokes as a secondary disease after cytotoxic chemotherapy (Smith et 
al. 2003).  
 
Figure 2. Age-dependent new cases and deaths of AML patients. Percentage of newly diagnosed AML 
cases (upper panel) and percentage of deaths (lower panel) are presented in relation to age. Figure from 
https://seer.cancer.gov/statfacts/html/amyl.html (visited 28.03.2018) 
 
In 2008 AML has been classified by world health organization (WHO) in molecular 
groups according to chromosome aberrations (e.g. reciprocal translocations, inversions, 
insertions, deletions, trisomies, and monosomies) (Vardiman et al. 2009). More recent 
screening of 1540 AML patients has demonstrated that roughly 50 % of patients do not 
fit into this classification although carrying driver mutations (Papaemmanuil et al. 2016). 
Thus, a new classification of AML was performed including genomic issues. 11 new 
subgroups of AML have been evaluated partly corresponding to WHO classification 
(Papaemmanuil et al. 2016). Additionally so called diver mutations have been found in 
AML patients affecting treatment and survival.  
Molecular characterization of leukemia has demonstrated that genetic alterations in the 
leukemia clone frequently fall into two classes: Those affecting transcription factors 
interfering with hematopoietic differentiation (e.g. AML1-ETO, RUNX1, CEBPA, MLL, 
Hox genes) and mutations affecting genes involved in signal transduction conferring 
proliferative and survival advantage to cells (e.g. activating mutations of FLT3 and c-Kit). 
This has favored a two-hit model of leukemogenesis. The collaboration of these two 
classes of genetic alterations is necessary for malignant transformation of hematopoietic 
progenitor cells (Kelly and Gilliland 2002, Fröhling et al. 2005, Schlenk et al. 2008, 
Schessl et al. 2005, Pinheiro et al. 2007). Mouse experiments have demonstrated that 
just one type of mutation affecting either proliferation or differentiation is sufficient to 
cause MPN but will not result in AML (Downing 2003). Recent genetic studies have 
demonstrated that another group of mutations targeting epigenetic modifications (e.g. 
TET2, IDH2, DNMT3a) also contributes to AML development and outcome (Lagunas-
Rangel et al. 2017). 
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1.2.2 Therapeutic strategies for AML 
Due to the fact that AML is a heterogeneous group of disorders, different treatment 
strategies are inevitable. In young AML patients (< 60 years), intensive chemotherapy is 
often used with Cytarabine and Anthracyclines leading to 25 - 75 % cure. Allogenic bone 
marrow transplantation represents an alternative treatment. Since only less than 10 % of 
older patients will survive such a harsh therapy, alternative treatment strategies are 
urgently needed (Estey and Döhner 2006, Schlenk et al. 2008). Supporting 
chemotherapy by inhibition of receptor tyrosine kinases (RTK) which are involved in 
tumor progression via tyrosine kinase inhibitors (TKI) has been demonstrated as 
alternative therapy. These small-molecule inhibitors have been first used for inhibition of 
BCR-ABL fusion protein tyrosine receptor in chronic myeloid leukemia (Druker et al. 
2001). All TKI interact with the ATP-binding site of TKD and competitively inhibit ATP 
binding. Thereby, TKI prevent receptor phosphorylation and activation of downstream 
signaling. Small inhibiting molecules targeting RTK e.g. FLT3 exist in first and second 
generation. First generation TKI like Midostaurin (PKC412) lack specificity for FLT3, and 
also target other RTK and downstream targets of FLT3. This increases cytotoxicity but 
also increases off target effects. Midostaurin has been approved by the Food and Drug 
Administration in April 2017 (Levis 2017). Combined with chemotherapy Midostaurin has 
been introduced as new AML treatment strategy (Stone et al. 2017). Second generation 
TKI like Quizartinib (AC220) mainly targeting FLT3 have less off target effects and are in 
phase III of clinical trials. Because epigenetic modifications have been demonstrated to 
be linked to AML hypomethylating agents have been tested in AML patients. In older 
patients, the use of hypomethylating agents has improved median and short-term overall 
survival but has not translated into improved cure rates, which remain disappointingly 
low (Dombret and Gardin 2016). 
1.3 Receptor-type tyrosine kinases  
1.3.1 General aspects on receptor-type tyrosine kinases  
Balanced protein tyrosine phosphorylation is essential to regulate several cellular 
processes including differentiation, cell growth, migration, survival and apoptosis (Cohen 
2002, Hendriks and Pulido 2013). Besides, reversible phosphorylation plays a pivotal 
role in intracellular communication, e.g. PI3K/AKT pathway, Ras/ERK1/2 and SFK 
pathway. Signal transfer is tightly regulated by activity of protein tyrosine kinases (PTK), 
resulting in phosphorylation and activity of protein tyrosine phosphatases (PTP), 
dephosphorylating substrate proteins carrying a phosphorylated tyrosine residue. PTK 
can be subgrouped into two classes: cytoplasmic and transmembrane receptor-type 
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tyrosine kinases (RTK). RTK were subgrouped on basis of amino acid (aa) sequence 
homologies (Ullrich and Schlessinger 1990, Robinson et al. 2000). All RTK consist of an 
extracellular domain to interact with ligands e.g. growth factors, hormones and 
cytokines, a membrane spanning part and an intracellular domain with protein tyrosine 
kinase activity and a C-terminal domain. Within all classes of mammalian RTK the 
consensus sequence the in kinase domain is conserved. Activation of RTK is induced by 
ligand binding accompanied by conformational alterations in the extracellular domain. 
RTK catalyzes trans-autophosphorylation of their tyrosine residues within their 
polypeptide chains (Ullrich and Schlessinger 1990). Several gene encoding RTK have 
been identified as proto-oncogenes, particularly for EGFR, PDGFR  (Golub et al. 1994), 
c-KIT (Beghini et al. 2000) and FLT3 (Drexler 1996, Lyman and Jacobsen 1998).  
1.3.2 FMS-like tyrosine kinase 3  
1.3.2.1 Structure and expression profile of FLT3  
FMS-like tyrosine kinase 3 (FLT3) also designated as fetal liver kinase 2 (FLK2) or     
CD-marker antigen 135 (CD135) has been independently cloned by two groups using 
murine fetal liver cells or placental cells (Matthews et al. 1991, Rosnet et al. 1991). FLT3 
belongs to class III RTK. Murine FLT3 has been identified to share 86 % sequence 
identity of protein level with human FLT3. Human FLT3 encodes two splicing forms: a 
993 aa and a 952 aa long form. Murine FLT3 encodes a 1000 aa long protein. It is 
comprised of five immunoglobulin-like domains in the extracellular domain, a single 
transmembrane domain (TMD), a juxtamembrane domain (JMD) and a split tyrosine 
kinase domain linked by a kinase-insert, followed by a C-terminal domain (Agnes et al. 
1994, Griffith et al. 2004, Takahashi 2011, Small et al. 1994) (Figure 3). The most 
frequent mutations of FLT3 are internal tandem duplications (ITD) in the JMD of FLT3 
resulting in ligand-independent constitutive active kinase (Figure 3).  
 
Figure 3. Wild type FLT3 and oncogenic FLT3 ITD. FLT3 consists of five extracellular immunoglobulin-like 
domains, a transmembrane domain, a juxtamembrane domain and a split tyrosine kinase domain linked by a 
kinase-insert domain, and a C-terminal domain. FLT3 WT dimerizes upon ligand binding of FLT3 ligand (FL). 
FLT3 ITD has an ITD mutation in the JMD resulting in ligand-independent dimerization and constitutive 
active kinase (modified according to (Müller et al. 2012)) 
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FLT3 expression slightly differs in man and mouse. In humans FLT3 expression occurs 
at low level in HSC and CMP and at high levels in CLP and GMP but not in mast cells 
(Hjertson et al. 1996) and MEP (Kikushige et al. 2008). Murine FLT3 expression has 
been demonstrated in CLP (Kikushige et al. 2008). For the myeloid lineage controversial 
results have been obtained concerning the expression of FLT3. While Kikushige and 
colleagues have demonstrated FLT3 expression in all progenitors of 
granulocyte / macrophage pathway including CMP and GMP, Boyer and colleagues 
have demonstrated a lack of FLT3 expression on CMP (Kikushige et al. 2008, Boyer et 
al. 2011). Furthermore, FLT3 is expressed in lymphoid organs such as liver, spleen, 
thymus and placenta but probably just because of invasion of FLT3-expressing 
hematopoietic cells and not due to organ FLT3 expression itself (Rosnet et al. 1993). 
FLT3 WT is expressed at high levels in cells of most AML patients (Gilliland and Griffin 
2002, Carow et al. 1996, Rosnet et al. 1996).  
 
1.3.2.2 FLT3 activation, signaling and function in hematopoiesis  
Biogenesis of FLT3 comprises synthesis in the ER and subsequent transit to Golgi 
compartment and finally to cell membrane, with accompanying changes in glycosylation 
pattern (Schmidt-Arras et al. 2005). The immature high-mannose form of FLT3 (130 
kDa) is located in the endoplasmic reticulum (ER) (Schmidt-Arras et al. 2005) or ER near 
compartments (Koch et al. 2008). Mature FLT3 (150 kDa) is highly glycosylated and 
membrane associated. 
Wild type FLT3 receptor is localized in the cell membrane in a monomeric form. This 
inactive state conformation of the receptor prevents dimerization by steric inhibition. The 
phosphoryl acceptor site of the tyrosine kinase domain is blocked by the JMD (Stirewalt 
and Radich 2003). Upon ligand binding of FLT3 ligand (FL) dimerization of FLT3 is 
promoted and subsequent activation of intrinsic kinase activity occurs resulting in trans-
autophosphorylation of tyrosine residues. Of special importance for this thesis are in 
particular phosphorylation sites Y589 and Y591 in the JMD (Verstraete and Savvides 
2012, Griffith et al. 2004). The phosphorylated receptor serves as a docking site for 
several intracellular signaling molecules including the p85 subunit of phosphatidyl-
inositol 3-kinase (PI3K), phospholipase C- (PLC-), SH2 (Src homology domain 2) 
containing proteins, growth factor receptor-bound protein 2 (Grb2), extracellular signal-
regulated kinase 1/2 (ERK1/2), Fyn kinase (Src family kinase), protein kinase B (AKT) 
and Src-like non-receptor kinases (Rosnet et al. 1996, Dosil et al. 1993, Zhao et al. 
2000, Levis et al. 2006, Chougule et al. 2016, Schmidt-Arras et al. 2009). 
FLT3mediated phosphorylation of these adapter proteins results in activation of 
PI3K/AKT pathway which is involved in cell cycle progression and Ras-Raf-ERK1/2 
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signaling cascade that regulates mitosis and proliferation (Dosil et al. 1993). Only minor 
effects of FLT3 on activation of signal transducer and activator of transcription 5 a 
(STAT5a) and STAT5b have been demonstrated (Zhang et al. 2000, Rocnik et al. 2006).  
FLT3 plays a pivotal role in hematopoietic development. In normal hematopoiesis 
FLT3 is known to promote proliferation, survival and differentiation of MPP and CLP 
(Hudak et al. 1995). Its expression is associated with loss of self-renewal potential of 
HSC (Adolfsson et al. 2001). Interestingly, mice deficient for FLT3 demonstrated normal 
mature hematopoietic populations, disruption of FLT3 led to deficiencies in primitive 
hematopoietic progenitors. In addition, the positive role of FLT3 on MPP and lymphoid 
differentiation, especially B cells was demonstrated (Mackarehtschian et al. 1995). 
However, several studies demonstrated that FLT3 function is cell-type specific and 
dependent on growth factors and cytokines (Hudak et al. 1995, Hirayama et al. 1995, 
Gabbianelli et al. 1995, Haylock et al. 1997). Deregulated activity of FLT3 has been 
shown to lead to disrupted cellular homeostasis and has been involved in 
leukemogenesis. Activating internal tandem duplication (ITD) mutations of FLT3 has 
been found in about 25 % of AML patients (see chapter 1.3.3). Other FLT3 mutations 
found in leukemia and hematopoietic malignancies are point mutations in the activation 
loop of tyrosine kinase domain (predominantly D835Y), represented in 5 % of AML 
cases (Abu-Duhier et al. 2001, Yamamoto et al. 2001, Meshinchi and Appelbaum 2009, 
Gilliland and Griffin 2002) and ITD mutations in the tyrosine kinase domain 
(Breitenbuecher et al. 2009). FLT3 ITD mutations contribute to growth factor 
independent growth, resistance to apoptosis as well as resistance to tyrosine kinase 
inhibitors (TKI) in chemotherapy (Fröhling et al. 2007, Gilliland and Griffin 2002, Kayser 
et al. 2009).  
1.3.3 FLT3 ITD  
1.3.3.1 Altered signaling quality and transforming capacity of oncogenic FLT3 ITD  
In 1996 ITD mutations in the JMD of FLT3 have been first reported in AML patients 
(Nakao et al. 1996). These mutations are localized mainly between exon 14 and 15 of 
the JMD. Their length varies from 3 to 1236 base pairs from case to case (Stirewalt and 
Radich 2003, Schnittger et al. 2002, Gilliland and Griffin 2002). The ITD mutation in the 
JMD abrogates its inhibitory function of this domain for the TKD. Thus, ITD mutations of 
FLT3 results in ligand-independent dimerization and tyrosine autophosphorylation (Kiyoi 
et al. 1998) leading to constitutive active tyrosine kinase (Griffith et al. 2004) (Figure 3). 
While FLT3 WT predominantly occurs in its 150 kDa complex glycosylated form, FLT3 
ITD predominantly exists in the high-mannose form (Schmidt-Arras et al. 2005). Impaired 
maturation is dependent on kinase activity. It has been demonstrated that because of 
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complex formation with chaperone calnexin FLT3 ITD trafficking is impaired and receptor 
is retained in the ER or ER near compartments (Schmidt-Arras et al. 2005, Koch et al. 
2008). Constitutively active FLT3 ITD contributes to growth factor-independent 
proliferation and drives aberrant phosphorylation of STAT5, which is tightly associated 
with strong transforming potential (Stirewalt and Radich 2003, Mizuki et al. 2000, 
Hayakawa et al. 2000). FLT3 ITD also promotes the production of reactive oxygen 
species (ROS) by activation of a STAT5-Nox4 axis consequently resulting in genomic 
instability and reversible inactivation of PTP (Jayavelu et al. 2016, Sallmyr et al. 2008). 
The SFK Fyn and Src have been reported to interact with FLT3 and contribute to STAT5 
driven transformation (Chougule et al. 2016, Leischner et al. 2012). Additionally, 
FLT3 ITD suppresses CCAAT/estradiol-binding protein alpha (C/EBPalpha) and PU.1, 
transcription factors that promote myeloid differentiation (Choudhary et al. 2005, Mizuki 
et al. 2003). 
Transgenic mouse models were established to analyze in vivo the molecular pathways 
that play an important role for generation of leukemia with physiologic aberrancies of 
FLT3. FLT3 ITD knockin mice developed a fully penetrating MPN closely resembling 
human chronic myelomonocytic leukemia (CMML) (Lee et al. 2007). FLT3 ITD-
expressing bone marrow (BM) and spleen cells showed enhanced phosphorylation of 
FLT3 and STAT5 (Lee et al. 2007). Heterozygous FLT3+/ITD knockin mice developed 
MPN, characterized by splenomegaly, leukocytosis, and myeloid hypercellularity but did 
not develop leukemia-like disease. The disease progressed to mortality by 6 to 20 month 
(Li et al. 2008). Increased levels of granulocytes / monocytes and dendritic cells have 
been observed. Moreover, a decreased fraction of B lymphocytes has been 
demonstrated. Activation of FLT3 downstream signaling through STAT5 has been 
showed by increased expression of STAT5 targets (Chu et al. 2012). Depletion of 
functional HSC was completely reversible upon treatment with the TKI Sorafenib 
inhibiting oncogenic FLT3 ITD kinase activity. Loss of wild type allele contributed to 
myeloid expansion and disease aggressiveness in FLT3 ITD background. Thus, these 
mouse models revealed that FLT3 ITD alone was capable of developing MPN but no 
leukemia. Similar results were observed in BM transplantation studies (Kelly et al. 2002). 
Additional cooperating events, e.g. expression of NUP89-HOXD13 fusion gene, appear 
to be required to initiate progress to acute leukemia (Greenblatt et al. 2012). 
 
1.3.3.2 Clinical impact of FLT3 ITD  
FLT3 ITD is the most common FLT3 mutation and occurs in about 25 % of AML cases 
(Schlenk et al. 2008, Papaemmanuil et al. 2016). It is associated with poor prognosis, 
increased relapse and short survival of patients after chemotherapy and transplant 
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(Fröhling et al. 2005, Kiyoi and Naoe 2006, Olesen et al. 2005). A number of inhibitors of 
FLT3 signaling have been identified and are in clinical trial to improve clinical outcome of 
AML patients with FLT3 activating mutation (described in chapter 1.2.2).  
Chimeric Antigen Receptor (CAR) T cell therapy is another recent treatment strategy for 
leukemia. The therapy resulted in long term remission in acute lymphoblastic leukemia 
(leukemia and lymphoma society 2018). FLT3-CAR T cells has been demonstrated to 
effectively target FLT3 expressing AML blasts as well as FLT3 expressing cell lines. It 
has been shown that combinatorial treatment of immunotherapy with TKI treatment 
increased FLT3 surface expression especially in FLT3 positive AML cells and thus, 
enhanced recognition of malignant cells by CAR T cells (Reiter et al. 2018, Jetani et al. 
2018, Wang et al. 2018).  
Another promising AML treatment strategy may be the use of monoclonal FLT3 
antibodies. An Fc-optimized antibody directed to FLT3 (termed 4G8SDIEM) has been 
shown to induce strikingly enhanced cellular toxicity in FLT3 expressing cell lines and 
AML blasts (Hofmann et al. 2012). Last year, the biotechnology company SYNIMMUNE 
presented the first Fc-optimized FLT3 directed antibody (FLYSYN) which is used for 
phase I clinical studies in AML patients (Steiner 2017). 
1.4 Protein-tyrosine phosphatases 
Dysregulation of tyrosine phosphorylation processes can result in uncontrolled growth, 
undifferentiated phenotype, impaired apoptosis and increased migration which are 
characteristics of neoplastic and metastatic diseases. Aberrant PTP signaling is 
frequently linked to human diseases including cancer, diabetes, as well as 
cardiovascular, autoimmune and neuropsychiatric disorders (Östman et al. 2006, Tonks 
2006, Julien et al. 2011, Hendriks and Pulido 2013, Böhmer et al. 2013a, Alonso et al. 
2004, Tautz et al. 2013). Thus, PTP may have the potential to be used as important drug 
targets and molecular markers in the clinic. Within the PTK family several PTK were 
identified to have an oncogenic potential. Since PTP counter the activity of PTK it has 
been assumed that PTP act mainly as tumor suppressors. However, PTP can also 
activate PTK function. By dephosphorylation of inhibitory tyrosine residues PTP can 
activate PTK which potentially lead to increased proliferation and activation of known 
cancer pathway, e.g. Src. The activity of PTK and PTP is a dynamic process which may 
also result in mutual activation (Fournier et al. 2016). 
Most PTP have a catalytic cysteine in their PTP domain. They can be grouped into 3 
classes. Class I consists of 111 PTP and represent the biggest class of PTP. It is further 
subclassified into classical PTP and dual-specific protein phosphatases (DUSP) 
representing the two biggest subgroups and 4 further groups with few members only 
(Alonso et al. 2016). The classical PTP are further subdivided into 20 receptor-like 
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protein tyrosine phosphatases (RPTP) and 17 non-receptor protein tyrosine 
phosphatases (NRPTP). 13 out of these 20 RPTP contain two conserved intracellular 
catalytic domains. The membrane proximal domain D1 harbors the catalytic activity and 
the membrane distal domain D2 as well as the C terminal domain has regulatory 
function (Barnea et al. 2016). Intracellular and extremely variable extracellular segments 
are linked by a transmembrane domain (Alonso et al. 2004, Fischer et al. 1991, Alonso 
et al. 2016). Some RPTP, e.g. Ptprj, have a single intracellular catalytic domain only 
(Östman et al. 1994).  
The majority of PTP are post-translationally modified whereby RPTP are mainly 
glycosylated. N- and O- linked carbohydrates are linked to the extracellular domain of 
RPTP. Glycosylation is the prerequisite for surface localization and prop 
er maturation of the proteins. Furthermore the catalytic cysteine of the PTP domain of 
class I and class II PTP is highly susceptible to reversible oxidation by ROS, which leads 
to inactivation of PTP activity (Alonso et al. 2004).  
1.4.1 Receptor protein-tyrosine phosphatase J (Ptprj) 
1.4.1.1 Structure and expression profile of Ptprj 
Receptor protein-tyrosine phosphatase J, also designated as HPTP-, CD148 or density 
enhanced phosphatase 1 (DEP-1) is encoded by the Ptprj gene. In 1994 two separate 
groups characterized Ptprj in WI-38 human embryonic lung fibroblasts cell line (Östman 
et al. 1994) or in the human leukemic cell line F36O (Honda, Inazawa et al. 1994). In 
humans the gene is located at the short arm of chromosome 11 (11p11.2). Human Ptprj 
is composed of a 970 aa long extracellular domain comprised of eight fibronectin-type   
III-like (FN-III) domains, a transmembrane domain of 25 aa and an intracellular region of 
342 aa containing a single phosphatase domain with intrinsic phosphatase activity 
(Figure 4) (Östman et al. 1994, Honda et al. 1994). An alternative splice variant of 
human Ptprj exists, called sPtprj with 539 aa corresponding to the N-terminus of Ptprj 
extracellular domain. 1996 murine and rat homologues of Ptprj have been identified, 
exhibiting the same structure as the human Ptprj. Murine Ptprj reveals 71 % sequence 
identity of the entire protein compared to human Ptprj.  
Surface localized Ptprj is highly glycosylated at several residues and has a molecular 
weight of 180 - 230 kDa in all species. Unglycosylated Ptprj has a molecular weight of 
148 kDa (de la Fuente-Garcia et al. 1998).  
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High expression levels of murine Ptprj were found in brain, kidney, spleen, liver, 
intestines and low level in all other tissues (Kuramochi et al. 1996, Honda et al. 1993).  
Initial studies on adherent cell lines demonstrated a density-dependent increase of Ptprj 
with highest expression level before the saturation of culture had been reached (Östman 
et al. 1994, Keane et al. 1996). It was shown that Ptprj is involved in VE-cadherin 
mediated cell contact inhibition in endothelial cells by dephosphorylation of VEGFR and 
inhibition of proliferative ERK1/2 pathway (Grazia Lampugnani et al. 2003). Flow 
cytometric analyses demonstrated Ptprj expression on all human hematopoietic lineages 
with higher intensity on granulocytes than on monocytes and lymphocytes, on peripheral 
blood lymphocytes, including CD4 and CD8 positive T cells, B cells, platelets, NK cells, 
mature thymocytes, dendritic cells and microglia (Schneble et al. 2017). However, a low 
expression level of Ptprj has been demonstrated in cell lines of B and T cell origin (de la 
Fuente-Garcia et al. 1998, Gaya et al. 1999).  
 
1.4.1.2 Ptprj mode of action  
Both, positive and negative regulation of different signal transduction pathways in 
hematopoietic cells, have been described for Ptprj including platelets (Senis et al. 2009, 
Mori et al. 2012), T cells (de la Fuente-Garcia et al. 1998, Tangye et al. 1998), B cells 
(Skrzypczynska et al. , Zhu et al. 2008), macrophages (Zhu et al. 2008) and myeloid 
cells (Jayavelu et al. 2016, Arora et al. 2011, Godfrey et al. 2012). Inhibited breast 
cancer and colon carcinoma growth have been reported due to increased Ptprj 
expression, introducing Ptprj as tumor suppressor gene with a regulatory function on cell 
growth (Keane et al. 1996, Balavenkatraman et al. 2006). Loss of the short arm of 
chromosome 11, including Ptprj gene, has been detected in various tumors like breast 
cancer, cell carcinoma of bladder, hepatoblastoma and hepatocellular carcinoma 
(Ruivenkamp et al. 2002). Loss of heterozygosity of Ptprj as well as single nucleotide 
Figure 4. Schematic drawing of Ptprj. Ptprj 
is a transmembrane PTP consisting of an 
extracellular domain composed of eight 
fibronectin-type III-like domains, a 
transmembrane domain and an intracellular 
part with phosphatase domain (according to 
(Müller et al. 2012)). 
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polymorphisms (SNP) have been demonstrated in thyroid tumors where Ptprj is 
downregulated compared to normal thyroid tissues (Iuliano et al. 2004). Low levels or 
loss of Ptprj have been also observed in colon, mammary and lung cancer (Trapasso et 
al. 2000), inflamed tissues and high grade carcinomas (Autschbach et al. 1999). 
Furthermore, Ptprj has been indicated as a candidate for the mouse colon cancer 
susceptibility locus, Scc1 (Ruivenkamp et al. 2002).  
Besides tumor suppressor functions of Ptprj further studies indicate pro-tumorigenic 
functions of Ptprj. In vivo studies in Ptprj-/- mice revealed an essential role of Ptprj in 
tumor-associated angiogenesis and introduced stroma derived Ptprj as a promoter of 
tumor progression (Fournier et al. 2016). In addition, an alternative splicing variant of 
Ptprj (sPtprj), was shown to have pro-angiogenic activity in HUVEC cells. It has been 
demonstrated that sPtprj is upregulated in glioblastoma, one of the most angiogenic 
tumors (Bilotta et al. 2017).  
 
1.4.1.3 Substrates of Ptprj 
Within others known substrates Ptprj phosphorylates growth factor receptors and PTK 
like PDGF (Kovalenko et al. 2000); VEGFR2 (Chabot et al. 2009), MET (Palka et al. 
2003), Lyn (Skrzypczynska et al.), Fyn (Schneble et al. 2017), ERK1/2 (Sacco et al. 
2009), FLT3 WT as well as FLT3 ITD (Arora et al. 2011, Godfrey et al. 2012). An 
interplay of VEGFR2 and Ptprj which leads to activation of Ptprj and subsequently 
dephosphorylation of Src kinase (Spring et al. 2012, Fournier et al. 2016, Le Pera et al. 
2016). Src activity is regulated by two phosphorylation sites: an inhibitory tyrosine and 
an autophosphorylation site.  Originally identified in chicken activating tyrosine residue is 
at position 416 and inhibitory tyrosine residue 527 (Cooper et al. 1986, Weijland et al. 
1996). In mouse Src activity is regulated by tyrosine residues 424 (activating) and 535 
(inhibitory) whereas in humans it is regulated by tyrosine residues 419 (activating) and 
530 (inhibitory). Autophosphorylation of Y416 is dependent on previous 
dephosphorylation of the inhibitory Y527. Phosphorylation sites of Src differ slightly in 
different organisms. Upon Src activation subsequent AKT activation was demonstrated 
(Chabot et al. 2009). Taken together Ptprj is an important regulator of several cancer 
pathways such as Ras/ERK1/2, Src and PTEN/PI3K/AKT pathway and shows up mainly 
as a tumor suppressor gene.  
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1.4.1.4 Phenotype of Ptprj-/- mice 
At organismic level inactivation of Ptprj in mice by in frame replacement of intracellular 
domain with enhanced green fluorescent protein (GFP) resulted in severe 
developmental consequences, defects of vascularization and early mortality (Takahashi 
et al. 2003). Mice lacking Ptprj expression in all cells of hematopoietic origin displayed 
normal life span but partially impaired B cell development (Zhu et al. 2008). Total genetic 
ablation of Ptprj is reported to result in normal growth, viability, fertility and development 
and does not predispose to spontaneous tumorigenesis (Trapasso et al. 2006).  
 
1.4.1.5 Role of Ptprj on FLT3 and FLT3 ITD  
In 2011 Ptprj has been identified to negatively regulate FLT3 WT signaling and activity in 
vitro (Arora et al. 2011). Is was also shown that Ptprj directly interacts with FLT3 WT 
(Böhmer et al. 2013b). Downrregulation of Ptprj resulted in increased AKT and ERK1/2 
phosphorylation. Overexpression of Ptprj resulted in decreased phosphorylation of AKT 
and ERK1/2 phosphorylation. Moreover, it has been shown that FLT3 was 
hyperphosphorylated in murine myeloblast-like 32D cell line expressing murine FLT3 WT 
protein (named subsequently 32D muFLT3 WT) cells but not in 32D cell line transduced 
with murine oncogenic FLT3 ITD (named subsequently 32D muFLT3 ITD (Grundler et al. 
2005)) and MV4-11 cells. In vitro investigations on FLT3 ITD revealed high ROS levels 
that oxidize catalytic cysteine of Ptprj and thus impair phosphatase activity. Quenching 
of cellular ROS levels reactivated Ptprj leading to dephosphorylation of FLT3 ITD in cells 
in vitro (Godfrey et al. 2012). The origin of high ROS levels in cells overexpressing FLT3 
ITD and in FLT3 ITD positive primary AML samples has been identified in NADPH 
oxidase 4 (Nox4), a downstream target of activated STAT5 in oncogenic FLT3 ITD 
signaling pathway (Jayavelu et al. 2016).  
Gene expression study of 285 adults with AML (Valk study GEO accession GSE1159 
(Valk et al. 2004)) revealed a negative correlation of Ptprj downregulation and patient 
survival in FLT3 ITD positive AML patients (Figure 5A). Patients carrying FLT3 ITD 
mutation and low levels of Ptprj showed a close to significant lower overall survival 
probability than patients carrying FLT3 ITD with high expression of Ptprj. To the contrary, 
high Ptprj expression level in AML patients bearing FLT3 WT showed decreased overall 
survival probability compared to FLT3 WT AML patients with low Ptprj expression level 
(Figure 5B). These data may indicate an important role of Ptprj in development of FLT3 
ITD-driven AML. 
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Figure 5. Ptprj expression affects prognosis of AML patient. Overall survival of AML patients (GEO 
accession GSE1159 (Valk et al. 2004)) with low (red, dotted) and high (blue) PTPRJ expression in FLT3 ITD 
and FLT3 WT background. Survival curves of AML FLT3 ITD positive (A, cutoff = 33.3, p = 0.07) and FLT3 
WT patients (B, cutoff = 34.9, p = 0.21) are presented. 
 
1.4.1.6 Ptprj as clinical target 
The tumor suppressor role of Ptprj has been identified in several human cancers as 
mentioned above. Preclinical models of human thyroid and pancreatic tumors have 
demonstrated the possibility of using Ptprj as a therapeutic target (Iuliano et al. 2003, 
Trapasso et al. 2004). In addition, activation of tumor suppressor function of Ptprj by 
agonists showed beneficial effects in clinical trials. Paduano et al. identified a Ptprj 
agonist peptide from a random peptide phage that activates Ptprj by binding, leading to 
reduced ERK1/2 phosphorylation, proliferation and increased apoptosis (Paduano et al. 
2012). Ortuso and colleagues discovered another Ptprj agonist peptide (PTPRJ-
pep19.4) and revealed that the peptide inhibits proliferation in breast cancer cells as well 
as ERK1/2 phosphorylation but has no effect on normal breast cells (Ortuso et al. 2013). 
Thrombospondin1 and Syndecan-2 have been identified as naturally occurring ligands of 
Ptprj. Increased PTP activity has been demonstrated upon Thrombospondin1 binding 
(Takahashi et al. 2012, Whiteford et al. 2011). In combination with bone morphogenic 
protein 4 (BMP4) Thrombospondin1 inhibited tumor angiogenesis and suppressed 
growth of solid tumors (Tsuchida et al. 2014).  
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1.4.2 Receptor protein-tyrosine phosphatase C (Ptprc) 
1.4.2.1 Structure and expression profile of Ptprc 
In the middle of 1970s, Ptprc was identified by two independent groups characterizing 
the functionally important ‘leukocyte specific antigen’ (Trowbridge et al. 1975, Fabre and 
Williams 1977). In 1988 CD45 was identified as first RPTP based on aa sequence 
homology with PTP1B and PTP activity in CD45-containing cell fractions (Charbonneau 
et al. 1988, Tonks et al. 1988). CD45, encoded by the Ptprc gene, is also designated as 
lymphocyte common antigen (L-CA), T200, B220, or Ly-5. Ptprc consists of a variable, 
isoform-specific extracellular domain of 391-552 aa, a membrane spanning domain of 21 
aa and a 704 aa large intracellular part consisting of a tandem phosphatase domain (D1 
and D2, each 300 aa) and a C-terminal domain (about 80 aa) (Thomas et al. 1985). In 
mammals the Ptprc gene consists of 35 exons. Exons 4(A), 5(B), 6(C) and 7 are 
involved in alternative mRNA splicing and generate RA, RB and RC isoforms of Ptprc. 
Due to alternative splicing several theoretical splicing variants are possible but just 6 has 
been observed in reasonable levels, in particular isoform E3_8, (lacking exons 4-7, no 
O-linked glycosylation), CD45RO (lacking exons 4-6), CD45RB (carrying exon 5), 
CD45RAB (carrying exons 4 and 5), CD45RBC (carrying exons 5 and 6) and 
CD45RABC (carrying exons 4-6) (Holmes 2006).  
Among all Ptprc isoforms the extracellular part consists of 3 membrane proximal FN-III 
domains and a cysteine-rich domain followed by variable N-terminal end. The FN-III 
domains are highly N-glycosylated and important mediators of CD45 stability and 
maturation to the cell surface (Sato et al. 1993, Pulido and Sanchez-Madrid 1992). Since 
the majority of O-glycosylation of CD45 can be found in the alternatively spliced region 
encoded by exon 3 to exon 8, different CD45 isoforms vary extensively in their O-
glycosylation patterns (Figure 6) (Trowbridge and Thomas 1994, Thomas et al. 1985). 
Within different species (human, mouse, rat) the cytoplasmic domain of Ptprc exhibits 
90 % sequence identity whereas in the extracellular part these proteins share 50 % 
sequence identity only (Thomas et al. 1987). Ptprc has been detected in all higher 
mammals so far, in chicken and lower vertebrates as horn shark (Heterodontus francisci) 
and hagfish (Myxini), indicating that Ptprc is evolutionary conserved (Matthews et al. 
1990).  
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Isoforms have been expressed in cell type specific and differentiation-dependent manner 
in all nucleated hematopoietic cells but not on mature erythrocytes and platelets (Hall et 
al. 1988, Trowbridge et al. 1991, Thomas 1989). In addition, Ptprc has been detected in 
cells of hematopoietic origin like osteoclasts and microglia (Tan et al. 2000, Boyle et al. 
2003, Shivtiel et al. 2008). It represents 5 - 10 % of all cell surface proteins of B and T 
cells. Due to isoform specific expression Ptprc has a molecular weight of 180-220 kDa. 
In B cells the highest 220 kDa form is expressed whereas in immature thymocytes the 
180 kDa form has been predominantly found. Furthermore, Ptprc has been 
demonstrated to be one of the most abundantly expressed PTP in primary AML cells as 
well as in AML cell lines (Arora et al. 2012).  
 
1.4.2.2 Ptprc mode of action  
The intracellular part of Ptprc comprises a tandem phosphatase domain. In the 
membrane proximal D1-domain (Figure. 6) phosphatase activity has been demonstrated 
whereas in membrane distal D2-domain not (Figure 6). Sequence and mutagenesis 
studies have revealed that the aa proline (pro1517), serine (ser1523), alanine (ala1524), 
glycine (gly1525) and arginine (arg1528) surrounding the catalytic cysteine (cys1522) 
match the PTP consensus motive (V/I)HCSAG(V/I)GR(T/S)G and are essential for PTP 
activity in D1. In D2, in the sequence VHCRDGSQQTG 5 aa varied from the consensus 
sequence. By insertion of D2 sequence in D1 the PTP activity was abrogated (Streuli et 
al. 1990). Deletion of the D2 domain also suppressed PTP activity, indicating a 
regulatory function of D2 itself or of the C-terminal domain. Regulation of PTP activity by 
dimerization of CD45 has also been demonstrated (Majeti et al. 1998). Dimer formation 
is more likely for the small CD45RO isoform than for the highly glycosylated CD45RABC 
Figure 6. Schematic 
drawing of Ptprc. Ptprc is 
composed of a variable 
glycosylated extracellular 
domain with cysteine-rich 
domain and three FN-III 
domains, a 
transmembrane domain 
and an intracellular domain 
with tandem phosphatase 
domain and C-terminal tail 
(modified according to 
(Müller et al. 2012)). 
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isoform, depending on charged carbohydrate residues (Xu and Weiss 2002). 
Localization in membrane subdomains has also been demonstrated to play an important 
role in Ptprc activity due to the accessibility of specific substrates and phosphorylation 
(Wang et al. 1999). Transient oxidation has also been reported to regulate Ptprc activity 
(Singh et al. 2005). However, own studies indicated no ROS mediated inactivation of 
Ptprc in FLT3 ITD expressing AML cells, as opposed to other PTP in these cells 
(Godfrey et al. 2012). 
So far, a number of Ptprc ligands have been identified but most of them are not binding 
exclusively to Ptprc. Some of the ligands are only present under certain clinical 
conditions like an ongoing infection or in pregnancy and there seems to be no natural 
extracellular ligand that can be found in all healthy adults. pUL11, a transmembrane 
protein of the cytomegalovirus RL11 (CMV RL11) family, has been identified as CD45 
ligand (Gabaev et al. 2014). Interaction of pUL11 with CD45 led to impaired T cell 
receptor (TCR) signaling and inhibited T cell development. Another ligand which has 
been identified is placental protein 14 (PP14), a glycoprotein expressed by endometrial 
deciduas during the first and second trimesters of pregnancy (Morrow et al. 1994). 
Because of its lectin-like properties it binds to CD45 and thereby leads to dimerization 
and inactivation of CD45 PTP activity.  
 
1.4.2.3 Ptprc substrates and signaling  
Ptprc is capable to dephosphorylate C-terminal and kinase domain phosphotyrosines in 
several SFK. Thereby the consequences of Ptprc action depend on site of 
phosphorylation and on the subcellular localization relative to its substrate (Gupta and 
DeFranco 2003, Thomas and Brown 1999). Dephosphorylation of SFK C-terminal 
phosphotyrosines e.g. pY505 of Lck activates the kinases whereas dephosphorylation of 
phosphotyrosines in the kinase domain, e.g. pY394 of Lck inhibit kinase activity. It has 
been demonstrated that Ptprc acts on C-terminal tyrosine of Lyn, Src, Fyn and Hck. 
Thereby the kinases were kept in a primed, slightly active state to get fully activated after 
antigen receptor stimulation (Stone et al. 1997, Trowbridge and Thomas 1994). 
Controversially, studies in Ptprc ko cells revealed no change in overall activity of the Lck 
and Fyn (Majeti et al. 1998). Conclusively, Ptprc acts as a positive and negative 
regulator of SFK (regulatory mechanism as described for Src in chapter 1.4.1.3).  
Moreover Ptprc targets janus kinase family (JAK) receptors and therefore negatively 
regulates cytokine receptor signaling involved in differentiation, proliferation and antiviral 
immunity of hematopoietic cells (Irie-Sasaki et al. 2001). Ptprc plays an important role for 
innate immunity. It is furthermore required for TCR and B cell receptor (BCR) mediated 
signaling (Justement et al. 1991, Desai et al. 1994). In mice, CD45 knockout could not 
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fully unmask the role of CD45 in B cells due to the expression of the receptor protein 
tyrosine phosphatase CD148 (Autschbach et al. 1999). Mice genetically inactivated for 
CD45 and CD148 show a very early block in B-cell development. Thus, CD45 and 
CD148 share a certain level of functional redundancy in B cells and the myeloid lineage 
(Zhu et al. 2008). However, more recent work has demonstrated that there are other 
non-overlapping functions of Ptprc and Ptprj in B cells. Ptprj was more important for B1 
BCR signaling than Ptprc (Skrzypczynska et al. 2016, Zikherman et al. 2012).  
In conclusion, Ptprc has a positive role in regulating TCR signal transduction in mature 
and immature T cells. CD45 regulates both, positive and negative selection of B cells 
(Cyster et al. 1996).  
 
1.4.2.4 Consequences of Ptprc inactivation 
Three distinct Ptprc knockout mouse strains were created lacking either exon 6 
(Kishihara et al. 1993), exon 9 (Byth et al. 1996) or exon 12 (Mee et al. 1999). 
Consistent in all Ptprc ko mice B cell development appeared normal. In mice lacking 
Ptprc exon 6 low remaining levels of CD45 were still detected due to the fact that some 
CD45 isoforms skip the mutated exon 6 by alternative splicing. A block of early 
thymocyte development, block of T cell development at transition of immature CD4+ 
CD8+ double positive cells to mature CD4+ or CD8+ T cells and strikingly, reduced 
amounts of T cells in peripheral lymphoid organs have been observed. Furthermore, 
reduced cytotoxic cell response after challenge with lymphocytic choriomeningitis virus 
(LCMV) has been demonstrated in Ptprc ko mice (Kishihara et al. 1993, Byth et al. 1996, 
Mee et al. 1999). Genetic inactivation of Ptprc was associated with reduced homing and 
reduced G-CSF mobilization of progenitor cells. Moreover, mice inactivated for Ptprc had 
less primitive cells in the BM but increased numbers of these cells in the spleen, yet with 
reduced homing and repopulation potential (Shivtiel et al. 2008). Interestingly, reduced 
bone turnover and impaired bone remodeling processes resembling a mild osteopetrosis 
have been observed in Ptprc ko mice. Moreover, an abnormal pattern of trabecular 
distribution has been demonstrated in femurs of Ptprc ko mice (Shivtiel et al. 2008). 
 
1.4.2.5 Clinical impact of Ptprc 
Ptprc plays a significant role in B and T cell development, autoimmune diseases and 
cancer as well as in infectious diseases including fungal infections. Loss of function 
mutations and a SNP at nucleotide 77, precisely C77G, were associated with disease 
development and virus susceptibility, reviewed in Hendriks & Pubilo 2013 and 
Rheinländer 2018 (Hendriks and Pulido 2013, Rheinländer et al. 2018). 
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Ptprc ko mice and humans develop severe combined immune deficiency (SCID) with 
defective T and B cell development and function (Tchilian et al. 2001b, Roberts et al. 
2012, Kung et al. 2000). A causative role of Ptprc in multiple sclerosis (MS) has been 
proposed (Nakahara et al. 2005). The C77G SNP has been detected to be associated 
with MS in several families (Jacobsen et al. 2000). This SNP does not result in change 
of aa sequence but blocks the alternative splicing of exon 4 (Thude et al. 1995). 
However, results of subsequent, much larger studies rather argue against an association 
between this Ptprc C77G SNP and MS (Szvetko et al. 2009). Interestingly, during these 
studies the C77G SNP has been found at a much higher frequency in hepatitis C virus-
infected patients than in healthy controls (Dawes et al. 2006). Furthermore this SNP has 
been correlated to increased risk of HIV infection (Tchilian et al. 2001a). 
An attenuating role of Ptprc on FLT3 WT has been demonstrated (Arora et al. 2011, 
Stopp 2009). Studies on the question if Ptprc is also negatively controlling the activity of 
mutated FLT3 ITD activity are still pending. Gene expression study of blasts from 285 
adults with AML (GEO ID GSE1159 (Valk et al. 2004), Figure 7A) and from BM or 
peripheral blood of 163 untreated AML patients with normal karyotype (GEO ID 
GSE12417 (Metzeler et al. 2008), Figure 7B) revealed negative correlation of diminished 
Ptprc activity and patient survival in FLT3 ITD mutated AML patients. In AML patient 
carrying FLT3 WT receptor no correlation has been observed between Ptprc activity and 
patient survival (Figure 7). Thus, it is tempting to speculate, that Ptprc negatively 
regulate FLT3 ITD activity, contributing to patient survival. 
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Figure 7. PTPRC expression is inversely correlated to survival of FLT3 ITD positive AML patients. 
Overall survival of patients with low (red, dotted) and high (blue) PTPRC expression is depicted. Data are 
based on data sets of Valk (Valk et al. 2004) (GEO-ID GSE1159, A) and Metzeler (Metzeler et al. 2008) 
(GEO ID GSE12417, B). Survival curves of AML FLT3 ITD positive (left) and FLT3 WT (right) patients as 
well as p values are presented. 
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2. Aims of the study 
Despite development and approval of small tyrosine kinase inhibitors (TKI) targeting 
FLT3 ITD, AML patients frequently relapse partially due to additional acquired mutations 
on FLT3 ITD resulting in resistance of kinases to TKI.  
 
Recently, our research group demonstrated an inhibitory role of Ptprj/DEP-1 and 
Ptprc/CD45 on FLT3 WT in a model cell system (Arora et al. 2011). In addition, 
counteracting activity of Ptprj on FLT3 ITD was also demonstrated in vitro (Godfrey et al. 
2012). Accompanying array data revealed that the survival of normal karyotype FLT3 
ITD positive AML patients with low level of Ptprj or Ptprc, respectively was shorter than 
in patients with high level of the particular phosphatase (Valk et al. 2004, Metzeler et al. 
2008).  
 
The purpose of this dissertation is therefore the deeper assessment of the role of Ptprj 
and Ptprc in regulating the oncogenic activity of AML-related oncoprotein FLT3 ITD in 
vitro and in vivo. For this aim, the following goals are to be addressed: 
 
I) Assessing the effect of complete inactivation of Ptprj, Ptprc or both in model 
cell systems in vitro. By using CRISPR/Cas9 system genes encoding Ptprj 
and/or Ptprc shall be inactivated in 32D muFLT3 ITD myeloid progenitor cells 
to investigate the effects on FLT3 ITD activity as well as downstream 
signaling. 
 
II) Study the role of Ptprj and Ptprc on FLT3 ITD-driven myeloproliferative 
disease in vivo. FLT3 ITD knockin mice (FLT3ITD/ITD) expressing the 
oncoprotein under control of its endogenous promoter shall be mated to 
either Ptprj-/- or Ptprc-/- mice to obtain homozygous FLT3ITD/ITD Ptprj-/- and 
FLT3ITD/ITD Ptprj-/- mice. These double mutated mice shall be analyzed 
regarding organ weight and architecture, hematopoiesis, blood cell 
composition in BM and peripheral organs and further possible physiological 
phenotypes. Moreover, FLT3 ITD phosphorylation shall be investigated in 
FLT3ITD/ITD mice genetically inactivated for RPTP as well as potentially 
abrogated downstream signaling of oncogenic FLT3 ITD (Figure 8). 
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The identification of natural antagonists of FLT3 ITD might provide new strategies for 
treatment of FLT3 ITD-driven AML because activation of FLT3 ITD counterparts should 
lower FLT3 ITD activity and its transforming potential. 
 
 
Figure 8. Schematic presentation of proposed actions of Ptprj and Ptprc on oncogenic FLT3 ITD.  
The potential antagonistic activity of Ptprj and Ptprc on oncogenic FLT3 ITD activity will be investigated. 
Especially FLT3 ITD phosphorylation and downstream signaling will be analyzed. In addition, physiological 
effects in hematopoiesis shall be checked as well as potential further effects. 
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3. Material 
3.1 Cell work  
3.1.1 Cell lines  
Table 1: Used and generated cell lines  
Cell line Description Plasmid 
backbone 
Origin/Source 
32D muFLT3 ITD murine myeloblast-like cell 
line, transduced with FLT3 
ITD-GFP  
pMSCV-IRES-
GFP 
provided by Dr. 
Justus Duyster and 
Dr. Rebecca 
Grundler, Munich, 
Germany (Grundler 
et al. 2005) 
32D muFLT3 ITD  
Ptprj ko  
32D muFLT3 ITD cells with 
CRISPR mediated Ptprj 
knockout (clone 1) 
lentiCRISPRv2  
 
 
 
 
 
 
 
generated within 
the scope of this 
project 
 
32D muFLT3 ITD  
Ptprc ko I 
32D muFLT3 ITD cells with 
CRISPR mediated Ptprc 
knockout (clone 1) 
pX330-
mCherrymut  
32D muFLT3 ITD  
Ptprc ko II 
32D muFLT3 ITD cells with 
CRISPR mediated Ptprc 
knockout (clone 2) 
pX330-
mCherrymut 
32D muFLT3 ITD  
Ptprj/Ptprc ko I 
32D muFLT3 ITD cells with 
CRISPR mediated double 
phosphatase knockout of 
Ptprj and Ptprc 
lentiCRISPRv2 
32D muFLT3 ITD  
Ptprj/ Ptprc ko II 
32D muFLT3 ITD cells with 
CRISPR mediated double 
phosphatase knockout of 
Ptprj and Ptprc 
lentiCRISPRv2 
32D muFLT3 ITD 
empty vector 
32D muFLT3 ITD cells 
transduced with non-
targeting lentiCRISPRv2 
vector 
lentiCRISPRv2 
HEK293T human embryonic kidney 
cell line 
- Leibnitz Institute 
DSMZ 
3.1.2 Cell culture 
Table 2: Medium additives used for cell culture 
Additives Company (Order number) 
1,5-dimethyl-1,5-
diazaundecamethylenepolymethobromide 
(Polybrene) 
Sigma Aldrich (Tr-1003) 
AC220 (Quizartinib) Sigma Aldrich (kind gift from S. 
Mahboobi; University of Regensburg) 
CellTiter-Blue Reagent Promega (G8080) 
Diphenyleneiodonium chloride (DPI) Sigma Aldrich(D2926) 
Fetal bovine serum (FBS)  PAN BioTech (P40-37500) 
IL-3 ImmunoTools (12340032)  
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Iodonitrotetrazoliumchloride Sigma Aldrich (I8377) 
Penicillin/ Streptomycin solution Sigma Aldrich (P0781) 
PKC412 (Midostaurin) Selleckchem (S8064) 
Polyethylenimine (PEI) Sigma Aldrich (408727)  
Puromycin (puromycin dehydrochloride) Sigma Aldrich (P8833) 
Sodium pyruvate Sigma Aldrich (S8636) 
3.1.3 Plasmids 
Table 3: Plasmids 
Name  Description Source 
pX330-mCherrymut   CBh promotor, encodes 
Cas9-Flag, PCMV 
promotor, mCherry 
sequence without BbsI site  
 
kindly provided my Melanie 
Kahl (Jena, 2014) 
lentiCRISPRv2 Lentivector, EFS-NS 
promotor, encodes Cas9-
Flag, Puromycin resistance 
gene  
Addgene (Sanjana et al. 
2014) 
  
pPAX2 lentiviral packaging for 2nd 
generation vectors 
Addgene-Trono Lab 
Packaging and Envelope 
plasmids 
pVSVg viral envelope Kindly provided by Carol 
Stocking, University of 
Hamburg 
pRSV 3rd generation lentiviral 
packaging plasmid 
Addgene-Trono Lab 
Packaging and Envelope 
plasmids 
pMDL lentiviral packaging for 3rd 
generation vectors, 
(Contains Gag and Pol) 
Addgene-Trono Lab 
Packaging and Envelope 
plasmids 
3.1.4 Enzymes 
Table 4: List of enzymes used for CRISPR/Cas9 cloning 
Enzyme Company 
BbsI (for pX330-mCherrymut restriction) New England Biolabs 
BsmBI (for lentiCRISPRv2 restriction) New England Biolabs 
Shrimp alkaline phosphatase New England Biolabs 
RNase A  Applichem 
Ligase ZIMET, Akademie der Wissenschaften der 
DDR 
Polynucleotidkinase (PNK) Fermentas 
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3.1.5 gRNA 
Table 5 List of gRNA oligonucleotides  
Name Sequence 5 ’ - 3 ’ 
muPtprj FW CACCGGCCGCGGCCTTAGACTCGCAGGG 
muPtprj REV AAACCCCTGCGAGTCTAAGGCCGCGGC 
muPtprc FW CACCGCACAAACCCATGGTCATATCTGG 
muPtprc REV AAACCCAGATATGACCATGGGTTTGTGC 
3.2 Antibodies 
3.2.1 Flow cytometric Antibodies 
Table 6: List of antibodies for flow cytometry 
Antibody Clone Specificity Label Company 
7AAD - mouse - BD Pharmingen 
Annexin V - mouse FITC BD Pharmingen 
Annexin V - mouse PE Immunotools 
CD11b (Mac-1) M1/70 mouse APC eBioscience 
CD135 A2F10.1 mouse PE BD Pharmingen 
CD148 (Ptprj) MO86-5 mouse PE MBL 
CD19 eBio1D3 mouse FITC eBioscience 
CD19 1D3 mouse biotin BD Pharmingen 
CD3 145-2C11 mouse PerCP-Cyannine 5.5 eBioscience 
CD45 30-F11 mouse PE eBioscience 
c-Kit (CD117) 2B8 mouse APC eBioscience 
Gr-1 (Ly6G/Ly6C) RB6-8C5 mouse PE Biolegend 
Sca-1 (Ly6A/E) D7 mouse PE-Cyannine 7 eBioscience 
Streptavidin - mouse PerCP BD Pharmingen 
3.2.2 Western Blot Antibodies 
Table 7: List of Antibodies (Western Blot Analysis)* 
Antibody  Order 
number 
Size [kDa] Reacti
vity 
Host Dilution  Company 
-actin A5441 42 mouse/ 
human 
Mouse 1 : 5 000 Sigma 
Aldrich 
4G10 (pY) 05-321 - mouse/ 
human 
Mouse 1 : 1 000 Upstate 
AKT #9272 60 mouse/ 
human 
Rabbit 1 : 1 000 Cell 
Signaling 
CD45 AF114 147 mouse Goat 1 : 3 620 R&D 
Systems 
SFK 
(Y416)** 
#2101 60  mouse/ 
human 
Rabbit 1 : 1 000 Cell 
Signaling 
DEP-1 AF1934 146 mouse/ 
human/
rat 
Goat 1 : 500 R&D 
Systems 
ERK1/2  #9107 42/44 mouse/ 
human 
Mouse 1 : 5 000 Cell 
Signaling 
pAKT 
(S473) 
#4060 60 mouse/ 
human 
Rabbit 1 : 1 000 Cell 
Signaling 
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panFLT3  AF768 130/150*** mouse Goat 1 : 1 250 R&D 
Systems 
pERK1/2 
(T202/Y204) 
E10 
#9106 42/44 mouse/ 
human 
Mouse 1 : 1 000 Cell 
Signaling 
pFLT3 
(Y589) 
- 130/150*** mouse/ 
human 
Rabbit 1 : 500 Donation 
from Lars 
Rönnstrand  
pFLT3 
(Y591) 
#3461 130/150*** mouse/ 
human 
Rabbit 1 : 1 000 Cell 
Signaling 
pSTAT5 
(Y694) 
ab32364 90 mouse/ 
human 
Rabbit 1 : 1 000 Abcam 
cSRC sc-18 62/59/55 mouse/ 
human 
Rabbit 1 : 1 000 Santa Cruz 
STAT5 sc-835 90 mouse/ 
human 
Rabbit 1 : 1 000 Santa Cruz 
*Primary antibodies used for Western Blot detection were diluted in 1x TBS-Tween 
supplemented with 1 % BSA and 0.02 % sodium azide. 
**Activating tyrosine residue is indicated as Y416 (as originally indicated in chicken), 
activating Src tyrosine residues in mouse and human vary (see chapter 1.4.1.3.). Thus, 
antibodies detecting activating tyrosine residue of Src are commonly named Y416. 
***High-mannose and highly glycosylated form of FLT3 kinase. 
 
Table 8 Secondary antibodies (Western Blot)* 
Antibody Host Order Number Company 
Anti-goat Donkey sc-2020 Santa Cruz 
Anti-mouse Goat 074-1806 KPL 
Anti-rabbit Goat 074-1506 KPL 
* The secondary antibodies are horseradish peroxidase labeled. They were diluted     
1 : 10 000 in TBS-Tween supplemented with 1 % BSA. 
 
3.2.3 Immunohistochemistry Antibodies 
Table 9: Antibodies used for Immunohistochemistry 
Antibody Type Dilution Host Order 
number 
Company  
AF488 Donkey 
anti-Rabbit IgG 
secondary 1 : 250 Donkey A21206 Invitrogen 
biotin-SP 
conjugated 
Donkey anti-
Rabbit IgG  
secondary 1 : 200 Donkey 711-065-152 Dianova 
CD41 (Integrin 
Alpha2b) 
primary 1 : 500 Rabbit PB9647 Boster Biological 
Technologies 
Myeloperoxidase 
Ab-1 (MPO)  
primary  1 : 150 Rabbit #DLN-12930 Dianova 
pFLT3 (pY591) primary 1 : 50 Rabbit #3461 Cell Signaling 
pSTAT5 (Y694)  primary 1 : 50 Rabbit ab32364 Abcam  
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3.3. Buffers and Solutions 
Table 10: Recipes for buffers and solutions  
Buffers/ Solutions Content 
10x Electrophoresis buffer 250 mM Tris 
2 M Glycin 
35 mM SDS 
10x Erythrocyte lysis buffer 155 mM NH4Cl 
10 mM KHCO3 
100 nM EDTA 
10x TBS-Tween (TBS-T) 50 mM Tris HCl, pH 7.4 
500 mM NaCl 
0.5 % (v/v) Tween 20 
20x PBS 2.74 M NaCl 
54 mM KCl 
200 mM Na2HPO4  
36 mM KH2PO4 
adjust pH 7,4 
4 % Paraformaldehyde-Solution   Paraformaldehyde solved in PBS pH 7.4 
50x TAE buffer 2 M Tris HCL, pH 8.0 
0.05 M EDTA  
5.7 % HCl 
5x KCM buffer 0.5 M KCl 
0.15 M CaCl2 
0.25 M MgCl2 
5x Sample buffer (Laemmli) 20 % (v/v) Glycerin 
10 % (w/v) SDS 
4 mM -Mercaptoethanol 
0.02 % (w/v) Bromphenol blue 
200 mM Tris HCl, pH 6.8 
Citrate buffer 0.01 M Tri-Sodiumcitrate-Dihydrate 
Collecting gel buffer 0.5 M Tris HCl, pH 6.8 
DNA sample buffer 50 % Glycerol 
10 mM EDTA 
0.1 % Bromphenol blue 
0.1 % Xylene cyanol 
Immunohistochemistry (IHC) Blocking  PBS-T supplemented with 
1 % BSA 
5 % Normal goat serum (NGS) 
Mini prep Solution I 50 mM Glucose 
25 mM Tris-HCl, pH 8.0 
10 mM EDTA 
0.2 mg/ml RNase 
Mini prep solution II 0.2 N NaOH 
1 % SDS 
Mini prep solution III 3.0 M Natriumacetat 
PBS-T PBS with 0,05 % (v/v) Triton X 100 
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RIPA buffer 50 mM Tris HCl, pH 8.0 
150 mM NaCl 
1 % (v/v) NP-40 
0.5 % (v/v) Deoxycholate 
0.1 % (w/v) SDS 
Freshly add: 
cOmpleteTM (EDTA-free Phosphatase 
Inhibitor cocktail, Sigma-Aldrich) used 1 : 25 
phosSTOP Easy pack (Sigma-Aldrich) used 
1 : 10 
Separation gel buffer 2 M Tris HCl, pH 8.8 
Stripping buffer 62.5 mM mM Tris 
100 mM 2-Mercaptoethanol 
2 % SDS 
Tank blot buffer 48 mM Tris 
39 mM Glycin 
0.039 % (v/v) SDS  
20 % (v/v) Methanol 
TE buffer 10 mM Tris HCl pH 7.5 
1 mM EDTA  
 
3.4 Staining Solutions 
Table 11: Staining solutions for histology 
Staining solution Company 
Eosin Y solution alcoholic Sigma Aldrich, Steinheim, Germany 
Hematoxylin solution according to Mayer Sigma Aldrich, Steinheim, Germany 
PAPPENHEIM-staining kit (MAY 
GRÜNWALD & GIEMSA) 
Morphisto GmbH, Frankfurt a. M., 
Germany 
Sour hemealaun according to Mayer Dr. K. Hollborn & Söhne GmbH & Co. KG; 
Leipzig, Germany 
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3.5 Mouse models 
Experiments were approved by the committee of the Thuringian State Government on 
Animal Research (TVA Reg. no. 02-086/14) and performed according to the Protection 
of Animals Act of the Federal Republic of Germany. The animals were treated in 
accordance with the declaration of Helsinki and the guiding principles in the care and 
use of animals.  
 
Table 12: Used and generated mouse models  
Strain Description Company 
C57BL/6 wild type mice with black 6 background Jackson laboratory, Bar 
Harbor, Maine, USA 
FLT3 ITD knockin mutation in FLT3 gene leading to 
internal tandem duplication in 
juxtamembrane domain and constitutive 
active kinase 
Jackson laboratory (B6.129-
FLT3tm1Dgg mice); Bar Harbor, 
Maine, USA 
described in (Lee et al. 2007) 
Ptprc-/- mice carrying a disrupted exon 9, resulting 
in introduction of several stop codons 
downstream of the insertion and thus, 
knockout mutation in Ptprc gene (Byth et al. 
1996). 
MRC Harwell (The Mary Lyon 
Centre, Harwell Science and 
Innovation Campus, 
Oxfordshire, OXF0RD, UK)  
Ptprj-/- mice carrying a knockout mutation in Ptprj 
gene  
DELTAGEN INC. San Mateo, 
California, USA 
FLT3 ITD 
Ptprc-/- 
mice carrying knockin mutation of FLT3 and 
knockout of Ptprc 
generated within the scope of 
this project 
FLT3 ITD 
Ptprj-/- 
mice carrying knockin mutation of FLT3 and 
knockout of Ptprj 
generated within the scope of 
this project 
 
3.6 Reaction Kits, Chemicals and Consumables 
3.6.1 Reaction Kits 
Table 13: Reaction Kits  
Name Company 
First Strand cDNA Synthesis Kit Thermo Scientific 
Maxima SYBR Green/Rox qPCR Master Mix 
(2x) 
Thermo Scientific 
Mouse Direct PCR Kit (for Genotyping) Bimake 
Direct Lineage Cell Depletion Kit Milthenyi Biotec  
DNeasy Blood &Tissue Kit Qiagen 
ZymocleanTM Gel DNA Recovery Kit Zymoresearch 
Qiagen Plasmid Midi Kit Qiagen 
Biotin Mouse Lineage Panel BD Pharmingen 
ABC complex kit Biozol 
Bradford Reagent Sigma Aldrich  
2 x M-PCR OPTI™ Mix (Dye Plus)  Bimake 
CellTiter-Blue® Cell Viability Assay Promega 
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3.6.2 Chemicals 
Table 14: Chemicals and reagents  
Reagents/Chemicals Company 
Ammoniumpersulfate (APS) Serva, Heidelberg Germany 
Bromphenol blue Bio-Rad; Hercules, USA 
BSA-c Aurion, Wageningen, Netherlands 
Chloroform Roth, Karlsruhe, Germany 
DMSO Sigma Aldrich, Steinheim, Germany 
ECL-Detection solution Perkin Elmer Life Science; Waltham USA 
EDTA Applichem, Darmstadt, Germany 
Ethanol Nordbrand Nordhausen GmbH, Nordhausen 
Germany 
Fetal bovine serum  Sigma-Aldrich, Steinheim, Germany 
Fluoromount-G® Biozol, Echingen, Germany 
Isoflurane CP CP Pharma, Burgsdorf, Germany 
Normal donkey serum (NDS) Millipore, Billerica, USA 
Paraffin Merck KGaA, Darmstadt Germany 
Sodium dodecyl sulfate (SDS) Applichem, Darmstadt, Germany 
TEMED Promega, Madison, Wisconsin, USA 
Tris Serva, Heidelberg, Germany 
Tri-Sodiumcitrate dihydrate Sigma Aldrich, Steinheim, Germany  
Triton X-100 Roth, Karlsruhe, Germany 
Tween 20  Serva, Heidelberg, Germany 
Xylene VWR chemicals, Fontenay-sous-Bois, France 
β-Mercaptoethanol Roth, Karlsruhe, Germany 
RedSafe HISS Diagnostics GmbH, Freiburg, Germany 
BD Cytofix / Cytoperm  BD Bioscience; Heidelberg, Germany 
BD 10 x Perm / Wash buffer BD Bioscience, Heidelberg Germany 
Methylcellulose HSC001 R&D Systems. Minnesota, USA 
Methylcellulose M3434 STEMCELL technologies, Vancouver, Cannada 
PageRulerTM Prestained protein 
ladder 
Fermentas, Thermo Fisher Scientific, Massachusetts, 
USA 
3.6.3 Consumables 
Table 15: Comsumables  
Consumables Company 
LS columns (for MACS based cell 
separation) 
Milthenyi Biotec 
0.2 µm syringe filter Sarstedt 
PVDF membrane (0.45 pore size) Ammersham 
Amicon ultra 15 centrifugal filter units Merck Millipore 
Whatmann paper Applichem 
Cell culture flasks/plates Sarstedt and Greiner Bio-One 
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3.7 Software 
Table 16: List of Software  
Software Application Company 
FlowJo 7.6.5 Analyze flow cytometry data Tree Star Inc. Ashland, OR, 
USA 
ImageJ 1.49 m Analyze images Wayne Rasband, NIH, USA 
Graphpad Prism 5 Analyze data, prepare 
graphs and perform 
statistics 
Graphpad Software Inc., La 
Jolla, CA, USA 
Clone Manager 
Professional 9 
Perform in silico cloning Scientific & Educational 
Software, Denver, USA 
Chomas Version 2.4.4. Chromatogram viewer Freeware 
Fujifilm LAS4000 Imaging Software Fujifilm, Düsseldorf, Germany 
NIS Elements 5.01 Imaging Software Nikon, Tokio, Japan 
SigmaPlot 13.0 Analyze data, prepare 
graphs and perform 
statistics 
Systat Software, Inc, San 
Jose, USA 
MultiGauge V3.0 Analyze data Fujifilm, Düsseldorf, Germany 
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4. Methods 
4.1 DNA work/cloning 
4.1.1 Restriction 
The restriction mixtures were prepared according to the following recipe: 
restriction buffer for specific enzyme 3 µl 
restriction enzyme 1.5 µl 
DNA/plasmid (1µg) x µl 
ddH2O z µl  
 30 µl 
  
The restriction mixture was incubated for 1 h. The temperature was adjusted according 
to the manufacturer’s protocol for the used enzyme. To reduce the probability of re-
ligation, the plasmids were dephosphorylated by adding 3 µl Shrimp alkaline 
phosphatase into restriction mixture and incubated for one hour at 37 °C. The digested 
plasmids were gel purified with Zymoclean™ Gel DNA Recovery Kit following the 
manufacturer’s protocol. 
4.1.2 CRISPR/Cas9 oligonucleotide annealing 
The gRNA containing oligonucleotides (see Table. 5) were phosphorylated and 
annealed prior inserting into CRISPR/Cas9 plasmid. Therefore, the following mixture 
was used: 
 
Oligonucleotide FWD (100 μM) 1 µl 
Oligonucleotide REV (100 μM) 1 µl 
10 x T4 Ligation buffer 1 µl 
ddH2O 6.5 µl 
T4 PNK 0.5 µl 
 10 µl 
  
The phosphorylation mixture was incubated at 37 °C for 30 min followed by 95 °C for     
5 min. Finally, the temperature was ramped down to 25 °C (5 °C per min) to anneal the 
sense and antisense oligonucleotides. Annealed oligonucleotides were diluted 1:200 for 
further utilization. 
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4.1.3 Ligation  
For ligation of digested plasmid and annealed oligonucleotides the following ligation 
mixture was prepared: 
Vector (about 50 ng) x µl 
annealed oligonucleotides 1 µl 
10 x T4 Ligation buffer 2 µl 
T4 ligase 1 µl 
ddH2O z µl 
 20 µl 
  
Ligation was performed at 16 °C overnight and inactivated at 65 °C for 20 min. 
4.1.4 Transformation 
Transformation of CRISPR/Cas9 plasmids pX330-mCherrymut-gRNA and 
lentiCRISPRv2-gRNA into Escherichia coli (E. coli) was performed via heat shock. 
Therefore, heat inactivated ligation reaction was mixed with 20 µl 5 x KCM buffer and 
70 µl ddH2O. For transformation 100 µl competent E. coli XL-1 blue cells (kindly provided 
by Annette Böhmer) were mixed with DNA and incubated on ice for 30 min. Heat shock 
occurred by 10 min room temperature incubation. Transformed E. coli cells were 
suspended in 800 µl LB medium and incubated at 37 °C for 1 h prior to plating on an 
agar plate containing 100 µg / ml Ampicillin. Plates were incubated at 37 °C overnight. 
4.1.5 Plasmid preparation 
Depending on required purity and amount of DNA, plasmid preparations were performed 
in mini or midi scale. For mini prep 2 ml and for midi prep 50 ml LB media containing 100 
µg / ml Ampicillin were inoculated with one picked single clone from transformation agar 
plate. Cultures were incubated at 37 °C overnight with shaking 225 rpm. For mini prep 
2 ml bacteria culture were centrifuged and suspended in 100 µl mini prep solution I, 
followed by 2 min incubation at room temperature. For lysis, 200 µl of mini prep solution 
II were added to the cell suspension and incubated 5 min at room temperature. 150 µl of 
mini prep solution III were added, homogenized, incubated on ice for 2 min and 
centrifuged at 14 000 rpm for 10 min. The supernatant was transferred into a new 
reaction tube. DNA precipitation was performed by adding 900 µl 96 % ethanol, followed 
by 5 min incubation and centrifugation (14 000 rpm, 10 min). DNA pellet was washed 
with 800 µl 70 % ethanol, centrifuged and obtained plasmid DNA pellet was suspended 
in 50 µl TE buffer. Midi prep was performed using Quiagen Plasmid Midi Kit according to 
the manufacturer’s protocol. 
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4.2 Cell culture 
All eukaryotic cells were cultured in a humidified incubator at 37 °C and an atmosphere 
of 5 % CO2. For murine 32D muFLT3 ITD cell line and all prepared 32D muFLT3 ITD 
PTP ko cell lines RPMI medium with 25mM HEPES and L-Glutamine (Millipore) was 
used. Cells were cultivated in media supplemented with 10 % heat inactivated (hi) FBS, 
1 % Penicillin / Streptomycin solution, 1 % sodium pyruvate and 2 ng/ml IL-3. 4 h before 
starting signaling experiments cells were starved in RPMI medium without supplements 
and treated with 0.5 µM DPI, if indicated. The cells were maintained by replacing 
medium every 2 to 3 days without exceeding a cell density of 1 x 106. 
For freezing, cells were harvested and suspended in hiFBS containing 10 % DMSO. Cell 
density was adjusted to 1-2 x 106 cells / ml. 1 ml cell suspension was transferred into 
freezing vials and immediately stored in a Styrofoam storage box at -80 °C. For thawing, 
cells were rapidly thawed in 37 °C water bath and immediately suspended in 10 ml RPMI 
medium to dilute DMSO. Cell suspension was centrifuged (500 g, 5 min) and cells 
suspended into fresh culture medium. 
4.3 Transfection of HEK293T cells 
1.2 x 106 HEK293T cells were seeded into a 10 cm dish one day prior transfection. 
Packaging plasmids were diluted in 500 µl DMEM media according to the following 
recipe: 
 
generation II system  
(for lentiCRISPRv2 derivative plasmids) 
 
Expression vector 10 µg 
pPax2  10 µg 
pVSVg 2 µg 
  
generation III system  
(for pX330-mCherrymut derivative plasmids) 
 
Expression vector 10 µg 
pMDL 10 µg 
pRSV 5 µg 
pVSVg  2 µg 
  
In 0.5 ml RMPI media Polyethylenamin (PEI, 2.5 µg/µg DNA) and DNA was thoroughly 
diluted. Medium-DNA and medium-PEI mixture were combined, vortexed immediately 
and incubated for 30 min at room temperature. Medium of HEK293T cells was 
exchanged to starvation medium without FBS and DNA-PEI-mixture was added drop-
wise to the cells followed by 6 h incubation at 37 °C. Afterwards medium was exchanged 
to DMEM supplemented with hiFBS and further incubated at 37 °C. 
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4.4 Transduction of 32D muFLT3 ITD  
For generation of CRISPR/Cas9 cell lines two different plasmid backbones were used. 
First constructs were cloned into BbsI restricted px330mCherrymut comprising mCherry 
fluorescent marker for selection. For better selection of transduced cells the system was 
later on changed to BsmBI restricted lentiCRISPRv2 backbone carrying a Puromycin 
resistance cassette (see Table 1). 
The produced virus particles were collected 24, 48 and 72 hours (h) after transfection. 
The virus containing medium of transfected HEK293T cells was collected and filtered by 
a 0.2 µm syringe filter to remove cells and cell debris. The medium was replaced with 
fresh DMEM medium containing 10 % hiFBS. Virus particles were concentrated with the 
help of Amicon ultra 15 centrifugal filter units by centrifugation at 3 000 rpm for 15 min. 
50 000 32D mu FLT3 ITD cells / ml were seeded per well into a 12 well plate. 
Concentrated virus particles and Polybrene (final concentration 8 µg / ml) were added to 
32D cells and plate was gently swirled to homogenize. Plates were centrifuged 1 h at 
500 g and incubated at 37 °C and 5 % CO2 atmosphere overnight. Transductions were 
repeated after 24 h and 48 h. One day after last transduction the Polybrene containing 
media was replaced with fresh RPMI media. Two days after infection the transduced 
cells were ether sorted on mCherry positive cells or selected by 2 μg / ml Puromycin or 
15 μg / ml Blasticidin, respectively. The antibiotic selection was maintained at least two 
days but not longer than one week. Clonal amplification was performed and clones 
analyzed by flow cytometry or sequencing. 
4.5 Polymerase chain reaction (PCR) 
4.5.1 Amplification for genotyping 
To amplify a specific DNA sequence PCR were used. In this work PCR                                                                                                                                                                      
for genotyping were performed using a 2 x M-PCR OPTI™ Mix (Dye Plus) (Bimake, 
München, Germany) and a Biometra T-Gradient thermocycler.  
Step FLT3 ITD / Ptprj Ptprc 
Initial denaturation 95 °C; 5 min 94 °C, 2 min 
Cycle Repeat 32 x Repeat 30 x 
     Denaturation 96 °C, 30 sec 94 °C, 45 sec 
     Annealing 62 °C, 30 sec 60 °C, 45 sec 
     Elongation 72 °C, 45 sec 72 °C, 45 sec 
Final elongation 72 °C, 5 min 72 °C, 5 min 
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4.5.2 Amplification for sequencing 
To validate the created 32D muFLT3 ITD Ptprj and Ptprc ko clones the regions of the 
targeted genomic DNA was amplified prior. First right annealing temperatures of the 
primers were determined by a gradient PCR.  
 
Table 16: Primers and sequences used for amplification of chromosomal DNA 
Name Sequence 5 ’ - 3 ’ 
Ptprc FW CTCTGAACAACGGCAAAC 
Ptprc REV CTGCAAAGAGGACCCTTTAC 
Ptprj FW TTACCTGGCCCTGGCGTAGCAAC 
Ptprj REV CTAGCTCGTGGCTCTGGAACAGT 
 
Setup for gradient PCR: 
 
5 x Taq reaction buffer 5 μl 
2 mM dNTP 2.5 μl 
10 μM FWD 1 μl 
10 μM REV 1 μl 
DMSO 1 μl 
ddH2O x μl 
Magic-Taq 0.5 μl 
Template - DNA (60 ng) y μl 
 25 μl 
  
Afterwards, genomic DNA was amplified with the following PCR program: 
 
Initial denaturation  92 °C   3:00 min 
Denaturation   92 °C   0:30 min  
Annealing  x °C   0:30 min         35 x 
Elongation  72 °C   1:00 min 
Finale elongation  72 °C  3:00 min 
 
PCR were carried out in an Eppendorf Thermocycler. Annealing temperature was set to 
58 °C for amplification of Ptprc genomic DNA and to 59°C for amplification of Ptprj 
genomic DNA. The efficiency of amplification was validated by loading 5 μl of the 
reaction mixed with 1 μl 6 x loading buffer on a 1 % agarose gel.  
The amplified PCR fragments were purified with the Zymoclean™ Gel DNA Recovery 
Kit. The purification with the kit was done according to the manufacturer’s protocol. 
Purified PCR products were sent for sequencing. 
4.6 Flow cytometric analysis 
4.6.1 Verification of CRISPR/Cas9 ko clones 
Clonally amplified cell populations were analyzed for successful knockout of Ptprj and/or 
Ptprc by flow cytometry. 1 x 106 cells were harvested, centrifuged and washed with 
phosphate buffered saline (PBS). Cells were suspended in 48 µl PBS and 2 µl of 
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antibodies of Ptprj or Ptprc (see Table 6). Cells were incubated on a spinning wheel at 
4 °C for 30 min, washed again and suspended in 300 µl PBS. Stained parental cells 
(non-transduced 32D muFLT3 ITD) were used as positive and unstained parental cells 
as negative control.  
4.6.2 B and T cell analysis 
1 x 106 murine primary bone marrow and spleen cells of respective mice were washed 
two times with PBS and suspended in 40 µl PBS + 1 % hiFBS. 2.5 µl of CD11b-APS, Gr-
1-PE, B220-FITC, CD3-PerCP, respectively were added to cell suspension prior to 
30 min incubation at 4 °C on a spinning wheel. Cells were washed subsequently two 
times with PBS and analyzed by flow cytometry. The subgating was perfomed as seen in 
the following figure 9. First via forward scatter and sideward scatter a gate was defined 
to exclude cell debris. Secondly, obtained cells were analyzed concerning CD11b and 
Gr-1 expresson. Cells positive for both markers were defined as myeloid differentiated 
cells including monocytes, granulocytes, dendritic cells but also myeloid suppressor 
cells. Cells which are negative for both markers were defined as myeloid undifferentiated 
cells, including lymphocytes, precursors and stem cells. Cells negative for CD11b and 
Gr-1 were further analyzed for expression of CD19 (representing B cells) and CD3 
(representing T cells).  
 
Figure 9. Gating scheme of B and T cell analysis. First, cells were analyzed for surface expression of 
myeloid markers CD11b and Gr-1. Secondly, cell population which was negative for myeloid differentiation 
markers was further investigated for CD19 and CD3. 
4.6.3 Analysis of committed myeloid progenitors and LSK cells 
5 x 106 murine primary bone marrow and spleen cells of respective mice were washed 
two times with PBS + 1 % hiFBS and suspended in 50 µl of Biotin Mouse Lineage Panel 
(BD Bioscience and separately added CD19; ratio 1:25) and incubated at 4°C for 30 min 
on a spinning wheel. Cells were washed two times washed with PBS + 1 % hiFBS and 
suspended in 25 µl and 20 µl Streptavidin-PerCP and 2.5 µl of c-kit-APC and Sca-1-PE-
Cy7, respectively for additional incubation at 4 °C spinning wheel for 30 min. Then cells 
were washed two times with PBS + 1 % hiFBS. Furthermore, for FLT3 staining cells 
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were fixed and permeabelized by suspending them in 200 µl Fixation / Permeabilization 
buffer (BD Cytofix / Cytoperm) and incubated at 4°C for 30 min. Afterwards, cells were 
washed with 800 µl 1x BD Perm/Wash buffer. For staining 2.5 µl of PE labelled anti-
mouse CD135 antibody were diluted in 47.5 µl 1x BD Perm/Wash buffer and cell pellet 
was suspended in this solution. Subsequently, cells were incubated for 30 min at 4 °C on 
spinning wheel and analyzed by flow cytometry. Unstained primary cells of the 
respective organ were used as negative control and to adjust the gate of lineage 
negative (Lin-) cells. All cells which were negative for differentiation markers used in the 
Biotin Mouse Lineage Panel (BD Pharmingen) were defined as Lin- cells, representing 
undifferentiated progenitor cells. Further characterization of these progenitor cells was 
performed by subgating as seen in the following figure 10. First, via forward scatter and 
sideward scatter a gate was defined to exclude cell debris. Secondly, in obtained cell 
population lineage negative cells were defined and further analyzed for expression of c-
Kit and Sca-1. Cells which were Lin-, Sca-1- and c-Kit+ were defined as committed 
myeloid progenitors. Lin-, Sca-1+ and c-Kit+ cells were defined as LSK cells, containing 
HSC and MPP. Myeloid progenitors and LSK cells were further investigated for FLT3 
expression.  
 
 
All flow cytometric analyses were performed on BD FACS Canto II (BD Bioscience, 
Heidelberg, Germany). 
4.7 Cell lysis 
Equivalent amount of transduced 32D cell lines were harvested into a 1.5 ml reaction 
tube and centrifuged (500 g, 5 min). Primary mouse cells were harvested as described in 
4.10.2 and cells pelleted by centrifugation. Per 1 x 106 cells 30 µl RIPA buffer were 
added and cell lysis performed by up-and-down pipetting and vortexing of the cells. After 
Figure 10. Gating scheme of Lin
-
 cells and 
subsequently progenitor and LSK analysis including 
FLT3 level investigation. Events which were defined as 
cells were investigated on expression of differentiation 
marker. Undifferentiated lineage negative (Lin
-
) cells were 
subsequently analyzed for expression of c-Kit and Sca-1. 
Committed myeloid progenitors (c-kit
+
, Sca-1
-
) and 
HSC+MPP (c-kit
+
, Sca-1
+
) populations were further 
analyzed for FLT3 expression.  
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10 min incubation on ice the samples were centrifuged (5000 g, 5 min). Supernatant was 
transferred into a fresh tube, mixed with 5 x Laemmli sample buffer and boiled at 95 °C 
for 5 min.  
4.8 SDS-PAGE and Western blotting 
Separation and visualization of proteins in cell lysates were performed by 
immunoblotting. First SDS polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to separate the different proteins according to their molecular weight. A 
reference Page Ruler was used as molecular size marker. A 10 % separation gel and a 
4 % collecting gel were casted for SDS-PAGE. 
 
 Separating gel (10 %)    Stacking gel (4 %) 
30 % Acrylamide 5 ml 30 % Acrylamide 1 ml 
Separation Gel buffer 2.85 ml  Stacking Gel buffer 1.88 ml  
20 % SDS 75 µl 20 % SDS 37.5 µl 
ddH2O 7.2 ml ddH2O 4.65 ml 
20 % APS 60 µl 20 % APS 45 µl 
TEMED 12 µl TEMED 6 µl 
 
Gels were run in 1 x electrophoresis buffer and 0.7 mA constantly per cm2 gel with Mini 
Vertical Electrophoresis System (Hoefer, Holliston, USA). Afterwards, proteins were 
transferred from the gel onto 0.45 µm pore size PVDF membrane (Ammersham) using 
Wet Blot Immunoblotting (Biorad, Callifornia, USA). Prior to submersion to blotting buffer 
membrane was pre-wetted with methanol. The gel was equilibrated in blotting buffer and 
then placed in the “transfer sandwich”. Wet Blot was performed in transfer buffer 
overnight at 10 V constantly. Following Wet Blot the membrane was incubated in 1 % 
BSA in TBS-T for 30 min and incubated with primary antibody overnight. The membrane 
was washed 3 times for 10 min with TBS-T prior to incubation with horseradish 
peroxidase (HRP)-conjugated secondary antibody (solved in 1 % BSA in TBS-T, ratio 
1:10 000; see Table 8) at room temperature for 30 min and 3 times washed in TBS-T for 
10 min. Development was done by using enhanced chemoluminescence (Western 
Lightning ECL) and LAS 4000 imaging device (Fujifilm, Düsseldorf, Germany) and 
quantified with MultiGaugeV3.0 software (Fujifilm, Düsseldorf, Germany). After 
exposure, membranes were stripped with stripping buffer (55 °C, 30 min), incubated with 
1 % BSA in TBS-T at room temperature for 30 min and re-probed with the desired 
primary and secondary antibody. Quantified site-specific phosphorylation divided 
through quantified pan phosphorylation of respective target was calculated to obtain 
specific phosphorylation of the protein.  
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4.9 Viability and Proliferation Assays 
4.9.1 Colony forming unit (CFU) assay  
32D muFLT3 ITD and 32D muFLT3 ITD PTP ko cells were harvested, counted and 
seeded in a density of 375 cells / well in 230 µl methylcellulose (R&D Systems) 
supplemented with 10 % hiFBS, 1 % Penicillin / Streptomycin solution and 220 µl IMDM 
media in a 24 well plate. After 6 days incubation at 37 °C 50 µl of 
Iodonitrotetrazoliumchloride (0.4 mg / ml) were added to stain the colonies overnight. To 
investigate the CFU forming capacity plates were scanned and colonies were counted 
manually.  
Purified lineage negative precursors from BM and spleen were plated at a concentration 
of 250 cells per well in a 24 well plate in M3434 methylcellulose, containing mouse stem 
cell factor (SCF), mouse interleukin 3 (IL-3), human interleukin 6 (IL-6) and human 
erythropoietin (EPO) (StemCell Technologies,Vancouver, BC). Total colony counts and 
colony counts of burst-forming unit (erythroid precursor, BFU-E), granulocyte / 
macrophage (GM) and granulocyte / erythroide / megakaryocyte / monocyte (GEMM) 
precursors were obtained after 10 days at 37 °C and 5 % CO2. Classification of colonies 
was done by cell and colony form and size. BFU-E colony clusters consisted of tiny cells 
with irregular shape, which were difficult to distinguish and appeared fused together. 
Colonies classified as CFU GM contained multiple cell clusters with dense core. Large 
monocytic cells had an oval to round shape. Granulocytic lineage cells were round and 
bright, and were much smaller with a more uniform size. CFU GEMM produced large 
colonies with a highly dense core and indistinct borders between core and peripheral 
cells. Monocytic and granulocytic cells were visible as well as cluster of large 
megakaryocytic cells. Afterwards, cells were harvested and used for replating, cytospin 
preparation and immunophenotypic characterization.  
4.9.2 The Cell Titer-Blue® Assay (IC50) 
To investigate the IC50 value of tyrosine kinase inhibitors in 32D muFLT3 ITD cell line 
and 32D muFLT3 ITD PTP ko cell lines, cells were seeded into a 96 well plate (Greiner; 
F-bottom, black) in a density of 2000 cells / well in normal cultivation media. Cells were 
treated with 11 different concentrations of AC220, PKC412 or DMSO as control for three 
days. After 3 days of incubation in a humid chamber at 37 °C, cells were treated with cell 
titer blue (Promega) for three hours. Thereby, viable cells were able to reduce the 
indicator dye resazurin to resorufin and generate a fluorescent signal. Nonviable cells 
have lost metabolic capacity and do not generate a fluorescent signal. Fluorescence was 
measured at TECAN Reader (Tecan, Salzburg, Austria) with excitation wavelength 
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540 nm and emission wavelength 610 nm. For each TKI concentration eightfold 
measurement was performed. IC50 values were calculated using non-linear best-fit 
regression analysis Sigma Plot V13.0 software.  
4.10 Mouse work 
4.10.1 Genotyping 
To detect the knockout of Ptprj or Ptprc, respectively and presence of FLT3 ITD 
mutations in mice, the chromosomal DNA was extracted out of tail biopsies using the 
mouse direct PCR Kit (Bimake, München, Germany) following the manufacturers 
protocol. To amplify the isolated DNA PCR was performed using the primers listed in 
table 17. For validation of amplified DNA fragments agarose gel electrophoresis was 
used. Expected size of respective DNA fragments is shown in table 18. 
 
Table 17. Primer used for Genotyping 
Name  Sequence 5’-3’ 
Ptprj FWD AGCTGTCGTCAGCCCAACTAGTGTG 
Ptprj REV GGAGAATGTATACGAAGTGCCTGGG  
Ptprj Neo FWD GGGCCAGCTCATTCCTCCCACTCAT 
Ptprc WT FWD CGATGATGATTGTACTAATTTCCTTTTTTT 
Ptprc WT REV GCTGGAGCACATGAGTCATTAGACAC 
Ptprc ko FWD GTAATCAGACTTTTAAGGCAGACCTC 
Ptprc ko REV TTGGCTACCCGTGATATTGCTG 
FLT3 ITD FWD AGGTACGAGAGTCAGCTGCAGAT  
FLT3 ITD REV TGTAAAGATGGAGTAAGTGCGGG 
 
Table 18. Size of amplified PCR product 
gene + mutation size of PCR product (bp) 
Ptprj WT 168 
Ptprj ko 326 
FLT3 WT 200 
FLT3 ITD 224 
Ptprc WT 250 
Ptprc ko 300 
 
4.10.2 Isolation and characterization of mouse organs 
Mice were anesthetized with Isoflurane and terminated by cervical dislocation. The 
abdomen was opened to remove liver, kidneys and spleen for investigation of organ 
weight. The bones of the hind limbs were dissected and tissue and filaments completely 
removed. For preparation of bone marrow both ends of the bones were cut off and bone 
marrow was washed out with MACS Rinsing Solution (Milthenyi Biotech, Bergisch 
Gladbach, Germany) through a 0.4 µm sized mesh. Primary spleen cells were obtained 
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by pressing the spleen with PBS and a pistil through a cell strainer (0.7 µm). Cell 
solutions were centrifuged and erythrocyte-lysed at room temperature for 5 min with 1 x 
Erythrocyte lysis buffer. Afterwards cells were suspended in MACS Rinsing Solution 
(Milthenyi Biotech) and counted with a Neubauer counting chamber.  
4.10.3 Blood analysis  
Mice were anesthetized with Isoflurane and retro-orbital blood was collected with 
heparin-coated capillary tubes (Hirschmann Laborgeräte, Eberstadt, Germany). To 
determine the blood cell count 20 µl of blood were measured using a BC5300Vet 
Hematology system (Mindray, Darmstadt, Germany, kindly provided by Ilse Jacobsen 
group, Microbial Immunology, Leibniz Institute for Natural Product Research and 
Infection Biology, Hans Knöll Institute, Jena, Germany). To analyze the blood leukocytes 
and to obtain blood serum the mice were anesthetized and terminated by Isoflurane 
overdose (5 %) and final hearth puncture was performed with EDTA-coated syringes 
(EDTA concentration 1.6 mg/ml blood). The blood was centrifuged with 2000 g. The 
serum was aspirated and stored in 50 µl aliquots at -80 °C. Erythrocytes were lysed and 
the remaining blood cells were suspended in PBS + 2 % hiFBS and analyzed by flow 
cytometry. Furthermore, blood smears were prepared on poly-L-lysine-coated 
microscope slide (Thermo Scientific) for further cytological characterization.  
4.10.4 Cytospin preparation 
Primary cells of murine spleen and bone marrow, unpurified or Lin- purified cells were 
processed as described before (4.10.2) and 150 000 cells were solved in 200 µl MACS 
Rinsing Buffer. Cell solution was transferred into a funnel, which was fixed on top of a 
filter card and poly-L-lysine coated object slide. The samples were centrifuged at 
600 rpm for 5 min. The funnel and filtercard were carefully removed and the object slide 
was air-dried for 1 h and used for Pappenheim staining following the manufacturer’s 
protocol (Morphisto; Pappenheim staining Kit). Cytospin analyses were used to 
investigate composition of harvested CFU and to further specify the lineage of cells 
which form the CFU.  
4.10.5 MACS purification of lineage negative (Lin-) cells 
Purification of Lin- cells from bone marrow and spleen cells of mice was performed by 
using MACS-based cell separation system and the Direct Lineage Cell Depletion Kit 
(Milthenyi, Bergisch Gladbach, Germany) following the manufacturer’s protocol. In case 
of Ptprc knockout mice and FLT3 ITD knockin Ptprc knockout mice additional 5 µl of 
CD19 labeled MicroBeads were added per 2 x 107 cells and incubated at 4 °C for 
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10 min. Lin- cells were collected, counted with a Neubauer counting chamber and used 
for the experiments. 
4.10.6 Perfusion and Organ and Bone slice preparation 
Mice were anesthetized with an Isoflurane overdose (5 %, > 10 min) prior to cardiac 
perfusion. Upon heart beat rate under 30 bpm (irreversible cardiovascular dysfunction) 
the abdomen and thorax were opened and perfusion with PBS was started by cardiac 
puncture via the left ventricle. The right atrium was punctured to enable the blood and 
PBS to left the mouse after circulation through the whole body. The flow rate of the 
perfusion solution was adapted to 3 ml / min. Until no more blood was washed out of the 
mouse, perfusion solution was changed from PBS to 4 % paraformaldehyde (PFA) and 
was run for 10 min. The organs (liver, kidney, spleen) and bones (tibia and femur) were 
carefully removed after fixation and post-fixed for 24 h in 4 % PFA. Organs were cut to 
size and rinsed with water for 2 h, followed by waxing using Microm STP 120 (Thermo 
Scientific). The waxing was performed in the following steps: 2 x 1 h 70 % ethanol, 1 h 
96 % ethanol, 2 x 2 h 96 % ethanol, 2 x 2 h 99 % ethanol, 1 h 1/3 xylene and 2/3 
ethanol; 1 h 2/3 xylene and 1/3 ethanol, 1 h xylene, 2 h xylene and finally 3 h paraffin. 
Afterwards, tissue samples were embedded in paraffin and cutted into 4 µm slices. 
Bones were decalcified prior to waxing. Therefore, femur and tibia were stored in 
decalcifier (Roth) for 5 days, replacing decalcifier each day. 
4.10.7 µCT measurements  
To characterize the bone structure and density dead mice were scanned with an in vivo 
micro-CT scanner TomoScope® Synergy Twin imaging system using a standard protocol 
with 65 kV. Three-dimensional anatomical pictures were gained using Imalytics software. 
ImpactView software (CT Imaging GmbH) was used to generate image slices and for 
region of interest measurement. Average bone density was calculated in hind limb 
bones. The cortical thickness index (CTI) which was defined as     
        
    
 (     and 
    are the outer and inner radius of the cortical bone, respectively). The CTI is 
measured as the average value between 1.4 and 1.6 mm from the knee joint as the 
signal was reasonably stable for all mouse types in this range. The computations 
involved local orthogonalization of bone slices as previously described (Svensson et al. 
2017). Furthermore, the roughness of the bone surface of hind legs was computed, 
using intensity threshold 78 for surface reconstruction of all CT images and roughness 
radius r=3 as previously described (Hoffmann et al. 2017). Analysis of CT data was 
performed by group of M. T. Figge (Applied Systems Biology, Leibniz Institute for Natural 
Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany). 
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4.11 Staining of organ slices 
4.11.1 Immunohistochemistry 
Organ slices were dewaxed prior to staining. Therefore, slices were incubated three 
times in xylene for 5 min, washed in ethanol solution with decreasing ethanol 
concentration (99 % - 96 % - 96 % - 70 % - 50 %) 5 min each and rinsed in distilled 
water. Then antigen retrieval was performed by boiling the slices in 0.01 M citrate buffer 
(pH 6.0) at 630 W for 11 min. Samples were cooled down to room temperature, washed 
two times with PBS for 8 min and one times with PBS-T for 5 min followed by incubating 
the organ slices in blocking solution at 37 °C for 20 min. Organ slices were washed two 
times with PBS-T and incubated with primary antibody (diluted in blocking solution see 
table 10) at 4 °C overnight. Three times washing with PBS-T was performed prior to 2 h 
incubation with secondary AF488 goat anti-rabbit antibody diluted in blocking solution 
1:250. After two times washing with PBS-T co-staining with DAPI was performed 
(20 min, diluted 1:200 in PBS), followed by 4 times washing with PBS for 8 min each. 
The organ slices were coverslipped in Fluoromount G and representative images were 
acquired using a Nikon eclipse Ti-E invert microscope system. 
4.11.2 H & E staining 
Organ slices were dewaxed prior to staining with hematoxilin and eosin as described in 
4.10.6. Hematoxilin staining was performed for 24 min then slices were washed two 
times with ddH2O and rinsed with tap water for 10 min until the slices appeared black / 
dark blue. For eosin staining the slices were incubated in eosin staining solution for 
3 min and washed 2 times with ddH2O. Afterwards the organ slices were dewatered by 
incubating them in ethanol solutions with increasing concentrations (50 % - 70 % - 96 % 
- 96 % - 99 %) 1 min respectively followed by three times xylene incubation for 5 min. 
The stained slices were coverslipped in Neomount (Merck) and representative images of 
H & E-stained sections were acquired using a Nikon eclipse Ti-E invert microscope 
system. 
4.11.3 Myeloperoxidase (MPO) staining 
Organ sliced were prepared as described in 4.11.1 until the washing steps before first 
blocking step. Then the endogen peroxidases were blocked by incubating slices in 3 % 
H2O2 diluted in 50 % Isopropanol for 20 min at room temperature followed by 10 min 
washing in ddH2O. By incubating the slides in 50 mg NaBH4 solved in 100 ml ddH2O for 
20 min the aldehyde groups were also blocked, again followed by 10 min washing in 
ddH2O. The samples were washed in PBS and PBS-T for 5 min each prior to serum 
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blockage and incubation with primary and secondary antibody as described in 4.11.1. A 
biotinylated donkey anti-rabbit antibody was used as secondary antibody. After 2 times 
washing in PBS-T for 5 min the samples were incubated with vectostain ABC kit (Biozol, 
Echingen, Germany) according to the manufacturer’s protocol. After washing once with 
PBS-T, 2 times with PBS and once with ddH2O the samples were incubated with 3, 3` 
diaminobenzidine (DAB) (Sigmafast D4293) for 10 min followed by 4 times washing with 
ddH2O. Counterstaining was performed with sour hemalum solution according to Mayer 
for 5 min followed by 15 min rinsing under tab water. Dewatering was performed as 
described in H & E staining part prior to cover slipping in Neomount. Specification of the 
MPO-antibody was validated by incubating organ sections with secondary antibody only 
(negative control) and detecting no positive signal. 
4.12 Statistical analysis 
Results and data obtained from experiments were reported in mean ± standard error of 
the mean (SEM). Comparisons between groups were made with one way Anova 
followed by Bonferroni post-test if appropriate. Significance of survival was tested with 
Log rank test using Graph Pad 5 software. Calculations were done with SigmaPlot V13.0 
software and Graph Pad 5. Differences were considered significant if *p <0.05, **p <0.01 
and ***p <0.001 compared to WT and #p <0.05, ##p <0.01 and ###p <0.001 compared 
to FLT3ITD/ITD as indicated in the figure legends. 
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5. Results 
5.1 Effects of CRISPR/Cas9 mediated Ptprj and Ptprc ko in 32D muFLT3 ITD 
cells 
Regulatory role of Ptprj and Ptprc on FLT3 WT activity was demonstrated in 32D 
muFLT3 WT cells (Arora et al. 2011). Further studies revealed that upon reactivation of 
Ptprj by quenching of cellular ROS, Ptprj controls the activity of FLT3 ITD in 32D 
muFLT3 ITD, MV4-11 and human primary AML cells on basis of shRNA mediated Ptprj 
knockdown (Godfrey et al. 2012). In order to better elucidate how Ptprj and Ptprc affects 
FLT3 ITD activity and to investigate potential overlapping functions of Ptprj and Ptprc 
CRISPR/Cas9 mediated knockout of both was performed in 32D muFLT3 ITD cells.  
5.1.1 Generation of CRISPR/Cas9 mediated knockout of Ptprj and Ptprc 
In order to inactivate Ptprj and/or Ptprc lentiviral transduction of 32D muFLT3 ITD cells 
with gRNA encoding lentiCRISPRv2 (Sanjana et al. 2014) targeting either Ptprj or Ptprc, 
was performed. Post transduction resistant cells were selected by Puromycin and 
clonally amplified. Knockout of Ptprj and Ptprc was verified by immunoblot (Figure 11). 
and flow cytometric analysis. In addition, inactivation was confirmed by sequencing of 
both gene internal target region alleles (data not shown). To study the previously 
demonstrated redundant role of Ptprj and Ptprc (Zhu et al. 2008) double knockout (ko) 
cells were generated. One clone carrying Ptprj ko (in the following named 32D muFLT3 
ITD Ptprj ko), two clones carrying Ptprc ko (in the following named 32D muFLT3 ITD 
Ptprc ko I and ko II) and two clones carrying double PTP ko (in the following named 32D 
muFLT3 ITD Ptprj/Ptprc ko I and ko II) were selected from 32D muFLT3 ITD cells 
(Figure 11). The obtained cell clones were viable and did proliferate. 
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Figure 11. CRISPR/Cas9-mediated inactivation of Ptprj and Ptprc in 32D muFLT3 ITD cells. 32D 
muFLT3 ITD (control transduced), 32D muFLT3 ITD Ptprj ko, 32D muFLT3 ITD Ptprc ko
 
I and II and 32D 
muFLT3 ITD Ptprj/Ptprc
 
ko I and II cell lines were starved for 4 h in serum-free medium. DPI was added 
during starvation in a final concentration of 0.5 µM, untreated cells were incubated with respective amount of 
DMSO. Cells were lysed in RIPA buffer and equivalent amounts of protein were separated by SDS-PAGE 
and processed for immunodetection using antibody recognizing Ptprj. Blot was re-probed for Ptprc antibody 
and -actin as control. 
5.1.2 FLT3 ITD activity in 32D muFLT3 ITD cells lacking Ptprj and/or Ptprc 
In order to study the effect of the loss of Ptprj or Ptprc on FLT3 ITD signaling, specific 
phosphorylation of FLT3 ITD and known downstream targets were analyzed using 
immunoblotting in 32D muFLT3 ITD cells inactivated for Ptprj and/or Ptprc (Figure 12A, 
B).  
Specific FLT3 Y589 phosphorylation showed no significant changes in all PTP ko cell 
lines compared to 32D muFLT3 ITD cell line. Interestingly, STAT5 Y694 phosphorylation 
was significantly reduced in 32D muFLT3 ITD Ptprj ko and 32D muFLT3 ITD Ptprj/Ptprc 
ko I and II compared to 32D muFLT3 ITD cells. 32D muFLT3 ITD Ptprc ko I and II 
demonstrated reduced specific STAT5 phosphorylation, but without significance. In all 
PTP ko cell lines, except 32D muFLT3 ITD Ptprc ko II, specific AKT S473 
phosphorylation was significantly reduced. In addition, specific Src Y416 phosphorylation 
was strongly reduced compared to 32D muFLT3 ITD cell line. Reduced Src Y416 
phosphorylation indicates decreased Src activity. Insignificant effects on T202/Y204 
ERK1/2 phosphorylation were observed in PTP ko cell lines compared to 32D muFLT3 
ITD cells. Furthermore, the two clones of 32D muFLT3 ITD Ptprc ko cells reacted 
partially different. Because of clonal amplification after CRISPR/Cas9 transduced cells 
clonal effects cannot be excluded. 
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Figure 12. Signaling analysis in 32D muFLT3 ITD parental and indicated 32D muFLT3 ITD PTP ko 
cells. 32D muFLT3 ITD (control transduced), 32D muFLT3 ITD Ptprj
 
ko, 32D muFLT3 ITD Ptprc ko and 32D 
muFLT3 ITD Ptprj/Ptprc
 
ko cell line cells were starved for 4 h in serum free medium, lysed in RIPA buffer. 
Equivalent amounts of protein samples were separated by SDS-PAGE and processed for immunodetection 
using phosphosite specific antibodies recognizing FLT3 (pY589), pSTAT5 (Y694), pAKT (S473), pSFK 
(Y416) and pERK1/2 (T202/Y204). Blot was re-probed for total FLT3, STAT5, AKT, Src, ERK antibodies and 
-actin as control. (A) Representative immunoblot; (B) Quantification of specific phosphorylation of FLT3, 
STAT5, AKT, Src and ERK1/2 in relation to total protein level of indicated proteins, values are given in mean 
± SEM, n =4, expect Src probing n =1; ***p <0.001 compared to 32D muFLT3 ITD 
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5.1.3 Effect of ROS on Ptprj and Ptprc controlled signaling on FLT3 ITD 
downstream targets  
Due to NOX4-driven ROS formation in FLT3 ITD cells reversible oxidation of the catalytic 
cysteine of the PTP domain led to reduction of Ptprj activity. This effect was 
demonstrated in HEK293, MV4-11 and MOLM13 cells and in primary AML blasts 
(Godfrey et al. 2012, Jayavelu et al. 2016). Treatment of PTP ko cells with ROS 
quenching agent DPI should give information about oxidation susceptibility of Ptprj and 
Ptprc. Therefore, FLT3 phosphorylation and downstream signaling was investigated in 
PTP ko cells after DPI treatment.  
As previously published (Godfrey et al. 2012) 32D muFLT3 ITD cells showed reduction 
of specific FLT3 phosphorylation after DPI treatment. In all 32D muFLT3 ITD PTP ko cell 
lines specific FLT3 phosphorylation was downregulated upon DPI treatment (Figure 13A, 
B). Since this downregulation was still observed after DPI treatment in 32D muFLT3 ITD 
Ptprj/Ptprc ko cells, it can be speculated that further PTP or other mechanisms are 
involved in phosphorylation regulation of FLT3 ITD. Reduction of STAT5 Y694 
phosphorylation after DPI treatment was revealed in both 32D muFLT3 ITD Ptprc ko I 
and II cell lines and in 32D muFLT3 ITD cells. Untreated 32D muFLT3 ITD Ptprj ko cells 
demonstrated strongly decreased STAT5 phosphorylation compared to parental cells, 
which was not further reduced after DPI treatment. Y694 STAT5 phosphorylation was 
strongly decreased in 32D muFLT3 ITD Ptprj/Ptprc ko cells. Upon DPI treatment just 
minor effects on specific STAT5 phosphorylation were observed. In 32D muFLT3 ITD 
cells specific AKT phosphorylation was 2-fold increased due to DPI treatment. In 32D 
muFLT3 ITD Ptprj ko cells no effect of DPI-treatment was observed. In contrast, both 
32D muFLT3 ITD Ptprc ko cell lines as well as both 32D muFLT3 ITD Ptprj/Ptprc ko cell 
lines revealed slight up regulation of S473 AKT phosphorylation after DPI treatment. As 
already demonstrated above (Figure 12) phosphorylation of activating Src Y416 is 
strongly decreased in all investigated 32D muFLT3 ITD PTP ko cell lines. In 32D 
muFLT3 ITD Ptprj ko cells Y416 Src activity was further decreased upon DPI treatment 
whereas it did not alter in response to DPI treatment in 32D muFLT3 ITD Ptprc ko I and 
II and both 32D muFLT3 ITD Ptprj/Ptprc ko I and II. Most striking effects were observed 
on specific ERK1/2 phosphorylation upon DPI treatment in PTP ko cell lines. T202/Y204 
ERK1/2 phosphorylation level were drastically reduced compared to untreated PTP ko 
cells and 32D muFLT3 ITD parental cells. In 32D muFLT3 ITD cells only slightly reduced 
ERK1/2 phosphorylation was obtained upon DPI treatment.  
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Figure 13. Signaling analysis in DPI treated 32D muFLT3 ITD cells and indicated 32D muFLT3 ITD 
PTP ko cell lines. 32D muFLT3 ITD (control transduced) and 32D muFLT3 ITD Ptprj
 
ko, 32D muFLT3 ITD 
Ptprc ko and 32D muFLT3 ITD Ptprj/Ptprc
 
ko cell lines were starved for 4 h and in parallel incubated with 
DPI (0.5 µM). Untreated cells were incubated with respective amount of DMSO for 4 h. Afterwards, cells 
were lysed in RIPA buffer, equivalent amounts of protein samples were separated by SDS-PAGE and 
processed for immunodetection using phosphosite specific antibodies recognizing FLT3 (pY589), pSTAT5 
(Y694), pAKT (S473), pSrc (Y416) and pERK 1/2 (T202/Y204). Blot was re-probed for total FLT3, STAT5, 
AKT, Src, ERK1/2 antibodies and -actin as control. (A) Representative immunoblots; (B) Quantification of 
specific phosphorylation of FLT3, STAT5, AKT, Src and ERK in relation to total protein level of indicated 
proteins, values are given in mean ± SEM, n=4, expect Src probing n=1; *p <0.001 compared to 32D 
muFLT3 ITD. 
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5.1.4 Lack of PTP affect total tyrosine phosphorylation 
To investigate whether DPI treatment would influence Ptprj and Ptprc activity and 
whether further phosphatases except the both PTP analyzed would affect FLT3 ITD-
mediated signaling events total tyrosine phosphorylation was checked in 32D muFLT3 
ITD PTP ko cells (Figure 14A). Upon DPI treatment total tyrosine phosphorylation was 
about 30 % decreased in 32D muFLT3 ITD cells. In 32D muFLT3 ITD Ptprj ko and 32D 
muFLT3 ITD Ptprc ko I cells tyrosine phosphorylation was reduced to 65 % compared to 
32D muFLT3 ITD cells (Figure 14B). Total tyrosine phosphorylation in untreated Ptprj or 
Ptprc ko cells was comparable to DPI treated 32D muFLT3 ITD cells. DPI treatment 
further decreased tyrosine phosphorylation in Ptprj ko or Ptprc ko cells. In cells lacking 
both PTP the overall tyrosine phosphorylation was 2-fold reduced compared to untreated 
32D muFLT3 ITD cells. DPI treatment did not further decrease overall tyrosine 
phosphorylation in 32D muFLT3 ITD cells lacking both PTP (Figure 14B). Thus, it can be 
speculated that Ptprj and Ptprc mediate tyrosine phosphorylation in 32D muFLT3 ITD 
cells via Src. Furthermore, it may be concluded that these both PTP are the main 
regulators in 32D muFLT3 ITD cells.  
 
Figure 14. Total tyrosine phosphorylation pattern in 32D muFLT3 ITD and indicated 32D muFLT3 ITD 
PTP ko cell lines after DPI treatment. (A) 32D muFLT3 ITD (control transduced) and 32D muFLT3 ITD 
Ptprj ko, 32D muFLT3 ITD Ptprc ko
 
I and 32D muFLT3 ITD Ptprj/Ptprc ko
 
I cell lines were starved for 4 h and 
in parallel incubated with DPI (0.5 µM). Untreated cells were incubated with respective amount of DMSO for 
4 h. Afterwards, cells were lysed in RIPA buffer, equivalent amounts of protein samples were separated by 
SDS-PAGE and processed for immunodetection. Total tyrosine phosphorylation was detected by 4G10 
antibody. Blot was re-probed with -actin as control. (B) Quantification of overall tyrosine phosphorylation 
normalized to -actin expression, n=1. 
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5.1.5 Inactivation of Ptprj and Ptprc increase the IC50 of TKI 
Elevated kinase activity of FLT3 is known to shift the dose-response curve for TKI 
towards somewhat lower sensitivity (Tse et al. 2002). To investigate if inactivation Ptprj 
and Ptprc affect the activity of FLT3 ITD in 32D muFLT3 ITD cells IC50 assay was 
performed in 32D mu FLT3 ITD PTP ko cells. AC220 and PKC412, FLT3 ITD inhibitors, 
used for AML treatment in clinical trials, were analyzed for their respective IC50 value in 
PTP ko cells. Interestingly, 32D muFLT3 ITD Ptprj ko and 32D muFLT3 ITD Ptprj/Ptprc 
ko II cells revealed decreased AC220 sensitivity, demonstrated by significantly increased 
IC50 value. 32D muFLT3 ITD Ptprc ko
 cells also showed increased IC50 value of AC220 
but without significance (Figure 15A). In line with the results obtained with AC220 the 
susceptibility of PKC412 in 32D muFLT3 ITD PTP ko cells was decreased compared to 
parental 32D muFLT3 ITD cells depicted by a striking increase of PKC412 IC50 value 
(Figure 15B). 
 
 
Figure 15. Knockout of RPTP increased IC50 value of FLT3 inhibitors. 32D muFLT3 ITD (control 
transduced), 32D muFLT3 ITD Ptprj ko, 32D muFLT3 ITD Ptprc ko
 
I and II and 32D muFLT3 ITD Ptprj/Ptprc 
ko
 
I and II cells were analyzed for IC50 value of TKI AC220 and PKC412 using cell titer blue viability assay. 
Values are given as mean ± SEM, n=3, *p <0.05 compared to 32D muFLT3 ITD. 
5.1.6 Clonal growth of 32D muFLT3 ITD PTP ko cells  
Increased FLT3 ITD activity drives cell transforming capacity and uncontrolled 
proliferation. If Ptprj and Ptprc negatively regulate FLT3 ITD-driven transforming 
capacity, 32D muFLT3 ITD cells with genetic inactivation of either Ptprj or Ptprc or both 
should demonstrate increase clonogenic growth. 32D muFLT3 ITD Ptprj ko and 
32D muFLT3 ITD Ptprc ko I and II showed no altered CFU numbers compared to 32D 
muFLT3 ITD cells (Figure 16). In contrast, combinatory knockout of Ptprj and Ptprc in 
32D muFLT3 ITD cells revealed increased CFU numbers compared to 32D muFLT3 ITD 
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cells but without reaching statistical significance. In line with signaling results it can be 
concluded, that lack of Ptprj and Ptprc did not alter FLT3 ITD activity significantly. 
 
 
Figure 16. Colony formation of 32D muFLT3 ITD and indicated 32D muFLT3 ITD PTP ko cell lines. 
32D muFLT3 ITD (control transduced), 32D muFLT3 ITD Ptprj ko, 32D muFLT3 ITD Ptprc ko
 
I and 32D 
muFLT3 ITD Ptprj/Ptprc ko
 
I cells were plated in a density of 375 cells / well on methylcellulose medium. 
n=3, each experiment performed in duplicates; values are given as mean % normalized to 32D muFLT3 ITD 
 SEM 
5.2 Effects of inactivation of Ptprj and Ptprc on hematopoiesis in FLT3ITD/ITD 
mice 
FLT3 plays a pivotal role in hematopoiesis. Mutations of FLT3 have been linked to 
hematopoietic malignancies. In about 30 % of AML FLT3 ITD has been observed, 
causing constitutive kinase activity and transforming potential (Griffith et al. 2004). RPTP 
Ptprj and Ptprc are also expressed in the hematopoietic compartment. Several 
approaches have been used to unravel the potential regulatory role of Ptprj and Ptprc on 
mutated FLT3 ITD kinase at the cellular level (Arora et al. 2011, Godfrey et al. 2012). In 
order to study whether Ptprj and Ptprc affect FLT3 ITD activity in vivo, FLT3ITD/ITD mice 
(Lee et al. 2007) were crossed with Ptprj-/- or Ptprc-/- mice and phenotypically 
characterized. 
5.2.1 Lack of Ptprj promotes myeloproliferative disease in FLT3ITD/ITD mice 
5.2.1.1 Weight development and survival 
To investigate whether single or combinatorial mutation of FLT3 ITD and Ptprj impair 
normal mice developmental, body weight analyses were performed. Neither male nor 
female FLT3ITD/ITD Ptprj-/- mice did show aberrant total body weight compared to WT and 
mice with single mutation (Figure 17).  
  Results 
54 
 
 
Figure 17. Age dependent weight development of WT, FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD 
Ptprj
-/- 
mice. 
WT (black circle), FLT3
ITD/ITD
 (dark green square), Ptprj
-/-
 (white triangle)
 
 and FLT3
ITD/ITD
 Ptprj
-/-
 (light green 
triangle) male (left panel) and female (right panel) mice were analyzed for their total body weight (g) at the 
age of 10 to 40 weeks; values are given as mean, n=3 
 
Survival studies of WT, FLT3ITD/ITD, Ptprj-/- and FLT3ITD/ITD Ptprj-/- mice revealed mutation-
induced shortening of life expectancy. WT and Ptprj-/- mice did not show decreased life 
expectancy within 300 days. FLT3ITD/ITD mice showed a mean life expectancy of about 
250 days (35 weeks) whereas in FLT3ITD/ITD Ptprj-/- mice the life expectancy was only 200 
days (28 weeks), although with the number of mice analyzed so far, this difference was 
not yet statistically significant. The mean survival of FLT3ITD/ITD Ptprj-/- mice was 
significantly reduced compared to WT and Ptprj-/- littermates. Early onset of more 
progressive disease was observed in FLT3ITD/ITD Ptprj-/- mice compared to FLT3ITD/ITD 
mice (Figure 18). Due to the shortened life expectancy all subsequent experiments of 
this study were carried out with mice at the age of 30 - 35 weeks.   
 
Figure 18. Kaplan Meier Plot of WT, FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD 
Ptprj
-/-
 mice. WT (black, n=20) 
FLT3
ITD/ITD
 (dark green, n=14) Ptprj
-/-
 (grey, n=18) and FLT3
ITD/ITD
 Ptprj
-/- 
(light green,
 
n=11) mice were 
analyzed for life expectancy. Significance was tested using log rank and indicated in the figure. 
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5.2.1.2 Organ weight and histological structure 
Next, we addressed the question of organ weight and structure. Ptprj-/- mice did not show 
aberrant organ weight compared to WT mice. A progressive development of 
splenomegaly was observed in FLT3ITD/ITD mice (Lee et al. 2007), which was not further 
pronounced in FLT3ITD/ITD Ptprj-/- mice (Figure 19). FLT3ITD/ITD mice the liver weight was 
slightly increased compared to WT mice. In contrast, the liver weight of FLT3ITD/ITD Ptprj-/- 
mice was significantly increased compared to WT littermates, indicating hepatomegaly. 
In FLT3ITD/ITD mice kidneys showed the tendency of increased weight compared to WT 
littermates, which was more pronounced in FLT3ITD/ITD Ptprj-/- mice.  
 
 
Figure 19. Inactivation of Ptprj in FLT3
ITD/ITD
 mice results splenohepatomegaly. Spleen (left panel), liver 
(middle panel) and kidney (right panel) weight (% of total body weight) of 30 - 35 weeks old WT(black circle, 
n=24), FLT3
ITD/ITD
 (dark green square, n=20), Ptprj
-/-
 (white triangle, n=8) and FLT3
ITD/ITD
 Ptprj
-/- 
(light green 
triangle, n=17) mice were analyzed. *p <0.05,  **p <0.01, ***p <0.001 compared to WT mice. 
 
Since splenohepatomegaly was not further increased in response to depletion of Ptprj in 
FLT3ITD/ITD mice, we next addressed the question, if the tissue structures as well as the 
nature and amount of possible infiltrated cells would provide explanations of the 
shortened life span of the FLT3ITD/ITD Ptprj-/- mice. Tissue sections stained with H & E 
displayed no abundant alteration of spleen and liver structure of Ptprj-/- mice compared to 
WT controls. In contrast, FLT3ITD/ITD mice exhibited loss of spleen separation in white 
and red pulp and demonstrated expansion of red splenic pulp. This effect was even 
more prominent in FLT3ITD/ITD Ptprj-/- mice (Figure 20). Histopathology of liver sections 
demonstrated infiltration of leukemic cells in FLT3ITD/ITD mice and more progressive in 
FLT3ITD/ITD Ptprj-/- mice. Infiltrations occurred predominantly around liver sinusoids, but 
were also spread throughout the organ. While histopathology of kidneys derived from 
FLT3ITD/ITD or Ptprj-/- mice revealed similar histological structures as WT organs, 
FLT3ITD/ITD Ptprj-/- kidneys showed a massive infiltration of leukemic cells in the renal 
medulla resulting in an obvious reduction of the Bowman’s space around the glomerula 
capsule (Figure 20 arrow head, indicated as GC). Similar to liver sinusoids accumulation 
of these cells appeared to be linked to arteries. 
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Figure 20. Infiltration of leukemic cells in peripheral organs due to inactivation of Ptprj in FLT3
ITD/ITD 
mice. Representative H & E histopathology showing spleen (top), liver (middle) and kidney (bottom) 
architecture from 30 - 35 weeks old WT, FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD
 Ptprj
-/-
 mice (WP= white pulp, 
RP= red pulp; GC, glomerulus capsule with arrows), scale bar: 100 µm. 
 
To identify the nature of infiltrated cells immunohistochemistry of paraffin-embedded 
spleen, liver and kidney sections was carried out. Myeloperoxidase (MPO) is a hallmark 
enzyme of the myeloid lineage (Kim et al. 2012). Analysis of Ptprj-/- mice showed no 
abnormalities compared to WT mice. MPO staining of spleen sections could 
demonstrate the expansion of red pulp (MPO-positive cells) in FLT3ITD/ITD mice but more 
pronounced in FLT3ITD/ITD Ptprj-/- mice. This was accompanied by impaired separation of 
white and red pulp of spleen in FLT3ITD/ITD mice and more pronounced in FLT3ITD/ITD  
Ptprj-/- mice. Staining of organs from FLT3ITD/ITD Ptprj-/- mice demonstrated infiltration of 
MPO-positive cells in liver and kidney. MPO-positive cell infiltration was not observed in 
age-matched WT littermates (Figure 21).  
Splenomegaly was less prominent in FLT3ITD/ITD Ptprj-/- mice than in FLT3ITD/ITD mice 
(Figure 19). However, analysis of organ structure revealed a more progressive infiltration 
of MPO-positive cells in FLT3ITD/ITD Ptprj-/- mice compared to mice with single mutation 
and WT mice (Figure 21). The severe destruction of organ architecture probably led to 
impaired organ function. 
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Figure 21. Accumulation of MPO positive cells in organs of FLT3
ITD/ITD 
Ptprj
-/- 
mice. Representative 
images of MPO stained spleen, liver and kidney sections from WT, FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD 
Ptprj
-/- 
mice. Sections from FLT3
ITD/ITD 
Ptprj
-/-
 mice incubated without primary antibody were used as negative 
control. Scale bar indicates 100 µm. 
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5.2.1.3 Peripheral blood analysis 
In order to analyze the myeloproliferative phenotype the composition of the peripheral 
blood was characterized. The peripheral blood composition of Ptprj-/- mice did not show 
an aberrant phenotype compared to WT littermates. Consistent with earlier findings in 
FLT3ITD/ITD mice (Lee et al. 2007, Li et al. 2008), 3- and 6- fold increased numbers of 
neutrophils and monocytes were observed in 30 - 35 weeks old mice. Inactivation of 
Ptprj in FLT3ITD/ITD mice further pronounced this effect. Elevated white blood cell count 
(WBC, Figure 22A) and WBC differentials (Figure 22E) confirmed the expansion of 
monocytec / granulocytic population in FLT3ITD/ITD Ptprj-/- mice indicating a more 
progressive myeloproliferative disease. Moreover, a decrease of the lymphocytic 
population was observed in FLT3ITD/ITD animals, which was more pronounced in 
FLT3ITD/ITD Ptprj-/- mice pointing to an impaired lymphocyte development or displacement 
of lymphocytes. Red blood cell count (RBC, Figure 22B), number of platelets (Figure 
22C) and hemoglobin (HGB, Figure 22D) of FLT3ITD/ITD animals were significantly 
reduced compared to age-matched WT littermates. Knockout of Ptprj in FLT3ITD/ITD mice 
did not further elevate this effect.  
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Figure 22. FlT3
ITD/ITD 
Ptprj
-/-
 mice develop myeloproliferative neoplasm. White blood cell count (WBC; 
A), red blood cell count (RBC, B), number of platelets (C) and hemoglobin (HGB, D) are presented for WT, 
FLT3
ITD/ITD
, Ptprj
-/-
 FLT3
ITD/ITD
 Ptprj
-/-
 mice at the age of 30 – 35 weeks. WBC differentials (E) normalized to 
total amount of leukocytes are demonstrated. Samples of peripheral blood were analyzed using a Mindray 
BC5300Vet Hematology system. Bar (A-D) indicates mean ± SEM. White blood cell count differentials are 
shown in means ± SEM indicating. *p <0.05, **p <0.01, ***p <0.001 compared to WT. #p <0.05 compared to 
FLT3
ITD/ITD
. 
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5.2.1.4 Impaired lymphopoiesis and extramedullary hematopoiesis 
Myeloid expansion was analyzed by flow cytometric analyses. In BM no changes of the 
myeloid population compared to WT littermates were observed in none of the mutated 
mice investigated (Figure 23A). Splenic cells from FLT3ITD/ITD mice demonstrated a slight 
increase of CD11b / Gr-1 positive population which was significantly increased in 
FLT3ITD/ITD Ptprj-/- mice (Figure 23B). Strongly reduced amount of CD19+ B lymphoid cells 
out of myeloid undifferentiated (Gr-1- / CD11b-) population was observed in both BM and 
spleen of FLT3ITD/ITD animals compared to WT mice. In FLT3ITD/ITD Ptprj-/- mice the 
reduction of CD19+ B cells was further increased compared to WT mice. CD19+ splenic 
B cells were about 2-fold down regulated in FLT3ITD/ITD Ptprj-/- mice compared to 
FLT3ITD/ITD mice (Figure 23B). CD3+ T cell population did not show any changes in 
spleen and BM of mice with single mutation and FLT3ITD/ITD Ptprj-/- mice compared to WT 
controls.  
 
Figure 23. Mutant FLT3
ITD/ITD 
Ptprj
-/-
 mice show B cell lymphocytopenia. Immunophenotype of BM and 
spleen cells from 30 - 35 weeks old WT, FLT3
ITD/ITD
, Ptprj
-/- 
and FLT3
ITD/ITD 
Ptprj
-/-
 mice were analyzed 
concerning CD11b, Gr-1, CD19 and CD3 expression. Graphical presentation of CD11b / Gr-1 expression 
and CD19 as well as CD3 expression in CD11b
- 
/ Gr-1
- 
population in BM (A) and spleen (B) were 
demonstrated as absolute cell number. Values are given as mean ± SEM out of 1x10
5
 cells analyzed;          
*p <0.05,***p <0.001 compared to WT; # p <0.05 compared to FLT3
ITD/ITD
; n=5 per genotype. 
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Next, we addressed the question whether the stem cell population was changed in BM 
or spleen of mice harboring a single or double mutation to investigate possible 
extramedullary hematopoiesis. Interestingly, splenic lineage negative (Lin-) cells of Ptprj-/- 
mice were 50 % reduced compared to WT mice (Figure 24A). Lin. BM cells, myeloid 
progenitor and LSK population of Ptprj-/- mice did not show any alterations compared to 
WT littermates. Flow cytometric characterization revealed a 2.5-fold elevation of Lin-cells 
in BM of FLT3ITD/ITD Ptprj-/- mice compared to FLT3ITD/ITD mice In BM the amount of Lin- 
cells in FLT3ITD/ITD mice did not change significantly by contrast with WT littermates. The 
Lin- population in spleen (Figure 24B) was changed marginally in FLT3ITD/ITD and 
FLT3ITD/ITD Ptprj-/- mice. According to Li and co-workers the number of Lin- Sca-1- c-Kit+ 
(committed myeloid progenitors) cells in spleen was severely enhanced in FLT3ITD/ITD 
mice (Li et al. 2008, Li et al. 2011). A similar increase was also observed in our 
experiments with FLT3ITD/ITD mice which was further pronounced in FLT3ITD/ITD Ptprj-/- 
mice in BM and spleen. Similarly, the numbers of Lin- Sca-1+ c-kit+ (LSK) cells, which 
were already several-fold enriched in FLT3ITD/ITD spleens compared with WT mice, were 
significantly further enhanced in FLT3ITD/ITD Ptprj-/- mice. In BM only small differences of 
these cell populations were observed. Taken together, these data demonstrate that 
inactivation of Ptprj in FLT3ITD/ITD mice results in an increase of Lin-, myeloid progenitors 
and LSK cells showing a pronounced accumulation in spleen and indicating 
extramedullary hematopoiesis.  
In murine hematopoiesis, WT FLT3 expression was demonstrated in all progenitors of 
granulocytes/macrophages including GMP and CMP (Kikushige et al. 2008). Here FLT3 
expression was analyzed in myeloid progenitors and LSK cells of BM and spleen. Ptprj 
knockout did not change the amount of FLT3-positive myeloid progenitors in BM and 
spleen compared to WT mice. Interestingly, in Ptprj-/- mice the number of FLT3-positive 
LSK was increased in BM whereas in spleen no alteration was observed compared to 
WT littermates. In myeloid progenitors, FLT3 ITD mutation resulted in 5- or 39-fold 
elevation of FLT3-positive cells in BM and spleen, respectively compared to WT 
littermates (Figure 24C, D). There was a trend of further enhanced numbers of FLT3-
positive progenitors in FLT3ITD/ITD Ptprj-/- mice; however, the differences did not reach 
statistical significance. In FLT3ITD/ITD Ptprj-/- mice FLT3-positive LSK cells were enhanced 
in spleen only compared to WT mice indicating extramedullary hematopoiesis. In BM the 
number of FLT3-positive LSK cells was comparable to WT littermates and even lower 
than compared to FLT3ITD/ITD and Ptprj-/- mice.  
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Figure 24. FLT3
ITD/ITD 
Ptprj
-/-
 animals show extramedullary hematopoiesis in spleen. Immunophenotype 
of BM and spleen cells derived from 30 – 35 weeks old WT, FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD 
Ptprj
-/- 
mice 
were investigated. Total amount of Lin
- 
, Lin
-
 c-kit
+
 Sca-1
-
 (committed myeloid progenitors) and Lin
-
 c-kit
+
 
Sca-1
+
 (LSK) cells in BM (A) and spleen (B) are demonstrated. Graphical presentation of FLT3
+
 cells within 
these populations is shown for BM (C) and spleen (D). Values are given as mean ± SEM demonstrating cell 
number out of 1x10
6 
 cells analyzed; *p<0.05, **p<0.01 compared to WT. n=4 per genotype. 
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5.2.1.5 Clonogenic growth and transforming capacity 
Repopulation capacity of progenitor cells was investigated to analyze the transforming 
capacity of Lin- cells and to get information whether the phenotype describes a leukemic 
or proliferative disease. A leukemic phenotype is characterized by repopulation capacity 
of these cells. Increased clonogenic growth would indicate increased FLT3 ITD activity in 
response to Ptprj inactivation. Furthermore, the myeloproliferative phenotype could be 
assessed by the respective CFU units. Thus, progenitor cells of BM and spleen were 
MACS sorted for Lin- immunophenotype and subsequently evaluated by in vitro 
clonogenic assay in M3434 methylcellulose.  
While the number of colony forming units of BM granulocytes/macrophages (CFU GM) of 
WT, FLT3ITD/ITD or Ptprj-/- mice showed no significant change, the number of CFU GM 
from BM of FLT3ITD/ITD Ptprj-/- mice was significantly elevated compared with all other 
genotypes (Figure 25A). While Lin- cells purified from spleen of FLT3ITD/ITD mice revealed 
only a slight increase of clonogenic growth, splenic Lin- cells from FLT3ITD/ITD Ptprj-/- mice 
showed a significantly upregulated clonal growth, compared with Lin- cells of WT mice 
(Figure 25B). The numbers of multipotential granulocyte, erythroid, macrophage, 
megakaryocyte progenitor cells (CFU GEMM) and erythroid progenitor cells (CFU BFU) 
showed no alterations within the genotypes. For assessment of the potential 
repopulation capacity cells from CFU GM were harvested and reseeded in M3434 
methylcellulose. No subsequent colony formation was observed irrespective of the 
genotype indicating lack of repopulating capacity. Subsequent cytospin analyses 
confirmed myeloid lineage of cells (Figure 25C).  
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Figure 25. Promotion of clonogenic growth of splenic Lin- cells of FLT3
ITD/ITD 
Ptprj
-/-
 mice. Lin
-
 BM (A) 
and spleen (B) cells from 30 - 35 week old WT, FLT3
ITD/ITD 
, Ptprj
-/-
 and FLT3
ITD/ITD 
Ptprj
-/-
 mice were plated 
on M3434 methylcellulose medium (containing SCF-1, IL-3, EPO) and scored for colony formation 7 days 
later, n=9. Values are given in mean  SEM, BM colonies were harvested and analyzed by cytospin (C). 
Scale bar indicates 25 µm. *p <0.05, ***p <0.001 compared to WT; ###p <0.001 compared to FLT3
ITD/ITD
. 
 
5.2.1.6 Specific FLT3 activity 
The ITD mutation of FLT3 results in retention of mutated receptor in intracellular 
membranes, indicating by impaired maturation, e.g. a prevalence of the incompletely 
glycosylated, high-mannose form of 130 kDa and aberrant signaling towards 
downstream targets (Schmidt-Arras et al. 2005, Schmidt-Arras et al. 2009, Choudhary et 
al. 2009). In order to assess FLT3 ITD kinase activity and maturation in response to 
inactivation of Ptprj, MACS-purified Lin- cell from the BM of 30 week old mice were 
probed for activity-specific phosphorylation of the receptor. While in WT or Ptprj-/- cells 
the level of FLT3 expression was too low to be detected by immunoblotting, FLT3 ITD 
ligand-independent phosphorylation activity of Y591 and Y589 could be detected in 
FLT3ITD/ITD. FLT3ITD/ITD Ptprj-/- mice showed a moderately but significantly increased FLT3 
Y591 phosphorylation compared to FLT3ITD/ITD mice (Figure 26).  
 
 
 
 
 
C 
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Figure 26. Increased specific FLT3 phosphorylation in 
FLT3
ITD/ITD 
Ptprj
-/-
 mice. Lin
-
 purified BM cells of 30 weeks old 
FLT3
ITD/ITD
 and FLT3
ITD/ITD
 Ptprj
-/- 
mice were lysed in RIPA 
buffer and equivalent amounts of protein were separated by 
SDS-PAGE and processed for immunodetection using 
phosphosite specific antibodies recognizing pY591 and pY589 
of FLT3 protein. Blot was re-probed for total FLT3 antibody 
and -actin as control. Quantification of signal intensity 
normalized to FLT3 ITD is shown as mean  SEM, n=3. 
*p<0.05 compared to FLT3
ITD/ITD 
mice. 
 
To further investigate the signaling activity of FLT3, splenic cells of 30 weeks old WT, 
FLT3ITD/ITD, Ptprj-/- and FLT3ITD/ITD Ptprj-/- mice were probed for specific phosphorylation of 
FLT3 ITD downstream targets. Specific AKT S473 phosphorylation was significantly 
down regulated in FLT3ITD/ITD, Ptprj-/- and FLT3ITD/ITD Ptprj-/- compared to WT mice (Figure 
27A, B). Interestingly, in FLT3ITD/ITD Ptprj-/- mice specific Src Y416 phosphorylation was 
significantly increased compared with WT mice whereas mice harboring a single 
mutation showed no effects. ERK1/2 (T202/Y204) phosphorylation did not show any 
effect due to FLT3ITD/ITD mutation or Ptprj knockout. Immunoblot investigation of STAT5 
failed due to highly unspecific antibody although several pSTAT5 antibodies were tested. 
 
Figure 27. Signaling analysis of splenic FLT3
ITD/ITD 
Ptprj
-/-
 cells. Spleen cells of 30 - 35 weeks old WT, 
FLT3
ITD/ITD
, Ptprj
-/-
 and FLT3
ITD/ITD
 Ptprj
-/- 
mice were lysed in RIPA buffer and equivalent amounts of protein 
were separated by SDS-PAGE and processed for immunodetection using phosphosite specific antibodies 
recognizing AKT (S473), SFK (Y416) and ERK1/2 (T202/Y204). Blot was re-probed for total AKT, Src and 
ERK antibody and -actin as control. (A) Representative immunoblot; (B) Quantification of specific 
phosphorylation of, AKT, Src and ERK in relation to total protein level of indicated proteins, values are given 
in mean ± SEM, n=3; *p<0.05, ***p <0.001 compared to WT mice.  
* 
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5.2.2 Lack of Ptprc promotes MPN and bone aberrancies in FLT3ITD/ITD mice  
5.2.2.1 Weight development and survival 
To investigate whether mutation of FLT3 ITD or knockout of Ptprc or combinatory 
mutation resulted in impaired mice development mice weight was investigated. 
Comparative analysis of age-dependent weight development from WT, FLT3ITD/ITD,  
Ptprc-/- and FLT3ITD/ITD Ptprc-/- mice showed no significant difference neither in male nor 
in female mice (Figure 28).  
 
 
Figure 28. Age dependent weight development of WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD 
Ptprc
-/-
 mice. 
WT (black circle), FLT3
ITD/ITD
 (dark blue square), Ptprc
-/-
 (white triangle) and FLT3
ITD/ITD
 Ptprc
-/-
 (light blue 
triangle) male (left panel) and female (right panel) mice were analyzed for their total body weight (g) at the 
age of 5 to 15 weeks; values are given as mean, n =3. 
 
Life span of mice was analyzed to address the question if FLT3ITD/ITD Ptprc-/- mice 
developed a more progressive phenotype than FLT3ITD/ITD mice. As seen in Figure 29, 
FLT3ITD/ITD mice had a shortened mean survival compared to WT littermates and started 
to die from day 170 (24 weeks). FLT3ITD/ITD mice showed a mean life expectancy of 250 
days (35 weeks). Remarkably, the life span of FLT3ITD/ITD Ptprc-/- mice was drastically 
shortened. They started to die from day 37 already demonstrating a more progressive 
phenotype than FLT3ITD/ITD mice. The mean life expectancy of FLT3ITD/ITD Ptprc-/- mice 
(157 days/ 22 weeks) was significantly shortened compared to WT and Ptprc-/- 
littermates and even close to significantly decreased compared to FLT3ITD/ITD littermates 
(p <0.06). Statistical analyses of animal survival within the first 150 days showed a 
significantly reduced survival of FLT3ITD/ITD Ptprc-/- mice compared with WT mice and 
mice harboring single mutations (log rank test p=0.0014). Shortened life span of 
FLT3ITD/ITD Ptprc-/- mice indicates increased aggressiveness of FLT3 ITD-driven disease. 
Due to the short life span of FLT3ITD/ITD Ptprc-/- mice all subsequent experiments were 
carried out with mice at the age of 12 - 17 weeks.   
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Figure 29. Kaplan Meier Plot of WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD 
Ptprc
-/-
 mice. WT (black, n=10) 
FLT3
ITD/ITD
 (dark blue, n=15) Ptprc
-/-
 (grey, n=10) and FLT3
ITD/ITD
 Ptprc
-/- 
(light blue,
 
n=12) mice were 
analyzed for life expectancy; Statistical significance was validated by log rank test.  
 
5.2.2.2 Organ weight and architecture 
Comparative analysis of organ weight revealed no change in FLT3ITD/ITD and Ptprc-/- mice 
compared to WT littermates. In FLT3ITD/ITD Ptprc-/- mice significantly increased organ 
weights were observed compared to WT mice (Figure 30). Spleen weight of mice 
harboring both mutations was more than 3-fold increased, liver weight was doubled 
compared to mice with single mutation and WT littermates. Kidney weight was 
significantly increased compared to WT littermates. These results point to a severe 
disease in FLT3ITD/ITD Ptprc-/- mice probably affecting hematopoiesis. 
 
 
Figure 30. Inactivation of Ptprc in FLT3
ITD/ITD
 mice results in severe splenohepatomegaly and 
nephromegaly. Spleen (left panel), liver (middle panel) and kidney (right panel) weight (% of total body 
weight) of 12 - 17 weeks old WT (black circle, n=4), FLT3
ITD/ITD
 (dark blue square, n=4), Ptprc
-/-
 (white 
triangle, n=7) and FLT3
ITD/ITD
 Ptprc
-/- 
(light blue triangle, n=6) mice were analyzed. **p <0.01, ***p <0.001 
compared to WT mice. ##p <0.01 ###p <0.001 compared to FLT3
ITD/ITD
 mice. 
 
In order to elucidate the reason of decreased life span and splenohepatomegaly in 
FLT3ITD/ITD Ptprc-/- mice, histopathological analyses of the peripheral organs were 
performed. In Ptprc-/- mice, no aberrancies of organ architecture were discovered 
compared to WT controls. As outlined before, an infiltration of leukemic cells and 
disturbance of red and white pulp separation of the spleen compared to WT spleen was 
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already observed in FLT3ITD/ITD mice, but it was clearly more pronounced in FLT3ITD/ITD 
Ptprc-/- mice (Figure 31). Leukemic cell infiltration was observed in kidney of FLT3ITD/ITD 
Ptprc-/- mice, but none of the mice with single mutation displayed aberrancies compared 
to WT controls. In liver samples of FLT3ITD/ITD mice few infiltrated cells were observed 
predominantly at liver sinusoids. The infiltration was much stronger in FLT3ITD/ITD Ptprc-/- 
mice. Leukemic cells were observed close to liver sinusoid but also spread throughout 
the tissue. Disturbed tissue structures of peripheral organs might result in impaired 
organ function and in turn shortened life span of FLT3ITD/ITD Ptprc-/- mice.  
 
 
Figure 31. Infiltration of leukemic cells in peripheral organs due to Ptprc inactivation in FLT3
ITD/ITD
 
mice. Representative H & E histopathology showing spleen (top), kidney (middle) and liver (bottom) 
architecture from 12 - 17 weeks old WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD
 Ptprc
-/-
 mice (WP= white pulp, 
RP= red pulp). Scale bar indicates 100 µm. 
To further elucidate the lineage origin of infiltrated cells the peripheral organs were 
checked for MPO-positive cells by immunohistochemistry. MPO is the hallmark enzyme 
of the myeloid lineage (Kim et al. 2012). Livers of FLT3ITD/ITD Ptprc-/- mice exhibited 
multiple accumulations of MPO-positive cells around the liver sinusoids but also spread 
throughout the tissue, which was observed in any of the controls (Figure 32A). In spleen, 
MPO-positive cells normally occur in areas of red pulp as it was found in mice with single 
mutation and WT controls (Figure 32B). However, in FLT3ITD/ITD mice clearly increased 
amount of MPO-positive cells was observed in spleen when compared to WT controls. A 
drastically increased quantity of MPO-positive cells, spread throughout the complete 
tissue, was observed in spleens of FLT3ITD/ITD Ptprc-/- mice, indicating the loss of 
segmentation of the spleen by propagation of red pulp and the infiltration of MPO-
positive cells in spleen. Although the kidney weight was significantly increased and H & 
E staining indicated slight infiltration of leukemic cells no infiltration of MPO-positive cells 
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was detected in FLT3ITD/ITD Ptprc-/- mice (Figure 32C). Specification of the MPO-antibody 
was validated by negative controls (Figure 32D).  
 
Figure 32. Infiltration of MPO-positive cells in organs of FLT3
ITD/ITD 
Ptprc
-/-
 mice. Representative images 
of MPO stained liver (A), spleen (B) and kidney (C) sections of WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD
  
Ptprc
-/- 
mice at the age of 12 - 17 weeks as well as negative controls (D) of liver, spleen and kidney from 
FLT3
ITD/ITD
 Ptprc
-/-
 mice, which were incubated without primary antibody. Organs were co-stained with sour 
hemalaun according to Mayer, Magnification 4 x and 20 x as indicated. Scale bar indicates100 µM. 
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5.2.2.3 Analysis of peripheral blood 
Next, the peripheral blood composition was investigated to address whether FLT3ITD/ITD 
Ptprc-/- mice developed a hematopoietic disease. FLT3ITD/ITD mice were reported to 
develop a myeloproliferative disease (Lee et al. 2007) or rather a leukemia-like disease 
(Li et al. 2008) characterized by an increased white blood cell count (WBC) and anemic 
features. 15 weeks old FLT3ITD/ITD mice showed no significant alterations of WBC, red 
blood cell count (RBC), platelets and hemoglobin (HGB) (Figure 33A - D). In contrast, 
FLT3ITD/ITD Ptprc-/- mice at the same age demonstrated a 22-fold significantly increased 
WBC compared to WT mice and FLT3ITD/ITD mice. Thus, the hematologic profile indicates 
a leukocytosis (Figure 33A). In addition to leukocytosis, RBC and HGB were significantly 
decreased compared to FLT3ITD/ITD mice revealing anemia and potentially an impaired 
erythropoiesis (Figure 33B, D). Furthermore, the amount of platelets was significantly 
diminished in FLT3ITD/ITD Ptprc-/- mice compared to FLT3ITD/ITD animals (Figure 33C). 
Analysis of WBC differentials unraveled an increase of granulocytic and monocytic 
leukocytes in FLT3ITD/ITD mice which was more pronounced in FLT3ITD/ITD Ptprc-/- mice and 
accompanied by an almost total loss of lymphocytes (Figure 33E). Moreover, the 
absolute cell number of myeloid cells was severely increased compared to mice with 
single mutation and WT littermates, pointing to a myeloproliferative disease (Figure 33F). 
Comparative analysis of stained peripheral blood smears demonstrated that FLT3ITD/ITD 
Ptprc-/- mutated mice were suffered by a severe monocytosis quite in contrast to 
FLT3ITD/ITD mice (Figure 33G). Interestingly, in Ptprc-/- mice significantly decreased RBC 
numbers were observed compared to WT mice. 
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Figure 33. FLT3
ITD/ITD 
Ptprc
-/-
 mice develop severe monocytosis. Samples of peripheral blood were 
analyzed from 12 – 17 week old WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD
 Ptprc
-/-
 mice using a Mindray 
BC5300Vet Hematology system. White blood cells count (A), red blood cell count (RBC, B), platelets (C) and 
hemoglobin (HGB, D) are demonstrated. WBC differentials (E) and absolute amount of cells (F) are shown. 
Bar indicates mean ± SEM. *p <0.05, **p <0.01, ***p <0.001 compared to WT. #p <0.05 compared to 
FLT3
ITD/ITD
. (G) Representative Images of peripheral blood smears of 12 – 17 week old WT, FLT3
ITD/ITD
, 
Ptprc
-/-
 and FLT3
ITD/ITD
 Ptprc
-/-
 mice stained with Pappenhain staining kit (Morphisto GmbH). 
 
5.2.2.4 Block of lymphopoiesis and extramedullary hematopoiesis 
To verify the expansion of myeloid cells and loss of lymphocytes flow cytometric 
analyses were performed. Analysis of the myeloid differentiation markers CD11b and Gr-
1 demonstrated a 6-fold increase of CD11b / Gr-1 positive cells in spleen of FLT3ITD/ITD 
mice compared to WT mice, which was further increased 12-fold in spleen of 
FLT3ITD/ITD Ptprc-/- mice (Figure 34A, B). In contrast, in BM no aberrancies were observed 
in the CD11b+ / Gr-1+ cell population. The cell population, which was negative for CD11b 
and Gr-1, was significantly decreased in BM and spleen of FLT3ITD/ITD and 
FLT3ITD/ITD Ptprc-/- mice compared with WT mice. This was mainly due to a significantly 
decreased population of CD19-positive B cells. The latter effect was clearly seen in BM 
and spleen of FLT3ITD/ITD mice and was even more pronounced in the FLT3ITD/ITD Ptprc-/- 
mice. Compared to WT mice the amount of CD3+ T cells was significantly reduced in 
BM of Ptprc-/- mice. In BM of FLT3ITD/ITD and FLT3ITD/ITD Ptprc-/- mice no change 
compared to WT mice was observed. In spleen CD3 positive T cells were significantly 
reduced in Ptprc-/- and FLT3ITD/ITD Ptprc-/- mice compared to WT mice. Taken together, 
these data indicate a myeloproliferative disease and lack of lymphocytes in FLT3ITD/ITD 
mice, a phenotype which was more pronounced in FLT3ITD/ITD Ptprc-/- mice.  
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Figure 34. FLT3
ITD/ITD 
Ptprc
-/-
 mice show B cell lymphocytopenia. Immunophenotype of BM and spleen 
cells were analyzed for CD11b, Gr-1, CD19 and CD3 expression. 12 - 17 weeks old WT, FLT3
ITD/ITD
, Ptprc
-/- 
and FLT3
ITD/ITD 
Ptprc
-/-
 mice were analyzed. Graphical presentation of CD11b/Gr-1 expression and CD19 as 
well as CD3 expression in CD11b
- 
/ Gr-1
- 
population in BM (A) and spleen (B) were demonstrated as 
absolute cell number. Values are given as mean ± SEM out of 1x10
5 
 cells analyzed; *p <0.05, ***p <0.001 
compared to WT; # p <0.05, ## p <0.01 compared to FLT3
ITD/ITD 
mice. n=5 per genotype. 
 
To further characterize the myeloproliferative phenotype in FLT3ITD/ITD Ptprc-/- mice, 
further flow cytometric analyses were performed to assess the composition of 
hematopoietic stem and precursor cells in BM and spleen. A slight elevation of Lin- cells 
in FLT3ITD/ITD, Ptprc-/- and in FLT3ITD/ITD Ptprc-/- mice was observed in BM and spleen 
compared to WT controls (Figure 35A, B). A several-fold increase of myeloid progenitor 
population was observed in BM and spleen of FLT3ITD/ITD mice, but this increase was 
more pronounced in FLT3ITD/ITD Ptprc-/- mice. Similar results were observed while 
analyzing LSK cell population. Specifically, the number of LSK cells in BM was more 
than 3-fold and in spleen more than 6-fold increased compared to FLT3ITD/ITD mice, 
indicating extramedullary hematopoiesis in FLT3ITD/ITD Ptprc-/- mice. Investigation of FLT3 
level in myeloid progenitors and LSK cells revealed a significant increase in the BM of 
FLT3ITD/ITD Ptprc-/- mice. Remarkably, a 70-fold increased amount of FLT3 expressing 
LSK cells in FLT3ITD/ITD Ptprc-/- mice compared to FLT3ITD/ITD mice was observed. In 
contrast, mice harboring a single mutation did not show any alteration in FLT3 level of 
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BM LSK cells compared to WT littermates Figure 35C). In spleen the FLT3 level of LSK 
cells was already increased in FLT3ITD/ITD mice but 6-fold further increased in FLT3ITD/ITD 
Ptprc-/- mice when compared to FLT3ITD/ITD mice. These data affirm extramedullary 
hematopoiesis in FLT3ITD/ITD Ptprc-/- mice.  
 
Figure 35. FLT3
ITD/ITD 
Ptprc
-/-
 mice show extramedullary hematopoiesis and increased FLT3 level. 
Immunophenotype of BM and spleen cells from FLT3
ITD/ITD 
Ptprc
-/-
 mice showed expansion in Lin
-
 c-kit
+   
 
Sca-1
-
 (myeloid progenitors) and Lin
-
 c-kit
+
 Sca-1
+
 (LSK) population and amount of FLT3
+
 cells. Graphical 
presentation of lineage negative (Lin
-
), myeloid progenitors, LSK cells in BM (A) and spleen (B) derived from 
12 – 17 weeks old WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD 
Ptprc
-/- 
mice. (C) FLT3 expression level of myeloid 
progenitors and LSK cells analyzed in BM or spleen cells. Values are given as mean ± SEM out of 1x10
6 
 
cells analyzed *p <0.05, **p <0.0, ***p <0.001 compared to WT. ##p <0.01, ###p <0.001 compared to 
FLT3
ITD/ITD
 mice. n =4 per genotype. 
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During histological examinations large multinucleated cells were observed in spleens of 
FLT3ITD/ITD Ptprc-/- mice. Further immunohistochemical analysis (CD41 and DAPI 
staining) identified these cells as megakaryocytes. CD41-positive megakaryocytes 
normally occur in BM and not in spleen as demonstrated in WT and Ptprc-/- mice (Figure 
36). In BM of FLT3ITD/ITD mice a reduced quantity of CD41-positive cells was observed 
and some megakaryocytes in spleen were detectable. Remarkably, only very low 
amounts of CD41-positive cells were observed in BM of FLT3ITD/ITD Ptprc-/- mice, but high 
amounts of CD41-positive cells in spleen, confirming extramedullary hematopoiesis.  
 
Figure 36. Detection of megakaryocytes in spleen. Immunohistochemistry of femur and spleen sections 
of indicated mouse genotypes were stained with megakaryocyte marker CD41 and DAPI.  Representative 
images are demonstrated. Magnification 20x. 
 
5.2.2.5 Clonogenic growth and transformation capacity 
Next, we addressed the question if the repopulating capacity of extramedullary Lin- cells 
was altered in FLT3ITD/ITD Ptprc-/- mice. The repopulation capacity gives information about 
the transforming and proliferating capacity of Lin- cells to assess an either leukemic or 
myeloproliferative phenotype. Increased clonogenic growth would indicate increased 
FLT3 ITD activity in response to Ptprc inactivation. To this end, MACS purified Lin- BM 
and spleen cells were seeded in M3434 methylcellulose, containing (SCF, IL-3, IL-6 and 
EPO) and analyzed for their clonogenic growth. The number of CFU GM in BM was not 
altered in mice with single mutation and FLT3ITD/ITD Ptprc-/- mice compared to WT mice 
(Figure 37A). In contrast, the amount of CFU GM was significantly increased in splenic 
Lin- cells of FLT3ITD/ITD Ptprc-/- mice when compared to FLT3ITD/ITD and WT mice. 
Colonies of CFU GEMM and CFU BFU were hardly observed. Increased numbers of 
CFU GM and unchanged numbers of CFU GEMM and CFU BFU in spleen are typically 
observed in a MPN. Comparative cytospin analyses of harvested CFU verified the 
granulocytic/ macrophage phenotype of the cells (Figure 37B). To assess the re-
 WT                         FLT3 ITD                       Ptprc-/-            FLT3 ITD Ptprc-/- 
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population capacity of GM CFU, cells were harvested and re-seeded. Since no colonies 
were observed it can be concluded that cells lacked re-population capacity indicating the 
development of a MPN rather than a leukemic disease.  
 
Figure 37. Promotion of clonogenic growth in splenic Lin- cells of FLT3
ITD/ITD 
Ptprc
-/-
 mice. (A) Lin
-
 BM 
and spleen cells from 12 - 17 week old WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD 
Ptprc
-/-
 mice were plated on 
M3434 methylcellulose medium (containing SCF-1, IL-3, EPO) and scored for colony formation 7 days later, 
colony counts of granulocytes/ macrophages (CFU GM), of granulocyte, erythrocyte, monocyte, 
megakaryocyte (CFU GEMM) and erythroid progenitors (CFU BFU) were shown; n=9. Values are given in 
mean  SEM; Colonies were harvested and analyzed by cytospin, (B). Scale bar indicate 25 µm. **p <0.01, 
***p <0.001 compared to WT; ###p <0.001 compared to FLT3
ITD/ITD 
mice. 
 
5.2.2.6 Signaling in FLT3ITD/ITD Ptprc-/- mice 
Immunoblotting analyses of Lin- purified BM cells also indicated an aberrant maturation 
of FLT3 due to the ITD mutation (described in 5.2.1.6). In cells of the FLT3ITD/ITD and 
FLT3ITD/ITD Ptprc-/- mice predominantly the high-mannose form of FLT3 was detectable, 
whereas in WT and Ptprc-/- mice both, the high-mannose and complex glycosylated 
receptor were observed (Figure 38). This result indicated retention of the receptor in the 
interior of the cell and impaired surface expression. To get information about the activity 
of FLT3 we next characterized the phosphorylation of FLT3. Phosphorylation of FLT3 
Y591 was increased in FLT3ITD/ITD mice which was even more pronounced in FLT3ITD/ITD 
Ptprc-/- mice compared to Ptprc-/- and WT controls. Phosphorylation of AKT S473 was 
significantly reduced in mice with single mutation already but much more reduced in 
FLT3ITD/ITD Ptprc-/- mice compared to WT controls. Src Y416 phosphorylation was 
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strongly increased in mice carrying FLT3 ITD. In mutated mice ERK1/2 phosphorylation 
was not altered compared to WT mice.  
 
Due to the fact that analysis of the FLT3 ITD downstream target STAT5 failed in 
immunoblotting analyses, immunohistochemical staining of pFLT3 and pSTAT5 was 
performed. An immunohistochemical analysis in spleen was not possible due to 
unspecific cross-reactions of the secondary antibody used. 
In WT and Ptprc-/- derived liver sections no pFLT3 signal was observed (Figure 39). 
pFLT3 (Y591) staining revealed an increased level of FLT3 phosphorylation of infiltrated 
cells in liver of FLT3ITD/ITD Ptprc-/- mice but not in FLT3ITD/ITD mice. Further investigation 
concerning pSTAT5 level showed that infiltrated cells, positive for FLT3, were also 
strongly positive for pSTAT5 in FLT3ITD/ITD Ptprc-/- mice. No pSTAT5 positive cells were 
detected in liver sections of mice harboring a single mutation or WT littermates. Similar 
Figure 38. Increased specific FLT3 phosphorylation in 
Lin- BM of FLT3
ITD/ITD 
Ptprc
-/-
 mice. MACS purified Lin
-
 
cells from BM of 12 - 17 weeks old WT, FLT3
ITD/ITD
, Ptprc
-/-
 
and FLT3
ITD/ITD
 Ptprc
-/-
 mice were lysed in RIPA buffer and 
equivalent amounts of protein were separated by SDS-
PAGE and processed for immunodetection using 
phosphosite specific antibodies recognizing FLT3 (pY589), 
pAKT (S473), pSFK (Y416) and pERK (T202/Y204). Blot 
was re-probed for total FLT3, AKT, Src, ERK antibodies 
and -actin as control. (A) Representative immunoblot; (B) 
Quantification of specific phosphorylation of FLT3, AKT, 
Src and ERK in relation to total protein level of indicated 
proteins, values are given in mean ± SEM, n=3;             
***p <0.001 compared to WT. 
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analysis of kidney sections did not show pSTAT5 positive cells in all phenotypes 
investigated (not shown). 
 
 
Figure 39. Specific phosphorylation of FLT3 and STAT5 was drastically increased in FLT3
ITD/ITD    
Ptprc
-/- 
mice. Representative images of pFLT3 (Y591, light green, top) and pSTAT5 (Y694, light green, 
bottom) stained liver sections (4 µm) from WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD 
Ptprc
-/- 
mice at the age of 
12 - 17 weeks. Samples were co-stained with DAPI. Negative controls were incubated without primary 
antibody. Magnification 20x. Squares in lower right corner demonstrate 2.5-fold increased part of the 
respective figure. 
 
5.2.2.7 Impact of Ptprc on bone formation in FLT3ITD/ITD mice 
While characterizing histopathology and organ architecture of FLT3ITD/ITD Ptprc-/- mice 
solid hardening zones were observed in spleen and kidney. H & E staining of spleen and 
kidney revealed ectopic bone formation zones in FLT3ITD/ITD Ptprc-/- mice (Figure 40 black 
arrows). 
 
Figure 40. Ectopic bone formation in FLT3
ITD/ITD 
Ptprc
-/-
 mice. Representative images of H & E stained 
spleen and kidney sections of FLT3
ITD/ITD
 Ptprc
-/-
 mice at the age of 12 - 17 weeks demonstrating ectopic 
bone formation (black arrow) in peripheral organs. Scale bar indicate 100 µl. 
 
Because of the aberrant bone formation in peripheral organs, we considered that bone 
formation in these mice may be affected in a more general way. Therefore, the femoral 
   WT                   FLT3 ITD                Ptprc
-/-
           FLT3 ITD Ptprc
-/- 
  FLT3 ITD Ptprc
-/-
  
                negative control
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bone architecture was analyzed. Indeed, a severely different bone structure was 
observed in H & E stained femur sections of FLT3ITD/ITD Ptprc-/- mice compared to WT 
controls (Figure 41). Cortical areas of the bone seemed to be completely disorganized 
and more trabecular-like. Moreover, the normally parallel lamellar structure of the cortex 
as it is seen in the WT femur was disturbed and wavy. In FLT3ITD/ITD and Ptprc-/- mice the 
lamellar structure of the cortical bone was still present but the diameter of the femur was 
increased compared to WT control (compare 4 x magnification). The femoral diameter of 
FLT3ITD/ITD Ptprc-/- mice was severely increased compared to mice with single mutations 
or WT controls. 
 
Figure 41. Aberrant bone formation in FLT3
ITD/ITD 
Ptprc
-/-
 mice. Representative images of H & E stained 
femur slices (decalcified) of 12 - 17 weeks old WT, FLT3
ITD/ITD
, Ptprc
-/-
 and FLT3
ITD/ITD
 Ptprc
-/-
 mice in 4-fold 
magnification (upper panel) and 20-fold magnification (lower panel) displayed disturbed cortical bone 
formation in double mutated mice. Scale bar indicates 100 µm. 
 
During bone marrow preparation rough surface structure of bones of FLT3ITD/ITD Ptprc-/- 
mice was observed. To further investigate the surface and overall bone architecture µCT 
analysis were performed. Preliminary results demonstrated a strongly increased 
roughness of femoral surface of FLT3ITD/ITD Ptprc-/- mice compared to mice with single 
mutation and WT controls which is visualized in the 3D model shown in figure 42A. The 
roughness angle (µ) is a unit for evaluating the roughness of the bone surface, as 
described earlier (Hoffmann et al. 2017). The µ value reflects the bone surface 
roughness. The roughness was increased in FLT3ITD/ITD Ptprc-/- mice compared to mice 
with single mutation and WT mice. Moreover, FLT3ITD/ITD Ptprc-/- mice displayed 
decreased femur length as well as bone density but increased bone volume, indicated 
as cortical thickness index (CTI) compared to mice with single mutation and WT 
littermates (Figure 42B).  
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Figure 42. Surface analysis and bone formation in FLT3
ITD/ITD 
Ptprc
-/-
 mice. Preliminary micro-CT 
measurements of WT, FLT3
ITD/ITD
, Ptprc
-/-
 or FLT3
ITD/ITD 
Ptprc
-/- 
mice at the age of 15 weeks were processed 
to quantify (A) calculated roughness distribution of femoral surface and (B) bone parameters as length of 
femurs (cortical bone length, left panel), average bone density (in Hounsfield units, middle panel) and 
average cortical thickness of the femur (cortical thickness index-CTI, right panel). n=1. Analysis of CT data 
was performed by group of M. T. Figge (Applied Systems Biology, Leibniz Institute for Natural Product 
Research and Infection Biology, Hans Knöll Institute, Jena, Germany). 
 
 
An overview about the molecular biological and physiological results obtained from 
FLT3ITD/ITD mice inactivated for either Ptprj or Ptprc is presented in summarizing table 19. 
The table shows similar and different responses of Ptprj or Ptprc inactivation in 
FLT3ITD/ITD mice and in 32D muFLT3 ITD cells. 
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Table 19. Molecular biological and physiological phenotype due to genetically inactivation of either 
Ptprj or Ptprc in FLT3 ITD background  
 FLT3 ITD Ptprj-/- FLT3 ITD Ptprc-/- 
Cell line 
based 
phenotype 
- IC50 of TKI ↑ 
- total tyrosine phosphorylation ↓ 
- STAT5, AKT, Src phosphorylation ↓↓ 
 
- total tyrosine phosphorylation ↓ 
- AKT, Src phosphorylation ↓↓ 
Physio-
logical  
phenotype 
- shortened life span  
 
 
- leukocytosis:  
 WBC ↑ 
 myeloid cells ↑ in spleen and 
peripheral blood 
 
 
 
 
 
- decreased B lymphocytes  
- extramedullary hematopoiesis 
 LSK ↑ in spleen 
 CFU GM ↑ in BM and spleen 
 
- increased FLT3 phosphorylation 
 
- drastically shortened life  
span  
- splenohepatomegaly 
- leukocytosis: 
 WBC ↑↑↑ 
 myeloid cells ↑↑ in  
spleen and peripheral blood 
 monocytosis 
- anemia: 
 RBC ↓ 
 HGB ↓ 
- drastically reduced of platelets 
- lack of B and T lymphocytes 
- extramedullary hematopoiesis: 
 LSK ↑ in spleen 
 CFU GM ↑ in spleen 
 detection of megakaryocytes 
in spleen 
- increased FLT3 and  
STAT5 phosphorylation 
- bone aberrancies 
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6. Discussion 
6.1 Effect of Ptprj and Ptprc on FLT3 ITD activity in 32D muFLT3 ITD cells 
By using stable shRNA expression our group demonstrated previously that shRNA-
mediated depletion of the PTP Ptprj and Ptprc in FLT3 ITD expressing 32D cells leads to 
increased FLT3 phosphorylation and downstream signaling upon ROS quenching (Arora 
et al. 2011, Godfrey et al. 2012). In order to address the question if Ptprj and Ptprc may 
affect FLT3 ITD activity and FLT3 ITD-mediated signaling their genes were completely 
inactivated using CRISPR/Cas9 mediated knockout. In addition, potential overlapping 
functions of Ptprj and Ptprc were investigated in 32D muFLT3 ITD cells lacking both 
RPTP. 
 
In contrast to further results of our research group, complete inactivation of either Ptprj 
or Ptprc or both did not show a regulatory role on FLT3 ITD pY589 phosphorylation. It 
can be speculated that different Ptprj level result in different regulation of FLT3 ITD 
activation. It was previously demonstrated in breast cancer cells that activation of Src 
was dependent on different protein level of Ptprj and correlated with patient prognosis 
(Spring et al. 2015). Similar regulatory mechanisms of FLT3 ITD phosphorylation by 
Ptprj may be speculated but has to be investigated further.  
Although phosphorylation of FLT3 Y589 was not changed in 32D muFLT3 ITD PTP ko 
cells compared to 32D muFLT3 ITD cells, the knockout of Ptprj and combinatory 
knockout of Ptprj and Ptprc in 32D muFLT3 ITD cells resulted in significantly increased 
IC50 of TKI AC220 and strongly increased IC50 of PKC412. Elevated kinase activity of 
FLT3 is known to shift the dose-response curve for TKI towards somewhat lower 
sensitivity (Tse et al. 2002). Higher IC50 values indicate higher tolerance and thereby 
lower TKI sensitivity. Thus, it can be indirectly concluded that ko of Ptprj as well as 
combinatorial ko of Ptprj and Ptprc resulted in increased FLT3 ITD activity. This result 
confirmed the regulatory role of Ptprj on FLT3 ITD in the 32D muFLT3 ITD model cell 
system. Since the decreased TKI sensitivity of 32D muFLT3 ITD Ptprj ko cells indicated 
a higher activity of FLT3 ITD it can be speculated that other phosphorylation sites 
controlling FLT3 ITD kinase activity were regulated by this RPTP. For instance, 
increased FLT3 Y591 phosphorylation has been demonstrated in 32D huFLT3 cells 
upon Ptprj downregulation (Arora et al. 2011). 
 
Quenching of cellular ROS by DPI treatment resulted in slightly decreased specific FLT3 
phosphorylation in 32D muFLT3 ITD cells and in all PTP ko cell lines. Ptprj has been 
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demonstrated to be reversibly inactivated by high ROS level in FLT3 ITD positive cells 
(Godfrey et al. 2012, Jayavelu et al. 2016). The above data were consistent with an 
oxidation-mediated inactivation of Ptprj. Oxidation susceptibility of Ptprc has been 
previously demonstrated in other context (Singh et al. 2005). However, own studies 
indicated no ROS-mediated inactivation of Ptprc in FLT3 ITD positive cells (Godfrey et 
al. 2012). Since in 32D muFLT3 ITD Ptprj ko cells FLT3 phosphorylation was still 
decreased upon ROS quenching it can be concluded that either re-activation of Ptprc or 
of other PTP may affect FLT3 phosphorylation. Reduced FLT3 phosphorylation in cells 
lacking Ptprj and Ptprc might be due to other PTP, probably SHP-1 and PTP1B, 
regulating FLT3 ITD activity in ER (Schmidt-Arras et al. 2005, Yudushkin et al. 2007). It 
may also be speculated that other mechanisms regulate FLT3 phosphorylation. 
However, in 32D muFLT3 ITD cells genetically inactivated for both RPTP total tyrosine 
phosphorylation was more decreased than in single PTP ko cells but not further reduced 
by ROS quenching. Based on this observation it can be speculated that Ptprj and Ptprc 
were the main oxidation susceptible PTP in 32D cell system or that both RPTP regulate 
a common target, e.g. Src. It is more likely that the impaired tyrosine phosphorylation 
was caused by impaired Src activity, which was downregulated due to lack of PTP, 
irrespective of DPI treatment, than by altered FLT3 ITD activity. 
 
Surprisingly, FLT3 protein level was strongly reduced in all PTP ko cells compared to 
32D muFLT3 ITD cells. Consistently, significant decreased FLT3 ITD protein level has 
been observed in Ptprj ko MV4-11 cells (Sapozhnikova 2017). Decreased protein level 
of FLT3 can be explained by increased turnover or reduced expression. Reduced TKI 
sensitivity of FLT3 ITD in response to PTP ko indicated elevated kinase activity. Since 
turnover of FLT3 ITD is dependent on its activity (Buchwald et al. 2010, Schindler 2010, 
Oshikawa et al. 2011) it may be speculated that reduced cellular FLT3 ITD protein levels 
in PTP ko cell lines were due to increased turnover. However, investigation on FLT3 
turnover demonstrated no significant changes in Ptprj ko MV4-11 cells (carrying FLT3 
ITD) but reduced mRNA level of FLT3 ITD (Sapozhnikova 2017). If the FLT3 ITD mRNA 
expression in 32D cells, where the receptor is expressed under control of a retroviral 
promotor, is diminished has to be characterized further.  
PTP knockout potentially resulted in further impairment of FLT3 ITD maturation. Since 
the degree of receptor retention was activity dependent (Choudhary et al. 2009, 
Schmidt-Arras et al. 2005, Choudhary et al. 2005), this observation may be an indication 
of increased FLT3 ITD activity in response to Ptprj as well as Ptprc knockout.  
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Increased receptor activity in PTP ko cells would suggest increased downstream 
signaling, e.g. elevated FLT3 ITD-mediated STAT5 activation (Choudhary et al. 2005, 
Choudhary et al. 2007, Choudhary et al. 2009, Schmidt-Arras et al. 2009). 
Unexpectedly, STAT5 Y694 phosphorylation was significantly reduced in Ptprj and 
double PTP ko cells and slightly reduced in Ptprc ko cells. Since FLT3 Y589 
phosphorylation was not changed in PTP ko cell lines it can be concluded that other 
factors mediate reduced STAT5 activity. For instance, JAK and SFK have been 
demonstrated to be important STAT5 activators (Ozawa et al. 2008, Beisenherz-Huss et 
al. 2001). Src has been reported to be important for FLT3 ITD-mediated STAT5 
activation (Leischner et al. 2012). Indeed, phosphorylation of the activating tyrosine 
residue of Src was drastically downregulated in PTP ko cells. Since Ptprj and Ptprc are 
reported to be involved in Src activation (Chabot et al. 2009, Spring et al. 2012, Fournier 
et al. 2016, Gupta and DeFranco 2003), it can be concluded that loss of Src activity was 
due to RPTP knockout. Decreased STAT5 phosphorylation as well as decreased AKT 
phosphorylation and reduced total tyrosine phosphorylation in 32D muFLT3 ITD PTP ko 
cells can be explained by decreased Src activity. Investigation on clonogenic growth 
demonstrated no change in 32D muFLT3 ITD PTP ko cell lines compared to 32D 
muFLT3 ITD cells. FLT3 ITD, STAT5 and AKT activity has been reported to contribute to 
uncontrolled cell proliferation and transforming capacity (Rocnik et al. 2006, Choudhary 
et al. 2007, Brandts et al. 2005). Unchanged colony formation in 32D muFLT3 ITD PTP 
ko cells can be explained by unchanged or rather reduced activity of FLT3 ITD, STAT5 
and AKT and thus indicated similar transforming capacity of FLT3 ITD in PTP ko cells.  
 
In 32D muFLT3 ITD PTP ko cells signaling analysis revealed no significant change of 
specific ERK1/2 phosphorylation. In 32D muFLT3 ITD cells ERK1/2 activity was slightly 
decreased upon DPI treatment. This was presumably mediated by re-activated Ptprj, 
which directly dephosphorylated tyrosine residue Y204 in ERK1/2 activation loop and 
thus, resulted in decreased ERK1/2 activity (Sacco et al. 2009). ERK1/2 was not 
activated by ER-retained high-mannose FLT3 ITD (Schmidt-Arras et al. 2009, 
Choudhary et al. 2009). Only low activity of ERK1/2 has been observed in 32D FLT3 ITD 
cells (Mizuki et al. 2000). Strong reduction of ERK1/2 phosphorylation in response to 
DPI treatment indicates a re-activation of PTP. Since this effect was similar in 32D 
muFLT3 ITD Ptprj/Ptprc ko cells it can be concluded that further phosphatases regulate 
ERK1/2 activity. DUSP6, a dual specific phosphatase targeting phosphoserine/ 
phosphothreonine and phosphotyrosine residues, has been demonstrated to be 
significantly upregulated in FLT3 ITD expressing cell lines and in AML patient samples 
with FLT3 ITD mutation (Arora et al. 2012). In addition, it has been reported that DUSP6 
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negatively regulate ERK1/2 activity (Camps et al. 1998, Dickinson and Keyse 2006). 
Thus, it is likely that increased DUSP6 activity counteracts ERK1/2 (T202/Y204) 
phosphorylation in PTP ko cells. 
 
Taken together, there were some hints that Ptprj and Ptprc regulate FLT3 ITD activity in 
32D muFLT3 ITD cells. The greatest effects in terms of inactivation of RPTP were 
observed in terms of Src activity. At present it cannot be differentiated whether the FLT3 
ITD activity is directly or indirectly influenced. It can be assumed that in addition to 
specific effects on FLT3 ITD, other physiological functions are influenced by the two 
RPTP.  
 
Figure 43. Proposed signaling events in Ptprj expressing (A) and Ptprj deficient (B) 32D muFLT3 ITD 
cells. Inactivation of Ptprj in 32D muFLT3 ITD cells resulted in decreased Src activity. Decreased Src 
activity subsequently led to decreased AKT and STAT5 phosphorylation. Phosphorylation of FLT3 ITD was 
not changed, but maturation was further abrogated. 
6.2 Effects of inactivation of Ptprj and Ptprc on hematopoiesis in FLT3ITD/ITD 
mice  
Cell line based studies indicated a possible negative regulatory role of Ptprj for FLT3 ITD 
activity. To analyze in vivo effects of knockout of RPTP Ptprj and Ptprc on FLT3 ITD 
activity in complex regulated systems, e.g. hematopoiesis, the respective genes were 
genetically inactivated in FLT3ITD/ITD mice.  
6.2.1 Increased disease aggressiveness in FLT3ITD/ITD RPTP ko mice  
While life expectancy of Ptprj-/- and Ptprc-/- mice was comparable to WT mice, genetic 
inactivation of Ptprj or Ptprc in FLT3ITD/ITD mice resulted in shortened survival compared 
to FLT3ITD/ITD mice. FLT3 ITD knockin mice, created by Gilliland and colleagues were not 
reported to undergo any alteration in life expectancy (Lee et al. 2007). In contrast, Small 
and colleagues demonstrated that FLT3 ITD mutation in one allele of FLT3 gene was 
already sufficient to end in mortality within 6 to 20 months (Li et al. 2008). No change of 
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life span and viability were reported in Ptprj-/- or Ptprc-/- mice (Trapasso et al. 2006, Byth 
et al. 1996, Mee et al. 1999), consistent with our own observations. The shortened life 
time of FLT3ITD/ITD mice with additional knockout of either Ptprj or Ptprc indicated a more 
progressive FLT3 ITD-driven disease, as it was indeed substantiated by a more detailed 
characterization and a negative control of FLT3 ITD-induced disease by both PTP.  
6.2.2 Augmented myeloproliferative phenotype associated by lack of lymphocytes 
in FLT3ITD/ITD RPTP ko mice  
Several findings indicated an augmented myeloproliferative phenotype in FLT3ITD/ITD 
mice with additional knockout of one of the investigated RPTP. Splenomegaly and 
disturbed spleen architecture were observed in FLT3ITD/ITD mice. Enlarged spleen of 
FLT3 ITD expressing mice has been discussed as consequence of MPN (Li et al. 2008, 
Lee et al. 2007, Li et al. 2011). Genetic inactivation of Ptprj in FLT3ITD/ITD mice further 
pronounced this effect leading to splenohepatomegaly, strongly disturbed spleen 
architecture with expansion of red pulp and excessive infiltration of myeloid cells in 
peripheral organs, explaining organ enlargement. Since FLT3ITD/ITD Ptprj-/- mice 
demonstrating an even more aggressive phenotype, e.g. shortened survival, it can be 
concluded that inactivation of Ptprj results in a more aggressive MPN. Observed organ 
aberrancies were not reported in mice with systemic Ptprj inactivation (Trapasso et al. 
2006).  
Similarly, genetic inactivation of Ptprc in FLT3ITD/ITD mice caused a significantly increased 
spleen and liver weight compared to age-matched FLT3ITD/ITD mice. In addition, the 
kidneys were significantly increased compared to age-matched WT mice. The severe 
infiltration of myeloid cells in peripheral organs as well as splenohepatomegaly and 
nephromegaly indicated a more aggressive form of fatal MPN possibly leading to organ 
failure and shortened life span of FLT3ITD/ITD Ptprc-/- mice.  
Concomitantly, peripheral blood analysis and flow cytometric investigation of spleen 
revealed significantly increased WBC and myeloproliferative phenotype in FLT3ITD/ITD 
mice genetically inactivated for Ptprj or Ptprc accompanied by a lack of lymphocytes. 
More precisely, elevated myeloid CD11b+/Gr-1+ population of FLT3ITD/ITD mice was 
significantly increased in FLT3ITD/ITD mice with additional knockout of RPTP in spleen but 
not in BM, indicating a monocytic / granulocytic character of MPN. Ligand-mediated 
activation of FLT3 WT (Gabbianelli et al. 1995) or constitutive activity of FLT3 ITD have 
been reported to result in an increased monocytic / granulocytic population (Li et al. 
2008, Lee et al. 2007). Thus, it can be concluded that reduction of Ptprj or Ptprc 
strengthens the FLT3 ITD-mediated myeloproliferative effect.  
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Increased amount of neutrophils associated with reduced number of lymphocytes were 
observed in response to genetic inactivation of RPTP. Previous studies demonstrated a 
regulatory role of Ptprc and Ptprj on B cell receptor signaling (Zhu et al. 2008, 
Skrzypczynska et al. 2016, Zikherman et al. 2012). In addition, an increased B cell 
population in Ptprc-/- mice has been reported (Byth et al. 1996). In contrast, a decreased 
fraction of B cells in FLT3ITD/ITD mice has been demonstrated (Lee et al. 2007, Li et al. 
2008). Because in Ptprj-/- and Ptprc-/- mice peripheral blood lymphocytes and splenic 
CD19+ population were normal it is likely that the observed lack of B cells in FLT3ITD/ITD 
mice with additional knockout of Ptprj or Ptprc is mediated by an enhancement of the 
FLT3 ITD-mediated phenotype. In order to distinguish between the possibilities that the 
development of B cells is impaired or that B cells are displaced by myeloid cells, further 
investigations would have to be carried out. A reduced T cell population has been 
demonstrated in Ptprc knockout mice previously (Byth et al. 1996, Kishihara et al. 1993). 
This study confirmed the decreased T cell population irrespective of absence or the 
presence of the FLT3 ITD mutation. On the basis of lack of lymphocytes septic 
inflammation in response to RPTP inactivation in FLT3 ITD mutated mice can be 
excluded. 
 
In addition, FLT3ITD/ITD Ptprc-/- mice but any of the age-matched controls demonstrated 
anemic features, e.g. significantly decreased RBC and HGB, as well as decreased 
numbers of platelets. These observations indicate a potential negative effect on 
erythropoiesis or potential negative effect on biogenesis of MEP, the precursors of 
erythrocytes and platelets. Although FLT3 is not expressed on MEP itself (Gabbianelli et 
al. 1995) an important role of FLT3 in hematopoiesis of MEP was reported (Boyer et al. 
2011).  
In FLT3ITD/ITD Ptprc-/- mice increased numbers of LSK cells, containing HSC and MPP, 
were observed. Igarashi and colleagues showed that MPP contain a cell population of 
earliest lymphoid progenitors, which differentiate into granulocyte-monocyte-lymphoid 
progenitor (GMPL), but lack megakaryocyte / erythrocyte lineage potential (Igarashi et 
al. 2002). It may be speculated that increased numbers of LSK resulted in increased 
numbers of GMPL and thus, result in impaired biogenesis of MEP as well as 
differentiated erythrocytes and platelets. 
Furthermore, increased numbers of FLT3-positive LSK cells were obtained in FLT3ITD/ITD 
Ptprc-/- mice. FLT3+ MPP cells have been shown to mainly differentiate into lymphoid 
lineage. These lymphoid–primed MPP cells, called LMPP also have the ability to 
differentiate into myeloid lineage but lack megakaryocytic / erythrocytic lineage potential 
  Discussion 
88 
 
(Adolfsson et al. 2005). Increased amount of LMPP cells within the FLT3+ MPP 
population might additionally explain the decreased RBC and platelet count.  
Increased GMPL and LMPP might also contribute to the myeloproliferative phenotype 
observed in FLT3ITD/ITD Ptprc-/- mice. 
As demonstrated previously, expansion of GMP and corresponding decrease of MEP 
was due to increased FLT3 ITD activity (Lee et al. 2007). Thus, reduced platelets and 
erythrocytes might be further indications of drastically increased FLT3 ITD activity. 
However, significantly decreased RBC was observed in Ptprc-/-.mice. It cannot be 
excluded that inactivation of Ptprc itself, which is expressed on all nucleated 
hematopoietic cells, could also mediate this phenotype irrespective of FLT3 ITD.  
6.2.3 Extramedullary hematopoiesis in FLT3ITD/ITD mice genetically inactivated for 
RPTP 
Evaluation of stem cell compartment in FLT3ITD/ITD mice demonstrated increased LSK 
and myeloid progenitor population (Lee et al. 2007, Li et al. 2008). Inactivation of Ptprj or 
Ptprc further elevated splenic myeloid progenitor and LSK population, indicating 
extramedullary hematopoiesis. Thus, RPTP abrogation augments the hematopoietic 
phenotype of FLT3ITD/ITD mice. In contrast to earlier reports on Ptprc-/- where less HSC 
were observed in BM but increased amount in spleen (Shivtiel et al. 2008) we could not 
observe any alteration in LSK population of Ptprc-/- mice. The differences can be 
explained by usage of two different Ptprc-/- mice. For this study a Ptprc deficient mice 
lacking exon 9 was used with no Ptprc protein expression. In contrast, Shivtiel and 
colleagues used an exon 6 lacking Ptprc-/- mice. Due to alternative splicing, low amount 
of CD45 was still detectable in those mice.  
Because of the severe infiltration of hematopoietic stem cells in peripheral organs 
extramedullary hematopoiesis can be assumed in FLT3ITD/ITD mice genetically inactivated 
for either Ptprj or Ptprc. Clonal growth of splenic Lin- cells was significantly increased in 
response to Ptprj or Ptprc inactivation compared to FLT3ITD/ITD mice. Subsequent 
morphological analysis validated the myeloid character of progenitor cells. Observation 
of megakaryocytes in spleen in FLT3ITD/ITD Ptprc-/- mice was a further indicator of 
extramedullary hematopoiesis. Conclusively, our data reveal severe extramedullary 
hematopoiesis in response to Ptprc knockout in FLT3ITD/ITD mice. Genetic inactivation of 
Ptprj in FLT3ITD/ITD mice led to extramedullary hematopoiesis as well, but to a lesser 
extent.  
Quantification of FLT3 positive cells among myeloid progenitors and LSK cells showed 
severely increased amount of FLT3 expressing cells in spleen of FLT3ITD/ITD Ptprj-/- mice 
and in BM and spleen for FLT3ITD/ITD Ptprc-/- mice, respectively. Therefore, it can be 
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speculated that extramedullary hematopoiesis and MPN is due to increased FLT3 
activity in FLT3ITD/ITD mice genetically inactivated for Ptprj or Ptprc, pointing to an FLT3 
ITD-driven development of this phenotype. Activating mutations of FLT3 are known to 
contribute to leukemic transformation. However, at least one second cooperative 
mutation impairing hematopoietic differentiation is required for development of an FLT3 
ITD-associated AML (Pinheiro et al. 2007, Schessl et al. 2005). Lack of repopulating 
capacity of CFU in FLT3ITD/ITD mice genetically inactivated for either Ptprj or Ptprc 
revealed a more aggressive MPN instead of leukemia, confirming the two hit model.  
 
Our data confirmed the FLT3 ITD phenotypes described earlier (Li et al. 2008, Lee et al. 
2007). However, different reactions, e.g. survival and disease aggressiveness, of 
FLT3ITD/ITD mice created by Gilliland group (Lee et al. 2007) and Small group (Li et al. 
2008) are currently not understood. It might be due to different ITD sequences used for 
generation of FLT3 ITD knockin mice. Li and colleagues suggested dependence of MPN 
aggressiveness in relation to FLT3 ITD expression level or FLT3 ITD activity (Li et al. 
2011). This study demonstrated a more aggressive fatal MPN in response of Ptprj or 
Ptprc inactivation. Thus, it can be concluded, that both phosphatases act antagonistic on 
FLT3 ITD activity. However, cell autonomous effects could not be excluded. 
 
To further investigate whether observed physiological effects in response to RPTP 
inactivation were mediated by direct regulation of FLT3 ITD activity, specific 
phosphorylation of FLT3 ITD and FLT3 ITD downstream targets was analyzed.  
Since genetic inactivation of Ptprj in FLT3ITD/ITD mice resulted in significant increased 
FLT3 Y591 phosphorylation in Lin- purified BM cells it can be reversely concluded, that 
Ptprj counteract FLT3 ITD activity. Similar results were obtained in response to Ptprc 
inactivation in FLT3ITD/ITD mice. Strongly increased FLT3 Y591 phosphorylation was 
observed in Lin- BM cells as well as in FLT3 Y591 IHC examination of liver of FLT3ITD/ITD 
Ptprc-/- mice. Contributing to this, STAT5 phosphorylation was strongly upregulated in 
FLT3 Y591 phosphorylated liver cells of FLT3ITD/ITD Ptprc-/- mice, indicating an increased 
FLT3 ITD-mediated signaling. Thus, our results clearly indicate a counteracting role of 
Ptprc on FLT3 ITD activity. 
In addition, abrogation of FLT3 ITD maturation was observed in FLT3ITD/ITD Ptprc-/- mice, 
similar to in vitro observations. Since the retention of the receptor was activity dependent 
(Choudhary et al. 2009, Schmidt-Arras et al. 2005, Choudhary et al. 2005) this 
observation is an indication of increased FLT3 ITD activity in response to PTP 
inactivation. 
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Similar to in vitro signaling analysis AKT S473 phosphorylation was significantly reduced 
in spleen cells of FLT3 ITD mutated mice as well as in Lin- purified BM cells compared to 
WT controls. Significantly decreased AKT S473 phosphorylation in Ptprj or Ptprc 
knockout animals cannot be explained with our current state of knowledge. It can be 
speculated that Ptprj and Ptprc or respective substrates regulate AKT activity by so far 
unknown mechanisms.  
In contrast to in vitro analysis, phosphorylation of activating tyrosine of Src was 
significantly increased in splenic cells of FLT3ITD/ITD Ptprj-/- mice. In Lin- purified BM cells 
of FLT3ITD/ITD Ptprc-/- mice the tendency of increased Src phosphorylation was observed 
as well. SFK Fyn, Lyn and Src have been reported to be activated by FL stimulated 
FLT3 WT and constitutive active FLT3 ITD to contribute to STAT5 activation as well as 
transforming potential (Chougule et al. 2016, Leischner et al. 2012, Robinson et al. 
2005). Therefore, it can be speculated that significantly increased FLT3 ITD activity 
results in increased phosphorylation of activating tyrosine residue of Src. A probable 
signaling path of FLT3ITD/ITD Ptprc-/- mice is shown in figure 44.   
 
 
Figure 44. Supposed signaling path in FLT3
ITD/ITD 
and FLT3
ITD/ITD 
Ptprc
-/-
 mice. Supposed FLT3 ITD 
signaling path in FLT3
ITD/ITD 
mice (A) and FLT3
ITD/ITD
 Ptprc
-/-
 mice (B). Inactivation of Ptprc resulted in 
increased FLT3 ITD activity which led to increased Src activity and STAT5 phosphorylation. Due to further 
abrogated FLT3 ITD maturation in Ptprc deficient mice, membrane localized AKT is not accessible anymore 
for high mannose FLT3 ITD.  
Because of experimental difficulties it was not possible to demonstrate STAT5 
phosphorylation in FLT3ITD/ITD mice inactivated for Ptprj. But based on the available 
results, it is justified to speculate that the assumed signaling is also true for FLT3ITD/ITD 
Ptprj-/- mice. In addition, it cannot be excluded that the effect of Ptprj or Ptprc inactivation 
on FLT3 ITD is indirect only. Pathways other than the regulatory role of both RPTP on 
FLT3 ITD could also mediate this phenotype. Since inactivation of Ptprj and Ptprc, 
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respectively resulted in elevated phosphorylation effects can at least be explained by 
increased FLT3 ITD activity.  
6.2.4 Unexpected role of FLT3 ITD and Ptprc in bone homeostasis  
Besides severe alterations in the hematopoietic differentiation profile FLT3ITD/ITD Ptprc-/- 
mice showed an unexpected bone phenotype. While in FLT3ITD/ITD or in Ptprc-/- mice no 
obvious alterations in bone formation were observed, inactivation of Ptprc in FLT3ITD/ITD 
mice resulted in shortened bone length, reduced bone density, increased bone volume 
and increased surface roughness along with ectopic bone formation in peripheral 
organs. These preliminary results indicate deregulation of bone metabolism and 
homeostasis and suggest a role of FLT3 ITD and probably FLT3 in bone formation and 
metabolism/homeostasis. Bone homeostasis is tightly regulated by balanced activity 
bone remodeling osteoblasts (OB) and bone resorbing osteoclasts (OC). 
It has been demonstrated that HSC regulate mesenchymal stromal cell induction into OB 
and thereby participating in the formation of this stem cell niche (Jung et al. 2008). Since 
FLT3ITD/ITD mice genetically inactivated for Ptprc demonstrated MPN with significantly 
increased HSC population one may speculate that an increased HSC population in 
FLT3ITD/ITD Ptprc-/- mice may guide mesenchymal differentiation into the osteoblastic 
lineage. Due to observed extramedullary hematopoiesis ectopic bone formation in 
peripheral organs could be explained by guided mesenchymal differentiation into 
osteoblastic lineage and thus subsequent bone formation by OB in peripheral organs.  
OC are of hematopoietic origin. OC precursors circulate in the monocyte fraction 
(Fujikawa et al. 1996). In addition dendritic cells are able to trans-differentiate into OC 
(Rivollier et al. 2004). FLT3ITD/ITD mice genetically inactivated for Ptprc had significantly 
increased amounts of myeloid progenitors. Thus, it can be speculated that an increased 
amount of OC was present which may contribute to cortical porosity.  
Ptprc has been identified as a positive regulator of OC activity. Loss of Ptprc led to 
unregulated OC function associated by impaired bone remodeling (Shivtiel et al. 2008). 
In contrast, the FL-FLT3-axis is a known negative regulator of the genesis of osteoclasts 
(Svensson et al. 2016, Voronov and Manolson 2016). Thus, one would expect that in the 
FLT3ITD/ITD Ptprc-/- mouse model the activated FLT3 signaling and the absence of Ptprc 
would result in a reduced OC activity and reduced genesis of osteoclasts. However, the 
observed phenotype of less bone mass indicated either decreased OB activity or 
increased OC activity or both. Moreover, this unique bone phenotype suggests further 
functions of Ptprc and FLT3 in bone remodeling.  
In Ptprc-/- mice bone aberrancies were reported earlier (Shivtiel et al. 2008). In particular, 
impaired OC function and increased amount of trabecular structures were observed, 
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indicating a higher bone volume. In contrast, preliminary results of our own experiments 
did not reveal aberrant bone structures in mice with single mutation. 
It is reasonable to further investigate the previously unrecognized role of FLT3 ITD (and 
presumably FLT3) because osteoporosis and osteopenia occur frequently in adult AML 
patients after stem cell transplantation therapy (Ebeling et al. 1999, Schulte et al. 2000). 
Loss of bone mass was frequently observed early after stem cell transplantation 
(Massenkeil et al. 2001, Weidner et al. 2017).  
6.3 Conclusion and Outlook 
FLT3 is considered as an attractive therapeutic target in AML. TKI treatment has been 
demonstrated to increase patient survival. However, clinical studies of TKI revealed a 
high susceptibility to mutations for FLT3 ITD and other RTK, leading to TKI resistance. 
Despite help of approved TKI Midostaurin treatment still about 50% of AML patients 
have poor prognosis (Levis 2017). Therefore, it is important to identify additional 
alternative treatment strategies to impair FLT3 ITD activity.  
In this study we could demonstrate in vivo that Ptprj and Ptprc are naturally occurring 
antagonists of FLT3 ITD, affecting its activity. Ptprj is a known tumor suppressor gene. In 
the context of an FLT3 ITD-driven myeloproliferative disease in mice we could confirm 
anti-tumor activity. It has been previously reported that inhibition of Ptprc negatively 
affects tumor development (Perron and Saragovi 2018). However, array data 
demonstrated correlation of low expression level of Ptprj and Ptprc with poor prognosis 
in FLT3 ITD positive AML patients. We observed aggravated disease progression in 
FLT3 ITD driven MPN due to Ptprc or Ptprj inactivation. Conversely, activation Ptprc or 
Ptprj could contribute to better prognosis of AML patients. Till now there are no Ptprj or 
Ptprc activators in clinical studies. Treatment of FLT3 ITD-positive AML patients with 
activators of natural occurring antagonists of FLT3 ITD may demonstrate an alternative 
therapy to TKI treatment. In addition, mutations of FLT3 ITD which affect TKI 
susceptibility will not affect negative regulatory role of RPTP on FLT3 ITD. It is clear that 
the complete inactivation of Ptprj and Ptprc in FLT3 ITD mice does not reflect the exact 
human phenotype. However, these mice are an appropriate model to study the role of 
the respective phosphatases on FLT3 ITD and corresponding signaling pathways at 
organismic level. 
 
The novel bone phenotype of FLT3ITD/ITD Ptprc-/- mice is a suitable model to study the 
role of FLT3 ITD (and presumably FLT3) and Ptprc on bone formation and remodeling. 
Osteoporosis, osteopenia and loss of bone mass frequently occur in AML patients after 
stem cell transplantation. Further investigations, which will explore regulatory 
mechanisms and the role of FLT3 in bone homeostasis, may possibly provide better 
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treatment approaches. In particular, the mechanism how the disturbed hematopoietic 
stem cell niche of FLT3 ITD Ptprc-/- mice affects hematopoiesis and bone formation can 
be characterized. Studies on osteoblast and osteoclast activity and their differentiation 
capacity of cells derived from FLT3ITD/ITD Ptprc-/- and control mice will provide insight in 
the in vivo role of FLT3 ITD and Ptprc.  
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